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RESUMEN 
 
 
 
Los caballos de Pura Raza Española (PRE) representan el 85% de los caballos 
de raza pura en España, y casi el 100% de las exportaciones a Europa y América, las 
cuales tuvieron un valor de 58 millones de euros en 2012 (Deloitte, 2013). En 
España, la inmensa mayoría de caballos PRE se crían en explotaciones de 
particulares con un sistema semi-intensivo, donde cada caballo se trata de manera 
individual y supone una inversión importante de tiempo y dinero (MAPA, 2003).  
 
Las enfermedades víricas equinas suponen un riesgo para las explotaciones 
de cría de caballos, debido a su rápida transmisión y a la inexistencia de un 
tratamiento específico para ellas. Entre las enfermedades víricas asociadas con 
problemas reproductivos y/o pérdidas económicas en las explotaciones de cría de 
caballos se encuentran la Anemia Infecciosa Equina (AIE), la Arteritis Vírica Equina 
(AVE) y los Herpesvirus equinos tipo 1 y tipo 4 (HVE-1/-4) (OIE, 2013d). 
 
La AIE está presente en todo el mundo y se transmite mediante insectos 
mordedores (Issel and Foil, 1984), aunque puede ser transmitida verticalmente en 
el útero (Kemen and Coggins, 1972; Stein and Mott, 1942) y también 
iatrogénicamente (Williams et al., 1981). La AIE puede producir enfermedad  aguda 
con episodios de fiebre, trombocitopenia, anemia, abortos en yeguas y en ocasiones 
muerte; o bien enfermedad subclínica (OIE, 2013d). A pesar de que España fue 
declarada libre de AIE en 1983, la situación en algunos países europeos vecinos es 
preocupante, ya que en 2013 se detectaron brotes de enfermedad clínica en Bélgica 
y Alemania (OIE, 2014a; OIE, 2014b) y la seroprevalencia de AIE en Holanda es del 
0.44% (de Boer et al., 1979).  
 
La AVE se transmite vía respiratoria o venérea (Timoney and McCollum, 
1993), aunque la transmisión puede ocurrir también de manera vertical en útero 
(Bryans et al., 1957a; Golnik, 1992; Vaala et al., 1992) y a través de fómites (Guthrie 
et al., 2003; Timoney and McCollum, 1993). Los signos clínicos más típicos de AVE 
son fiebre, leucopenia, edemas, la conjuntivitis, aborto en yeguas y neumonía 
intersticial en potros neonatos (del Piero et al., 1997; Golnik et al., 1981). Los 
sementales infectados con AVE son portadores asintomáticos y pueden excretar el 
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virus en semen (Neu et al., 1992). En 1992 se confirmó el primer brote de AVE clínica 
en Barcelona, España (Monreal et al., 1995). Más recientemente, en 2013, se han 
detectado brotes de AVE en Francia, Suiza y España (OIE, 2014b) y existen estudios 
de seroprevalencia que aportan datos que van de un 8.7% en Alemania (Herbst et 
al., 1992) a un 55.1% en Polonia (Rola et al., 2011). 
 
Herpesvirus equino tipo 1 y tipo 4 producen enfermedad respiratoria, 
aborto, neumonía intersticial y mieloencefalopatía (HVE-1) en los caballos (Allen 
and Bryans, 1986; Allen, 1999; Bryans, 1988; Crabb and Studdert, 1995). La 
transmisión ocurre vía respiratoria, pero también a través del contacto con la 
placenta o las membranas fetales infectadas (Patel and Heldens, 2005). Alrededor 
del 80% de las infecciones por HVE-1 y HVE-4 son sucedidas por un estado de 
latencia; en situaciones de inmunocompromiso o estrés el virus puede reactivarse 
(Borchers et al., 1999). El único estudio epidemiológico que evaluó la presencia de 
HVE-1/-4 en España data de 1992, y demostró una seroprevalencia del 4.9% 
mediante seroneutralización (Martin Otero, 1992). La presencia de brotes de HVE-
1/-4 en países como Reino Unido, Francia, Suiza, Finlandia y España en 2013 (OIE, 
2014b) y la publicación de estudios que demuestran datos de seroprevalencia de 
HVE-1/-4 del 76% en Holanda (de Boer et al., 1979) o del 86.8% en Lituania  
(Liutkevicien, 2006) sugieren que HVE-1/-4 podría estar ampliamente distribuido 
en España. 
 
Dada la ausencia reciente de estudios de seroprevalencia de AIE, AVE y HVE-
1/-4 en España, así como la importancia de estas enfermedades en las explotaciones 
de cría de caballos y la relevancia de la cría de caballos PRE en la industria del caballo 
en nuestro país, los objetivos principales del presente estudio incluyeron la 
determinación de la seroprevalencia de AIE, AVE y HVE-1/-4 en la población de 
caballos de PRE en explotaciones de cría de la región central de España, así como la 
descripción de las características y las prácticas de manejo en relación a la 
prevención y control de enfermedades infecciosas equinas implementadas en estas 
explotaciones y por último la determinación de la presencia y la naturaleza de los 
problemas reproductivos existentes en la población de yeguas y sementales 
reproductores PRE de la región central de España.  
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Los objetivos secundarios del presente estudio incluían la identificación de  
potenciales factores de riesgo asociados con la exposición a las enfermedades de 
interés (AIE, AVE y HVE-1/-4) entre las características y medidas de manejo en 
relación a la prevención y el control de enfermedades infecciosas equinas en 
explotaciones de cría de PRE en la región central de España, y la evaluación de 
posibles asociaciones entre la exposición a las enfermedades de interés (AIE, AVE y 
HVE-1/-4) y la presencia de problemas reproductivos en yeguas y sementales PRE 
de esta región.  
 
Entre Septiembre de 2011 y Noviembre de 2013, se obtuvieron 555 muestras 
de suero procedentes de caballos PRE residentes en 35 explotaciones de cría en la 
región central de España.  
 
Tras el análisis de anticuerpos frente a AIE en las 555 muestras de suero 
mediante ELISA (ID Screen® Equine Infectious Anemia Double Antigen; IDVet 
Innovative diagnostics, Montpellier, Francia), la ausencia de caballos seropositivos 
a AIE demostró, con un nivel de confianza del 95%, que la población de caballos PRE 
en explotaciones de cría de la región central de España está libre de infección por 
AIE, a pesar de los recientes brotes de esta enfermedad en países europeos vecinos 
y de los frecuentes movimientos nacionales e internacionales de caballos en esta 
zona.  
 
La seroprevalencia de AVE mediante seroneutralización en la población de 
este estudio fue del 17.3% (14.2% - 20.4%), demostrando la presencia actual y 
relevante de AVE en las explotaciones de cría de PRE de la región central de España; 
por tanto la AVE no debería ser considerada como una enfermedad esporádica en 
los caballos PRE en explotaciones de cría de esta región.   
 
En la población de caballos no vacunados frente a HVE-1/-4 de este estudio, 
la seroprevalencia de HVE-1/-4 mediante seroneutralización fue del 53.3% (47.9% 
- 58.6%), confirmando una amplia distribución de HVE-1/-4 en la población de 
caballos PRE en explotaciones de cría de la región central de España.  
 
Alrededor del 50% de las explotaciones de cría de PRE muestreadas en este 
estudio afirmaron realizar actividades equinas distintas adicionales a la cría de 
caballos PRE, salir con sus caballos PRE a ferias y competiciones y adquirir nuevos 
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caballos en los 12 meses previos a la toma de muestras, demostrando que los 
movimientos de caballos son frecuentes en las explotaciones de cría de PRE en la 
región central de España. La mayoría de las explotaciones de cría de caballos PRE 
tenían medidas básicas de prevención y control de enfermedades infecciosas 
equinas, tales como desparasitación (97% de las explotaciones), desinfección (83% 
de las explotaciones), medidas contra insectos (83% de las explotaciones) y medidas 
contra roedores (80% de las explotaciones). Sin embargo, casi la mitad de las 
explotaciones no presentaba medidas específicas de prevención y control, tales 
como la vacunación frente a HVE-1/-4 (ausente en el 46% de las explotaciones) o la 
separación de las yeguas reproductoras y los caballos jóvenes (ausente en el 49% 
de las explotaciones).  
 
De las yeguas PRE muestreadas en este estudio, el 29% (23%-34%) habían 
presentado al menos un problema reproductivo en los 12 meses anteriores a la toma 
de la muestra. Entre estas yeguas, la pérdida de la gestación fue el problema 
reproductivo más frecuente (51%). La AVE debería considerarse al investigar la 
causa de problemas reproductivos en las yeguas PRE de la región central de España, 
ya que en nuestro estudio la presencia de anticuerpos frente a AVE estuvo asociada 
con la presencia de irregularidades en el ciclo/yeguas repetidoras (p=0.006), 
abortos tardíos (p=0.006) y problemas neonatales (p=0.006).  
 
De los sementales PRE muestreados en este estudio, solo el 7% (1.5%-11-
7%) presentaron problemas reproductivos en los 12 meses anteriores a la toma de 
la muestra y, entre éstos, el 50% presentó falta de libido.  
 
Para mantener la población de PRE en la región central de España libre de 
infección por AIE, deberían implementarse medidas contra insectos en todas las 
explotaciones, así como el análisis rutinario de AIE en los caballos importados, antes 
de la salida del país de origen y a su llegada a España.  
 
De los caballos PRE muestreados en este estudio, aquellos residentes en 
explotaciones con una elevada densidad de población, o con un número elevado de 
visitas mensuales de personas, o donde existían frecuentes movimientos de caballos 
tenían mayores probabilidades de ser positivos a AVE; estas explotaciones deberían 
establecer una detección rápida y aislamiento de posibles portadores o caballos 
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infectados en fase aguda, así como análisis rutinario de AVE antes de introducir 
cualquier caballo a la explotación.  
 
Los caballos de mayor edad, y aquellos residentes en explotaciones con un 
elevado número de visitas mensuales de personas, movimientos frecuentes de 
caballos y otras actividades equinas en la explotación tenían mayores 
probabilidades de ser positivos a HVE-1/-4; la implementación de medidas de 
bioseguridad, un esquema de vacunación frente a HVE-1/-4 y medidas específicas 
como separar las yeguas preñadas de otros caballos serían clave para reducir el 
riesgo de introducción de HVE-1/-4 en estas explotaciones.  
 
En nuestra opinión, la información obtenida en el presente estudio debería 
animar a la Administración, las diferentes asociaciones de criadores y los 
veterinarios/as a perseguir la educación y concienciación de los dueños de 
explotaciones de cría equina acerca de la presencia, la prevención y el control de las 
enfermedades infecciosas equinas en las explotaciones de cría de PRE en España.  
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SUMMARY 
 
 
 
Spanish Purebred (SP) horses represent 85% of the pure breed horses in 
Spain and nearly 100% of exportations to Europe and America standing for more 
than 58 million euro in 2012 (Deloitte, 2013). The average SP horse in Spain is bred 
in privately owned stud farms with a semi-intensive system of exploitation, where 
each horse is individually treated and involves a major investment of time and 
money (MAPA, 2003).  
Equine viral diseases pose a risk for a breeding stud farm due to their rapid 
transmission and the lack of specific treatment. Viral diseases associated with 
reproductive problems and/or economic losses in a breeding stud farm include 
Equine Infectious Anaemia (EIA), Equine Viral Arteritis (EVA), and Equine 
Herpesvirus-1/-4 (EHV-1/-4) (OIE, 2013d). 
EIA is distributed worldwide and is transmitted mechanically by biting 
insects (Issel and Foil, 1984), although it may be passed from a mare to her foal in 
utero (Kemen and Coggins, 1972; Stein and Mott, 1942) and also iatrogenically 
(Williams et al., 1981). The disease can be acute, causing febrile episodes, 
thrombocytopenia, anaemia, abortions in mares, and death; or it can also be 
subclinical (OIE, 2013d). Even though Spain was declared free from EIA infection in 
1983, the situation in nearby European countries is of concern, with EIA outbreaks 
of clinical disease in Belgium and Germany in 2013 (OIE, 2014a; OIE,2014b) and a 
seroprevalence estimate of 0.44% for EIA in the Netherlands (de Boer et al., 1979).  
EVA is transmitted via respiratory or venereal routes (Timoney and 
McCollum, 1993b), but also vertically in utero (Bryans et al., 1957a; Golnik, 1992; 
Vaala et al., 1992) and via fomites (Guthrie et al., 2003; Timoney and McCollum, 
1993b). The most typical clinical signs of EVA are fever, leukopenia, oedema, 
conjunctivitis, abortion in the mare, and fatal interstitial pneumonia in young foals 
(del Piero et al., 1997; Golnik et al., 1981). Stallions infected with the EAV are 
asymptomatic carriers of the virus and can shed the virus in semen (Neu et al., 
1992). In 1992 the first confirmed outbreak of EVA clinical disease was reported in 
Barcelona, Spain (Monreal et al., 1995). Recently, EVA outbreaks of clinical disease 
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have been reported in France, Switzerland and Spain in 2013 (OIE, 2014b) and 
studies have shown EVA seroprevalences ranging from 8.7% in Germany (Herbst et 
al., 1992) to 55.1% in Hucul horses in Poland (Rola et al., 2011). 
EHV-1 and EHV-4 produce respiratory disease, abortion, neonatal 
pneumonia, or myeloencephalopathy in horses (Allen and Bryans, 1986; Allen, 
1999; Bryans, 1988; Crabb and Studdert, 1995). Transmission occurs via the 
respiratory route, but also through contact with the infected placentas and foetal 
membranes (Patel and Heldens, 2005). Around the 80% of primary infections by 
EHV-1 and EHV-4 are followed by a state of latency which can be reactivated with 
immunosuppression or stress (Borchers et al., 1999). The only epidemiological 
study to evaluate the presence of EHV-1/-4 in Spain dates back to 1992 and showed 
a seroprevalence of 4.9% by seroneutralization (SN) (Martin Otero, 1992). The 
occurrence of EHV-1/-4 outbreaks of clinical disease in the UK, France, Switzerland, 
Finland and Spain in 2013 (OIE, 2014b) and studies showing EHV-1/-4 
seroprevalence results of 76% in the Netherlands (de Boer et al., 1979) or 86.8% in 
Lithuania  (Liutkevicien, 2006) suggest that EHV-1/-4 could also be widespread in 
Spain. 
Given the absence of recent studies of EIA, EVA and EHV-1/-4 seroprevalence 
in Spain, as well as the importance of these diseases for the equine breeding stud 
farms and the relevance of the breeding of SP horses for the Spanish equine industry, 
the main objectives of this study included the determination of the seroprevalence 
of EIA, EVA and EHV-1/-4 in the SP breeding population in the central area of Spain 
as well as the description of the characteristics and management practices with 
regards to the prevention and control of equine infectious diseases implemented in 
these stud farms and the determination of the occurrence and nature of the breeding 
problems in SP mares and stallions in the central area of Spain. 
The secondary objectives of the study included the identification of any 
potential risk factors associated with the exposure to the infectious diseases of 
interest (EIA, EVA and EHV-1/-4) within the characteristics and management 
practices regarding the prevention and control of equine infectious diseases in SP 
stud farms in central Spain, and the evaluation of possible associations between the 
exposure to the infectious diseases of interest (EIA, EVA and EHV-1/-4) and the 
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occurrence of breeding problems in SP mares and stallions in the central area of 
Spain.  
Between September 2011 and November 2013, serum samples were 
obtained from 555 SP horses residing on 35 different stud farms in the central 
region of Spain.  
After testing the 555 serum samples for EIA antibodies by ELISA (ID Screen® 
Equine Infectious Anemia Double Antigen; IDVet Innovative diagnostics, 
Montpellier, France), the absence of any EIA seropositive animals provided 95% 
confidence that the SP breeding horse population in central Spain is free from EIA 
infection, despite the recent EIA outbreaks in nearby European countries and the 
frequent national and international horse movements in this area. 
The seroprevalence of EVA in the population of this study by SN was 17.3% 
(14.2% - 20.4%), showing a relevant presence of EVA in the SP breeding horse 
population in central Spain; therefore, EVA should not be considered a sporadic 
disease in the SP breeding stud farms of this region.  
In the population of horses unvaccinated against EHV-1/-4 of this study, the 
seroprevalence for EHV-1/-4 in this study by SN was deemed to be 53.3% (47.9% - 
58.6%), demonstrating that EHV-1/-4 is widely spread in the SP breeding horse 
population in central Spain.  
Nearly half of the SP stud farms sampled in this study (46%) reported having 
equine activities other than breeding in the premises, the same percentage (46%) 
reported outings to fairs and competitions with their horse and 54% acquired new 
horses in the past 12 months, demonstrating that horse movements are frequent in 
the SP stud farms in central Spain. Most of the SP stud farms sampled had basic 
measures of prevention and control of equine infectious diseases, such as a worming 
regime (present in 97% of stud farms), a disinfection regime (present in 83% of stud 
farms), measures against insects (present in 83% of stud farms) and rodents 
(present in 80% of the stud farms). However, nearly half of the SP stud farms 
showed an absence of specific measures, such as an EHV-1/-4 vaccination regime 
(absent in 46% of stud farms) and segregating breeding mares from young horses 
(absent in 49% of stud farms).   
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Of the SP breeding mares sampled in the study, 29% (23%-34%) were 
reported to have had at least one reproductive problem in the past 12 months and 
within these, gestation loss was the most frequent problem (51%). Within the SP 
mares with reproductive problems sampled, EVA seropositivity was significantly 
associated with cyclic irregularities/repeat breeding (p=0.006), late abortions 
(p=0.006) and problems with the neonate (p=0.006).  
Of the SP breeding stallions sampled in the study, only 7% (1.5%-11-7%) 
were reported to have reproductive problems during the past 12 months, and out of 
these horses, 50% showed a lack of libido.  
In order to maintain the SP breeding horse population in central Spain free 
from EIA infection, measures against insects should be implemented in every stud 
farm and judicious biosecurity that includes routine EIA testing of the horses prior 
to importation into Spain and after their arrival should be established to prevent the 
introduction of subclinically EIA infected horses from Europe. 
Within the SP horses of this study, those residing in stud farms where there 
was a high horse density of population, or had a large number of visits from people 
or frequent movements of horses were more likely to be EVA seropositive; these 
stud farms should establish good biosecurity measures in the premises as well as a 
prompt detection and isolation of possible carriers or acutely infected horses and 
routine EVA testing prior to the introduction of new horses.  
Older SP horses, and those residing in stud farms with a large number of 
visits from people, frequent movements of horses and other equine activities in the 
premises were more likely to be EHV-1/-4 seropositive; the implementation of 
biosecurity measures, routine EHV-1/-4 vaccination and specific measures such as 
separating pregnant mares from other horses would be key in order to reduce the 
risk of the introduction of EHV-1/-4 into these stud farms.  
In our opinion, the data obtained in the present study should encourage the 
Administration, the different Breeders´ associations and veterinary surgeons to 
pursuit the education and awareness of stud farm owners regarding the presence, 
prevention and control of equine infectious diseases in a breeding stud farm. 
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I. INTRODUCTION 
 
I.1 EQUINE BREEDING IN SPAIN 
 
I.1.1 Brief historical perspective 
 
Breeding based on the exploitation of the equine is one of the most ancient 
activities in Spain. The most ancient vestiges of the horse presence in Spain come 
from the Paleolithic period and appear in the shape of cave paintings that show the 
importance that equines had in the prehistoric systems of life.   
The origin of the horse influence in the Spanish culture coincides with the 
blooming of the first big civilizations in the Peninsula. The Carthaginians 
incorporated horses in great numbers into their armies due to their great resistance 
and strength. Later on, the Romans promoted the horse as a means of transport in 
civil life and in warlike conflicts as a sign of distinction for kings and emperors.  
During the Arabic expansion in Spain, Andalusian horses, which were 
admired by the Arabs, were included as part of a light cavalry in the invading army. 
In addition, important studs were created and horses were even exported to 
Constantinople, Baghdad and other big cities of the Islamic empire.  
After the reconquest, low demand for horses with aptitudes for war together 
with an increasing role in agriculture made mules more important than horses, since 
they were more practical for the hard work.  Nevertheless, at the end of the 15th 
century the monastery of the Carthusian was the cornerstone for breeding of the 
Andalusian horse. Over a period of three hundred years, the Carthusian monks 
established a stud that became one of the most famous and respected studs in the 
world.  
With the French Invasion in the 19th century, the national equine population 
was greatly reduced. In addition, the crossings of Andalusian mares with other 
European breeds, such as the Norman horse, the Trakehner, the Holsteiner and the 
Hanoverian resulted in a serious genetic deterioration to the purebred Spanish 
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equine population. Consequently, in the middle of the 19th century, the veterinary 
schools of Zaragoza, Leon and Cordoba were created, and were dedicated to the care 
and the genetic improvement of the horse in Spain. In 1893 the War Ministry co-
ordinated equine breeding in Spain; stallion studs were funded in Cordoba, Úbeda 
and Valladolid, followed by others in several Spanish cities.   
In 1912 the Department for Equine Breeding created the first studbook in 
Spain in order to register the Arab, Thoroughbred and Anglo-Arab horses, naming 
the traditionally named Andalusian horses as “Spanish Purebred” (SP) horses.  By 
the end of the 20th century, in 1972, the National Association for the Breeders of 
Spanish Purebred Horses (Asociación Nacional de Criadores de Caballos Españoles 
(ANCCE)) was created in Sevilla as a cornerstone for the breeding and genetic 
improvement of the SP horse in Spain.  
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I.1.2 The Spanish Purebred Horse and its present situation 
 
 Although nowadays the SP horse is considered one of the most important 
breeds in the present Spanish equestrian industry, its origins are unclear.   
Studies of mitochondrial deoxyribonucleic acid (DNA) carried out in the 
modern SP horse revealed that both breedlines in the SP breed (Andalusian and 
Carthusian), which originated from Iberian horses, also have an influence of the 
Bereber breed.  Iberian horses located predominantly in the South of the Iberian 
Peninsula were crossed during the Arab invasion in Spain with Bereber horses 
originating in North Africa (Royo et al., 2005). The influence of the Bereber breed, 
together with the work of conservation and recovery carried out by the Carthusian 
monks in the 15th century were probably the foundations of the present breed 
(Valera et al., 2005). 
Following the definition included in the Order APA/3319/2002, the SP horse 
is a eumetric, mesolinear horse with a subconcave to straight profile. It has 
appreciated elevations and extensions and a great ease for collection.  Its character 
is defined as noble, docile and balanced. These qualities make the SP the most 
important pure breed in Spain.  
The management of the Registry (or Stud-Book) is carried out by the 
Department of Equine Breeding (“Cría Caballar”). As of 31st December 2012, this 
department published an equine census with a number of 277,287 purebred 
equidae registered in Spain, of which 175,945 were SP horses (MAGRAMA, 2012). 
The census of SP horses by autonomous community in December 2012 in Spain, is 
shown in Table 1. 
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Table 1. Spanish Purebred Horse census by autonomous community in Spain (December 2012). 
Autonomous Community Spanish Purebred 
Total Horses 
Spanish Purebred 
Horses % 
ANDALUCÍA 
ARAGÓN 
CANTABRIA 
CASTILLA LA MANCHA 
CASTILLA LEÓN 
CATALUÑA 
COMUNITAT VALENCIANA 
EXTREMADURA 
GALICIA 
ILLES BALEARS 
ISLAS CANARIAS 
LA RIOJA 
MADRID 
MURCIA 
NAVARRA 
PAÍS VASCO 
PRINCIPADO DE ASTURIAS 
74,012 
1,760 
1,476 
13,327 
15,358 
16,976 
12,132 
13,544 
4,386 
3,300 
511 
442 
7,255 
7,561 
1,124 
866 
1,915 
42.1 
1.0 
0.8 
7.6 
8.7 
9.6 
6.9 
7.7 
2.5 
1.9 
0.3 
0.3 
4.1 
4.3 
0.6 
0.5 
1.1 
TOTAL 175,945 100.0 
 
Source: Arca database, data as of 31st December 2012 (MAGRAMA, 2012). 
 
According to the census of 2012, the central region of Spain (Castilla La 
Mancha, Castilla León and Madrid) included 20% of the total SP horses in Spain 
(MAGRAMA, 2012). 
In addition, a study on the impact of the equestrian sector in Spain was 
carried out by Deloitte for the Royal Spanish Equestrian Federation and it was 
published in June 2013. This study revealed that, in April 2013, the number of horses 
in Spain was 723,496. There were 220,006 purebred horses and of these, 85% were 
SP horses (187,005 horses) (Deloitte, 2013). According to this study and similarly 
to the census of 2012, the central region of Spain had 23% of the total SP horses in 
Spain. The distribution of pure breeds in Spain and the distribution of SP horses by 
autonomous community published by Deloitte in 2013 are shown in Figure 1 and 
Table 2 respectively. 
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Figure 1. Distribution of pure breeds in Spain. 
Source: Impact of horse industry in Spain. Study published by Deloitte for the National Equestrian 
Federation (June 2013) (Deloitte, 2013). 
 
 
Table 2. Spanish Purebred Horse census by autonomous community in Spain (June 2013). 
Autonomous Community Spanish Purebred 
Total Horses 
Spanish Purebred 
Horses % 
ANDALUCÍA 
ARAGÓN 
CANTABRIA 
CASTILLA LA MANCHA 
CASTILLA LEÓN 
CATALUÑA 
COMUNITAT VALENCIANA 
EXTREMADURA 
GALICIA 
ILLES BALEARS 
LA RIOJA 
MADRID 
MURCIA 
NAVARRA 
PAÍS VASCO 
PRINCIPADO DE ASTURIAS 
78,539 
1,870 
1,870 
14,960 
18,700 
18,700 
9,350 
16,830 
3,740 
1,870 
6 
9,350 
7,480 
1,870 
2 
1,870 
42.0% 
1.0% 
1.0% 
8.0% 
10.0% 
10.0% 
5.0% 
9.0% 
2.0% 
1.0% 
0.003% 
5.0% 
4.0% 
1.0% 
0.001% 
1.0% 
TOTAL 187,005 100.0 
 
Source: Impact of horse industry in Spain. Study published by Deloitte for the Royal Spanish Equestrian 
Federation (June 2013) (Deloitte, 2013). 
Spanish Purebred Spanish x Arab Mallorquin
Menorquin Trotter Thoroughbred
Anglo-Arab Arab Spanish Sport Horse
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According to the data published by the Department of Equine Breeding as of 
31st December 2012, the number of registered SP breeding stud farms in Spain was 
17,933 (MAGRAMA, 2012). 
In addition to being the most numerous breed in Spain, the SP breed accounts 
for the highest number of breeder associations. There are more than 25 different 
breeder associations (there is at least one for every autonomous community). Most 
of these associations are grouped into two federations: the ANCCE and the FENACE 
(Federación de Asociaciones de Ganaderos de Caballo Español). These associations 
continue to play an important role in the development of the SP breed.   
All these data show the high presence of the SP breed in Spain and the 
relevance of the SP horse for the Spanish equine industry.  
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I.2 CHARACTERISTICS OF A SP BREEDING STUD FARM IN 
SPAIN.  
 
Equine stud farms can be classified into five types, according to the activities 
that they are involved in (MAPA, 2003): 
- stud farms for the breeding and selection of pure breeds 
- equestrian facilities  
- breeding farms for the production of horse meat 
- farms associated with other type of farming activity 
- small private farms 
 
The vast majority of SP horses in Spain are bred in stud farms for the 
breeding and selection of pure breeds whether public or private, the latter being the 
most common. Main objectives of private breeding SP stud farms include technical 
development (management, breeding, replacement and training of horses) and 
business development (trade relations, services, sales, etc.). These premises tend to 
have several broodmares, although they do not always have a stallion. The second 
type of stud farms are the private artificial insemination (AI) and breeding centres. 
Breeders from other premises can bring their mares to these centres in search of 
quality genetic material for them. They usually have stallions or equine semen 
banks. They can house their own stallions and also stallions from other breeders, as 
well as mares used for the extraction of the semen (“teaser” mares) and also mares 
owned by other breeders (MAPA, 2003). 
 
The system of exploitation of pure breeds can be semi-intensive or extensive. 
The majority of the SP horse breeding is conducted with a semi-intensive system. 
With this system, the horses are subjected to a more exhaustive control, which 
facilitates higher production. These premises usually have grazing pastures or other 
outdoor facilities where the mares and their foals stay during the day, covered 
paddocks where they stay overnight and stables where the stallions are housed 
(MAPA, 2003). 
 
Due to the nature of the horses and the high investment in each horse, the 
handling and management in these stud farms needs to be specialized. The main 
objective in these farms, given that the gestation period of the mare lasts for 11 
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months, is to obtain one foal per mare and per year. Therefore it is essential that a 
mare conceives in the first days after foaling, which is positively influenced by a good 
reproductive management. Breeding in these stud farms is usually carried out by 
natural covering or AI with fresh or frozen semen. Some stud farms use the embryo 
transfer technique, allowing mares with a high genetic value to continue with their 
career in sport.  All these characteristics of this very common type of regime imply 
a high investment in the facilities, as well as higher maintenance costs than other 
animal productions (MAPA, 2003). 
 
According to the survey conducted by the Department of Equine Breeding in 
a study published in 2003, the average number of horses stabled in the stud farms 
for the breeding and selection of pure breeds was 23.  The majority of stud farms 
(74%) reported having less than 30 horses, while only 4% of the farms that 
responded to this survey had more than 90 horses (MAPA, 2003). 
 
The average SP horse in Spain would therefore be bred in a privately owned 
stud farm with a semi-intensive system of exploitation, by natural covering or AI 
with fresh or frozen semen, and with a total of 23 SP horses.  
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I.2.1 Importance of management for the prevention and 
control of equine infectious diseases in a breeding stud farm. 
 
The concept of health is essential for a breeding stud farm. Horses are 
susceptible to various infectious diseases, some of which are listed as “Diseases of 
compulsory Declaration" or "Annual communication diseases". The authorities with 
competences in the field of Animal Health (Subdirección General de Sanidad Animal 
(SGSA) of the Dirección General de Ganadería (DGG) at a central level and the 
Servicios de Ganadería de las Comunidades Autónomas (C.C.A.A.) at a regional level) 
establish measures for the prevention and control of these diseases, and determine 
a number of sanitary conditions to be imposed in all facilities that host equidae, as 
well as in the transport of these animals. 
 
The SP horse breeding industry differs from other livestock sectors (e.g. 
porcine, poultry, cattle, sheep) in that horses on a SP stud farm are managed at an 
individual, rather than herd level. Thus, each horse is individually treated, and 
horses enter and leave the premises for many reasons (for example to attend 
competitions or morphologic shows, or to other stud farms). This increases the risk 
of introduction and spread of viral and bacterial diseases (Rogers and Cogger, 2010).  
 
The implementation of good management practices for the prevention and 
control of equine infectious diseases is considered essential to reduce exposure to 
these diseases in a stud farm (Timoney and McCollum, 1988). In the United Kingdom 
(UK), guidelines for the management, prevention and control of equine infectious 
diseases (predominantly but not exclusively venereally transmitted) are published 
annually (since 1977) by the Horserace Betting Levy Board (HBLB) via the HBLB 
Codes of Practice (http://codes.hblb.org.uk/). These Codes of Practice have also 
been adopted by Thoroughbred breeders in France, Germany, Italy and Ireland, and 
they provide the horse breeding industry with valuable information regarding 
diseases of the greatest relevance. These diseases are contagious equine metritis 
(CEM), equine viral arteritis (EVA), equine herpesvirus-1 and/or -4 (EHV-1/-4), 
equine coital exanthema (equine herpesvirus-3), equine infectious anaemia (EIA), 
dourine (Trypanosoma equiperdum) and strangles (Streptococcus equi equi) (HBLB, 
2013). These codes of practice have not been implemented yet in Spain and until 
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publication of the Royal Decree 804/2011 for the regulation of sampling, prevention 
and control of EVA and CEM in June 2011 there was no regulation at all regarding 
equine infectious diseases for the equine breeding sector (BOE, 2011). In spite of 
this Royal Decree being a breakthrough for the industry of horse breeding, it only 
covers two of the most relevant infectious diseases for this sector, and currently 
there are no regulations or guidelines for the management, prevention and control 
of the other diseases included in the HBLB Codes of Practice. 
 
The existence of infectious diseases and/or poor management measures in a 
stud farm may cause reproductive problems in mares (such as irregularities in the 
oestrus cycle, anoestrus, repeat breeding, pregnancy loss, dystocia, or problems in 
the neonate) and also in stallions (alterations in any organs of the reproductive 
system, alterations in semen, in the ejaculate, or lack of libido). At present there are 
no data on the prevalence of reproductive problems in SP mares and stallions in 
Spain and the only studies that have been published on this subject were carried out 
either in Lusitano mares [a breed that has plenty of genetic similarities to the SP 
horse (Lopes et al., 2005)] or in Standardbred mares. Lusitano mares had a foaling 
rate (percentage of foalings in the mares within the covered or inseminated mares) 
of 74.5%, which means that 25.5% of mares had a problem that impeded foaling 
(Fradinho et al., 2014), whereas Standardbred mares had a foaling rate of 71% and 
therefore a 29% of mares with a reproductive problem (Katila et al., 2010). 
 
The only parameter that has been evaluated in the SP breed is the length of 
gestation in a study that used Arab and SP mares in the South of Spain (Valera et al., 
2006). The authors of this study noted that the variability in the length of gestation 
was higher in SP compared to Arab mares. Within the SP mares, the greatest number 
of normal foalings took place in the range of ages between 5 and 10 years, whereas 
mares over 14 years had the lowest number of normal foalings (Valera et al., 2006). 
 
In addition to compromising the welfare of the affected horses, any 
reproductive problem in the stallions or mares of a stud farm represents economic 
losses for the owner of the stud farm, since each horse involves a major investment 
of time and money.  
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I.3 EQUINE VIRAL DISEASES OF INTEREST IN A BREEDING 
STUD FARM.  
 
Equine infectious diseases are always a risk for a breeding stud farm. 
However, viral diseases tend to have a greater significance, due to their rapid 
transmission and the lack of specific treatment. Viral diseases associated with 
reproductive problems and/or economic losses in a breeding stud farm include EIA, 
EVA and EHV-1/-4. These three diseases are included in the World Organisation for 
Animal Health (OIE, 2014b) listed diseases and upon appearance, their notification 
to OIE is compulsory (OIE, 2013d). 
 
 
I.3.1 Equine Infectious Anaemia (EIA) 
 
 
I.3.1.1 Aetiology 
 
EIA is a disease caused by EIA virus, which belongs to the Lentivirus genus of 
the Retroviridae family, Orthoretrovirinae subfamily. Other viruses included in the 
same genus are bovine immunodeficiency virus, caprine arthritis and encephalitis 
virus, feline immunodeficiency virus, human immunodeficiency viruses type 1 and 
type 2 and the maedi/visnae virus (OIE, 2013d). 
 
 
I.3.1.2 Epidemiology 
 
The EIA virus is transmitted mechanically by haematophagous biting insects. 
The most effective in the transmission of the virus are biting insects of the Tabanidae 
family (Tabanus spp. and Hybomitra spp.) but the common fly (Stomoxys calcitrans) 
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can also act as a vector (Issel et al., 1988). The virus can also be transmitted through 
transfusions of blood and by the use of contaminated needles, surgical instruments 
or dental floats (Hall et al., 1988). In horses, the virus persists in leukocytes for life, 
and viraemia can occur during episodes of pyrexia (OIE, 2013d). EIA virus is also 
transmitted vertically in the pregnant mare (Kemen and Coggins, 1972; Stein and 
Mott, 1942). Other potential routes of transmission are via milk and semen, which 
carry the virus but appear to need to be inoculated subcutaneously for the virus to 
be transmitted (Stein et al., 1944). These two routes of transmission, although 
unlikely, have been shown in cases of nursing foals and in a mare with a vaginal 
laceration during a natural covering (Stein et al., 1944). The possibility of 
transmission from infectious material through aerosols by direct contact was 
suggested during an outbreak of the disease in 2006 in Ireland, although it was not 
confirmed (More et al., 2008a; More et al., 2008b). 
The incubation period is 7 to 45 days or more. Some horses remain 
asymptomatic until they are stressed. The transmission of the virus depends on the 
number and species of vectors, their feeding habits, the population density of horses, 
the level of viraemia in the host and the amount of blood transferred (OIE, 2013d). 
The infection rate varies with the geographical region; infections are common in 
humid and swampy regions (Sellon, 1993). In premises where the disease has been 
endemic for many years up to 70% seroprevalence rates were observed (Tashjian, 
1984). 
 
I.3.1.3 Pathogenesis and clinical signs 
 
There are several forms of the disease: the acute form in which clinical signs 
include pyrexia, depression, haemorrhages, ataxia, very rapid weight loss, 
haemorrhagic diarrhoea, oedema, jaundice, and petechiae in the mucosae, while  the 
chronic form is characterised by recurrent episodes of pyrexia, depression, anaemia 
and weight loss interspersed with periods of normality; and the subclinical form in 
which clinical signs may be absent but can be exacerbated during periods of 
concurrent disease or stress (Sellon, 1993). 
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The morbidity rate and the severity of the clinical signs are influenced by the 
strain and dose of the virus, and also by the health status of the horse. The disease 
usually goes unnoticed until some horses develop the chronic form of the disease or 
a routine EIA screening test is carried out (Cheevers and McGuire, 1985). Even 
though outbreaks of EIA with high rates of morbidity and mortality have been 
observed, death in naturally infected horses is uncommon; however, the 
experimental inoculation of a high dose of the virus has led to mortality rates of up 
to 80% (Cook et al., 2001). 
 
 
I.3.1.4 Diagnosis 
 
EIA is difficult to diagnose based solely on clinical signs shown by affected 
horses; therefore a combination of various methods is usually required for a 
definitive diagnosis. 
 
Clinical diagnosis 
 
EIA should be among the differentials in horses showing weight loss, oedema 
and intermittent pyrexia, particularly when new animals have been introduced into 
the herd (Garner et al., 2003). The differential diagnoses include other diseases that 
cause pyrexia, oedema and/or anaemia such as EVA, purpura haemorrhagica, 
leptospirosis, babesiosis, a severe infestation by strongylidae or Fasciola hepatica,  
phenothiazine toxicity, autoimmune haemolytic anaemia (Garner et al., 2003). 
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Diagnosis by serology 
 
Serological techniques are the most frequently used in the diagnosis of EIA. 
Infected horses are carriers during their lifetime and therefore they remain 
seropositive. The two most commonly used serological techniques are the agar gel 
immuno-diffusion test (AGID, also called the Coggins test) and several enzyme-
linked immunosorbent assay (ELISA) techniques. There is a third test, called 
Western blot or immunoelectrotransfer; however, it is not officially used and its use 
is restricted to cases where there are equivocal results to the ELISA and the Coggins 
test (Issel and Cook, 1993). 
The Coggins test is an internationally recognized standard for the diagnosis 
of EIA. During its validation, correlation between negative and positive test results 
with the absence or presence of EIA virus in blood, respectively, was evaluated 
(Coggins et al., 1972; Pearson et al., 1971). For this purpose blood samples from 
horses testing positive and negative to the Coggins test were inoculated in 
susceptible horses in order to validate the fact that horses inoculated with blood 
positive to the Coggins test (i.e. with antibodies against the EIA virus) were infected 
while horses that were inoculated with blood negative to the Coggins test (without 
antibodies to the EIA virus) remained free from infection. Given its proven 
reliability, the Coggins test is used worldwide as a reference method in order to 
officially certify absence of infection in horses to be exported or in any movement of 
horses (OIE, 2013d). 
Figure 2. Plate used in the Coggins test. 
 
 
 
 
 
Source: http://www.fao.org   
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The Coggins test presents the typical limitations of all serological tests. For 
example, horses infected by EIA virus tend to be seronegative to the Coggins test 
during the first 2-3 weeks after infection; some cases may even remain seronegative 
up to 60 days post-infection (Issel and Cook, 1993). Foals that acquire passive 
immunity via colostrum from EIA seropositive mares may have a positive Coggins 
test, even though they are not infected by the virus (Issel and Cook, 1993). 
When quality reagents are used and the internationally accepted procedures 
are followed, easily interpretable results are obtained within 24-48 hours (Pearson 
and Gipson, 1988). It is due to this and other advantages that the Coggins test has 
been used since its validation to help eradicate EIA in populations of horses around 
the world (Issel and Cook, 1993). 
ELISA techniques can detect antibodies before the Coggins test and they are 
more sensitive, but can result in false positives (lower specificity) (Singha et al., 
2013; Soutullo et al., 2001). For this reason, positive results for EIA obtained by 
ELISA must be confirmed by the Coggins test, which is the reference technique or 
"gold standard" according to the OIE (OIE, 2013d).  There are different ELISA tests 
for the diagnosis of EIA: the first ever ELISA developed for the diagnosis of EIA was 
a competition ELISA (cELISA) that detected antibodies against p26 antigen of EIA 
virus and it was validated at the end of the 1980s in the United States of America 
(USA) (Matsushita et al., 1989). The advantage of this test is that it is more objective 
than the Coggins test when using an ELISA reader, and it is also faster, since the 
results can be obtained in about two hours (Matsushita et al., 1989). The correlation 
between the results obtained using the Coggins test and the cELISA test is excellent 
provided that the standard protocols are followed (Pearson and Gipson, 1988). 
However, there can be discordant results, mainly due to two causes: the most 
common reason for a positive cELISA result and a negative Coggins test result is a 
low level of antibodies against p26 antigen in the sample, which are more readily 
detectable using the cELISA. The second reason for discordant results is the 
presence in the sample of antibodies directed to the interspecies determinant of p26 
antigen, which are not detected in the Coggins test. This situation could occur in 
horses after the exposure to other lentiviruses present in nature (Issel and Cook, 
1993).   
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Numerous further ELISA tests have been developed for the diagnosis of EIA. 
Some of them detect antibodies produced against the nucleic p26 protein antigen, 
whereas others incorporate p26 protein and gp45 (a viral transmembrane protein) 
antigen (Pourquier, 2010). The current trend is to use ELISA tests based on synthetic 
peptides  (Soutullo et al., 2001) or a recombinant protein produced by a synthetic 
gene so that handling a pathogenic strain of EIA virus can be avoided (Reis et al., 
2012; Singha et al., 2013). Typical ELISA protocols are used in all these techniques 
and all of them have very similar sensitivity and specificity (OIE, 2013d). 
 
Diagnosis by antigen detection molecular techniques 
 
In the diagnosis of EIA techniques such as the polymerase chain reaction 
(PCR) can be used to detect the DNA of EIA virus in the peripheral blood of horses 
(Nagarajan and Simard, 2001). This technique has proven to be sensitive when 
detecting natural strains of EIA virus in blood leukocytes from infected horses 
(Nagarajan and Simard, 2001, 2007). A real time reverse-transcriptase PCR (RT-
PCR) has also been described (Cook et al., 2002). 
PCR and RT-PCR techniques are useful when trying to diagnose infection by 
EIA virus in foals born from infected mares, since the foals may have maternal 
antibodies up to 6-8 months of age. These techniques can also be used as a 
complement or confirmation for the serologic tests, particularly when there are 
conflicting results or when the infection by EIA virus is suspected based on clinical 
signs and serology is negative or equivocal (e.g. in the early stages of the disease 
when an antibody response has still not been developed). Finally, these techniques 
are used as screening tests to ensure that the horses used as blood donors or those 
used in the production of vaccines and antisera are not infected (OIE, 2013d). 
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Diagnosis by whole virus detection techniques 
 
Viral isolation can be undertaken, although it is not usually necessary for the 
diagnosis of EIA. EIA virus can be found in the plasma and blood leukocytes during 
episodes of pyrexia; between these episodes, the virus is only found inside the blood 
leukocytes.  The virus can be isolated from affected horses by inoculating their blood 
in cultures of white blood cells from uninfected horses. The presence of virus in the 
cultures can be confirmed by detecting a specific antigen against the EIA virus by 
ELISA (Shane et al., 1984), by immunofluorescence (Weiland et al., 1982) or using 
molecular tests. Equine leukocytes are difficult to grow; therefore this technique is 
not used in the majority of laboratories. 
When the infection by the EIA virus in a horse is difficult to confirm, a 
susceptible horse can be inoculated with blood from the suspected case; a horse that 
has previously been determined to be negative for antibodies against EIA should be 
inoculated with blood from the suspected case and the status of its antibodies and 
clinical condition should be monitored for at least 45 days.  Usually, the inoculation 
of 1-25 ml of blood is enough to prove the infection, but in some cases the use of a 
greater volume of blood (250 ml) may be required (Coggins and Kemen, 1976). 
 
 
I.3.1.5 Treatment 
 
There is currently no effective treatment for EIA. Supportive therapy to 
relieve clinical signs of the disease are recommended until there is a definite 
confirmation of EIA diagnosis when the slaughter of the horse, which is mandatory 
in many countries (including Spain), is carried out (OIE, 2013d). 
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I.3.1.6 Prevention and control 
 
Many countries have established control measures against EIA. Frequently 
these measures predominantly consist of applying screening tests in horses due to 
be imported or transported. Performing a serological test for EIA in horses that 
come into a premises for the first time is very useful in order to have an EIA-free 
herd (OIE, 2013d). 
 Whereas in many countries the slaughter of any EIA-positive horse is 
mandatory, in other countries such as the United States of America (USA) slaughter 
of EIA-positive horses is not compulsory, although these should be isolated from 
other horses and they should be marked with an iron or a tattoo. In these countries, 
EIA-positive horses can only be transported if they go to their home premises, a 
slaughterhouse or research facilities (USDA, 2007). 
 Mares that are asymptomatic EIA carriers normally give birth to foals which 
are not infected by the virus. The risk of congenital infection increases when the 
mare presents with clinical signs prior to foaling. Foals born from infected mothers 
should be isolated from other horses until it is determined that they are free from 
infection (Garner et al., 2003). 
During an outbreak, spraying to control the insects as well as using repellents 
and mosquito nets on the premises are measures that can help to reduce disease 
transmission. Horses should be separated into small, isolated groups, and caution 
should be taken to prevent iatrogenic transmission through the use of contaminated 
needles. Encapsulated viruses such as EIA virus are easily destroyed with the use of 
disinfectants. EIA virus does not persist in insects; these are just mechanical vectors 
(Cheevers and McGuire, 1985). 
In EIA-free countries, any outbreaks of this disease can be contained by 
establishing quarantines, controlling horse movements, investigating the source of 
infection in the EIA-positive horses and carrying out seroepidemiological 
surveillance (More et al., 2008a; More et al., 2008b). 
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I.3.1.7 Worldwide distribution and seroprevalence studies 
 
EIA has been reported in North America and South America, Europe, Russia 
and South Africa at least since 1970 when the technique for the serologic diagnosis 
was validated (OIE, 2013d). 
According to the OIE, since 2005, EIA outbreaks of clinical disease have 
occurred in countries such as France (2005, 2006, 2007, 2008, 2009, 2010, 2011 
and 2012), Germany (2006, 2009, 2010, 2011, 2012 and 2013), Ireland (2006), UK 
(2006, 2010 and 2012), Uruguay (2007), Greece (2011 and 2012), Belgium (2010, 
2012 and 2013), Hungary (2010), Japan (2011) and the Reunion Island (2013) (OIE, 
2014b).  Even when the situation in Italy and Romania with regards to EIA has not 
been reported to the OIE, these two countries have had regular EIA outbreaks of 
clinical as well as subclinical disease since 2006 and the disease is widely spread 
throughout these countries (Defra). 
During the first six months of 2013, the distribution of EIA in the world, 
according to the OIE, was the following (Figure 3): 
 
Figure 3. Worldwide distribution of EIA in the first six months of 2013 (OIE, 2013a). 
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This map shows that, during the first six months of 2013, EIA outbreaks of 
clinical disease occurred in Canada, Colombia, Ecuador, Nicaragua, Belgium, 
Germany, Russia, Eritrea and Thailand (OIE, 2013a). 
In addition to reported  of outbreaks of EIA clinical disease in many countries 
of the world, there are numerous studies of EIA seroprevalence in countries of the 
five continents, since EIA is an OIE listed disease and therefore notifiable and subject 
to programs of serosurveillance and control in many countries.  
In the American continent, EIA seroprevalence studies have been published 
in countries such as Argentina (Etcheverrigaray et al., 1978), Brazil (Bicout et al., 
2006; Borges et al., 2013) and the USA (Issel and Adams, 1979; Loftin et al., 1990). 
In the African continent there are EIA seroprevalence studies published in Senegal 
in 1976 (le Jan et al., 1976), Guyana in 1981(Bamigboye and da Silva, 1981) and 
Tunisia in 1994 (Boussetta et al., 1994). In Oceania, and more specifically in 
Australia several studies to detect the presence of EIA carriers were conducted in 
1978 in Queensland and Victoria (Harrison, 1978; Thomas and Elder, 1978) and in 
1989 in the western part of Australia (Smith et al., 1980). In Asia there is serologic 
evidence of absence in Turkey and Oman and very limited presence of EIA in India 
(Albayrak and Ozan, 2010; Body et al., 2011; Malik et al., 2013; Yapklç et al., 2007). 
Finally, in Europe EIA seroprevalence studies have been published in the 
Netherlands and Switzerland (de Boer et al., 1979; Kaiser et al., 2009). Table 3 shows 
a summary of the characteristics and results of the EIA seroprevalence studies 
published in different countries all around the world. 
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Table 3. Characteristics and results of the EIA seroprevalence studies published worldwide. 
 
Study reference Country Study period Study area 
Number of 
horses sampled 
Serological assay Seroprevalence estimate 
Etcheverrigaray et al., 1978 Argentina -- Buenos Aires 870 Coggins test 21% 
Borges et al., 2013 Brazil January-June 2010 West 547 Coggins test 31.5% 
Bicout et al., 2006 Brazil 2002 - 2004 Southeast 8,981 Coggins test 
>0 to ≤ 0.5% in 49 cities, 
>0.5% to ≤1, 5% in 26 cities, 
>1.5% to ≤5% in 10 cities, 
>5% to ≤25% in 4 cities. 
Loftin et al., 1990 US 1984 - 1987 Southeast 891,131 Coggins test 1% - 2% 
Issel and Adams, 1979 US 1975 Louisiana 1,398 Coggins test 6.7% 
Le Jan et al., 1976 Senegal 1971 - 1975 Whole country 2,148 Coggins test 0.5% - 0.9% 
Bamigboye and da Silva, 1981 Guyana -- South 226 Coggins test 18.5% – 71.8% 
Bousseta et al., 1994 Tunisia -- North 533 Coggins test 0% 
Thomas and Elder, 1978 Australia 1973 - 1977 Queensland 1,288 Coggins test 21.7% 
Harrison, 1978 Australia 1976 Victoria 1,172 Coggins test 0.085% 
Smith et al., 1980 Australia 1975 - 1977 West 630 Coggins test 0% 
Albayrak and Ozan, 2010 Turkey May – August 2009 Northeast 8,769 ELISA 0% 
Yapklç et al., 2007 Turkey -- Centre 275 Coggins test and ELISA 0% 
Body et al., 2011 Oman 2007 - 2009 Whole country 593 Coggins test 0% 
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Table 3 (continuation). Characteristics and results of the EIA seroprevalence studies published worldwide. 
 
Study reference Country Study period Study area 
Number of horses 
sampled 
Serological assay Seroprevalence estimate 
Malik et al., 2013 India 1999-2012 Whole country 67,042 Coggins test 0.003% 
De Boer et al., 1979 Netherlands 
1963 – 1966 and 
1972 - 1979 
Whole country 
3032 resident horses 
+ 340 horses imported 
from Eastern Europe 
Coggins test 
0.07% in resident horses 
4.41% in horses imported 
from Eastern Europe 
Kaiser et al., 2009 Switzerland 2003 - 2008 Whole country 666 ELISA 0% 
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I.3.1.8 Equine Infectious Anaemia in Spain 
 
EIA was diagnosed for the first time in 1976, when an outbreak of EIA started 
in Madrid, with further cases of EIA clinical disease diagnosed in 1978 in two 
racecourses in Madrid and San Sebastian (Galaz, 1978; OIE, 2014a). Both 
racecourses were quarantined and nearly 900 Thoroughbred racehorses were 
considered at risk until 1983, when the last outbreak was declared resolved 
(Rodríguez, M., personal communication). Spain has been officially free from EIA 
since then, although strict importation control measures were never implemented. 
There are no data regarding the seroprevalence of EIA in the Spanish equine 
population. 
 
 
I.3.1.9 Economic importance and association with 
reproductive pathologies in a stud farm.  
 
Even though the main way of transmission of EIA virus takes place through 
insect vectors, the virus is also transmitted vertically in pregnant mares (Kemen and 
Coggins, 1972; Stein and Mott, 1942) and, although much less efficiently, through 
the semen during the covering of a mare; the presence of EIA virus has been 
determined in the semen from an infected stallion (Metcalf, 2001) and the 
transmission of the virus in a mare with a vaginal laceration during the covering by 
an infected stallion has been confirmed (Stein et al., 1944). 
Pregnant mares that show signs of acute EIA are those having the highest risk 
of infecting the foetus via placenta. Infected foetuses are usually aborted, and when 
born alive they often die in the first two months (Kemen and Coggins, 1972). 
These transmission routes, along with the main through insect vectors, make 
both the clinical and the economic consequences of EIA in a breeding stud farm more 
critical than in any other type of equine farm. The consequences of a possible 
outbreak of EIA in a stud farm include economic losses of great magnitude, mainly 
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due to mandatory euthanasia of affected horses in many countries, the total loss of 
economic value in the EIA carriers in countries where EIA-positive horses can be 
kept alive, the possible abortions caused in infected mares, the restrictions of 
movement that are established in the affected stud farm, the cost of implementing 
vector control measures, and other costs related to measures for the diagnosis and 
control in non-affected horses (OIE, 2013d). 
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I.3.2 Equine Viral Arteritis (EVA) 
 
 
I.3.2.1 Aetiology 
 
EVA is a contagious disease of equidae, named after the characteristic 
inflammatory lesions induced by the causal agent in the small arterioles in an acute 
infection (Bryans et al., 1957a; Bryans et al., 1957b). The disease is caused by a 
ribonucleic acid (RNA) virus, the equine arteritis virus (EAV), which belongs to the 
Arterivirus genus, Arteriviridae family, order Nidovirales (Bryans et al., 1957a; 
Cavanagh, 1997; Snijder and Meulenberg, 1998).  Another virus belonging to the 
same family and of great importance is the virus of the porcine respiratory and 
reproductive syndrome (PRRS) (Plagemann and Moennig, 1992). 
 
 
I.3.2.2 Epidemiology 
 
Exposure to the EAV can occur via respiratory or venereal routes, and can 
result in clinical or inapparent infections, depending on the viral strain involved, the 
dose of the virus, the age and physical condition of the infected animal, and several 
environmental factors (Timoney and McCollum, 1993b). Morbidity rates differ 
between outbreaks, with rates being higher in large concentrations of horses, for 
example in racetracks (McCollum and Swerczek, 1978). In clinical infections, the 
appearance of clinical signs is preceded by an incubation period of 3 to 14 days, 
although it varies according to the route of infection (shorter in the case of a 
respiratory infection, longer if the transmission takes place via the venereal 
route)(Timoney, 2003). 
EAV transmission can also occur vertically in utero, resulting in either 
abortion or the birth of an infected clinically affected foal (Bryans et al., 1957a; 
Golnik, 1992; Vaala et al., 1992). In these cases, the fluids, placenta and the foetus 
are important sources of virus (Timoney, 2003). 
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Finally, less frequently transmission can occur via fomites such as material 
used for handling the affected horses, the equipment used in AI, etc., contaminated 
with infective secretions or excretions (Guthrie et al., 2003; Timoney and McCollum, 
1993b). 
The EAV is not often isolated from affected horses after 28 days post- 
infection, except from semen in stallions that are carriers (Holyoak et al., 2008).  The 
carrier status has only been identified in the stallion, and in some cases after 
experimental infection in pre-pubertal colts (Holyoak et al., 1993a; Holyoak et al., 
1993b). The carrier status occurs in approximately 10-70% of the infected stallions 
after the resolution of the clinical signs (Timoney and McCollum, 2000). In the 
mature stallion the virus can persist for weeks, months, years or even for life in the 
accessory sex glands, being eliminated with the semen in 85-100% of services, 
either by natural mating or AI. The EAV can remain infective in frozen semen for 
years (Timoney, 2000). 
 
 
I.3.2.3 Pathogenesis and clinical signs 
 
The most typical clinical signs of EVA are fever, anorexia, depression, 
leukopenia, the presence of oedema (supraorbital and in the limbs but also in the 
scrotum, foreskin or mammary glands), conjunctivitis, urticaria, abortion in the 
mare and fatal interstitial pneumonia in young foals (del Piero et al., 1997; Golnik et 
al., 1981). 
 
Abortion caused by the EAV in pregnant mares is particularly important due 
to its economic consequences in a stud farm. Abortion may occur in the late acute 
phase or the early convalescent phase of the infection, and it may or may not be 
preceded by clinical signs of EVA in the infected mare (Bryans et al., 1957a; Golnik, 
1992; McCollum and Timoney, 1984; Timoney, 1999; Timoney and McCollum, 
1993b). Abortions have been reported to occur from the third month until the tenth 
month of gestation after a natural or experimental infection with EAV (Coignoul and 
Cheville, 1984; Timoney and McCollum, 1993b; Vaala et al., 1992). Abortion rates 
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published in EVA outbreaks vary between less than 10% to more than 50-60% 
(Timoney and McCollum, 1993b). Exposure to the virus in mares during late 
gestation could lead to vertical transmission and the birth of a foal that is infected 
with the virus. These foals present with progressive interstitial pneumonia, and they 
usually die in the first 3-4 days of life (Golnik, 1992; Vaala et al., 1992). 
 
Stallions infected with the EAV are asymptomatic carriers of the virus, 
although they may show subfertility for a short period that may persist from 16 to 
17 weeks after infection (Neu et al., 1992). 
 
 
I.3.2.4 Diagnosis 
 
There are several techniques that can be used for the diagnosis of EVA and 
each one presents advantages in a particular situation or phase of the disease.  
 
Clinical diagnosis 
 
In the clinical diagnosis of EVA, several equine infectious and non-infectious 
respiratory and systemic diseases may be confused due to the similarity of their 
clinical signs with EVA (Timoney and McCollum, 1993b). Among the most significant 
diseases to be included in the differential diagnosis of EVA are the infection caused 
by EHV-1/-4, equine influenza (EI), purpura haemorrhagica, EIA, urticaria and 
toxicosis by hoary alyssum (Bertero aincana). Additional exotic diseases, which may 
be differential diagnoses for EVA in other countries, include African horse sickness, 
dourine, and Getah virus infection (Timoney, 2003). 
Both abortion and neonatal death caused by EVA are extremely similar to 
those caused by EHV-1 and less frequently, EHV-4; therefore EHV-1/-4 should 
always be on top of the differentials when dealing with a possible EVA outbreak of 
abortions in a stud farm (Timoney, 2003). 
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Diagnosis by serological techniques 
 
Serological tests are used in different situations in the diagnosis of EVA: 
firstly, they can be used in the diagnosis of an acute infection, in this case a specific 
antibody seroconversion in paired sera (acute and convalescent) obtained at an 
interval of 2 to 4 weeks (Timoney and McCollum, 1993b).  Secondly, serology can be 
used to rule out the possible carrier state in a stallion; it is important to establish if 
the stallion is positive or negative for antibodies against the EAV (Timoney et al., 
1987a). Since the carrier status has never been demonstrated in a seronegative 
stallion, only stallions with titres of 1:4 or higher to the virus and no history of 
vaccination against EVA, should be considered potential carriers (Timoney and 
McCollum, 2000). Finally, the serological techniques are very useful for 
seroprevalence studies and serosurveillance surveys. 
Among the validated serological techniques that are most commonly used for 
the diagnosis of EVA are the seroneutralization (SN) (Senne et al., 1985), 
complement fixation (CF) (Fukunaga and McCollum, 1977), indirect 
immunofluorescence (Crawford and Henson, 1972), AGID (Crawford and Henson, 
1972), ELISA tests (Cho et al., 2000; Hedges et al., 1998; Kondo et al., 1998; Nugent 
et al., 2000) and the microsphere immunoassay (MIA)(Go et al., 2008). 
The SN or microneutralization test is currently the reference technique 
according to the OIE and the most widely used worldwide to diagnose EVA cases, 
carry out seroprevalence studies and perform screening before any horse 
movements (OIE, 2013d). Neutralizing antibodies against the EAV persist for many 
years after natural infection or vaccination with an EVA modified live vaccine 
(Timoney and McCollum, 1993b). The sensitivity of the SN test for the detection of 
antibodies against EAV is influenced by many factors, especially the source and the 
number of culture passes of the strain of virus used in the technique (Edwards et al., 
1998). 
The CF test has been used in the past to diagnose recent EVA infections, since 
antibodies that fix the complement have a relatively short average duration equine 
plasma following infection (Fukunaga and McCollum, 1977). This test has been 
replaced by the SN test and the different commercially available ELISAs. 
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Recently a technique of immunoassay based on fluorescent microspheres 
used to detect antibodies against the major structural proteins of the EAV has been 
developed (Go et al., 2008). 
Among the serological techniques, several ELISA tests with an excellent 
sensitivity and a similar specificity to the SN test have been developed (Cho et al., 
2000; Hedges et al., 1998; Kondo et al., 1998; Nugent et al., 2000).  These techniques 
are based on the use of viral antigens from a purified or recombinant virus. The 
discovery of the importance of viral GP5 protein in the stimulation of the humoral 
immune response against the EAV led to the development of several ELISA tests that 
use a part or the whole of this protein (Cho et al., 2000; Hedges et al., 1998). More 
recently, a synthetic peptide conjugated with ovalbumin and representing amino 
acids 81-106 of GP5 protein has been used (Nugent et al., 2000). 
Some of these ELISA tests offer similar levels of sensitivity and specificity to 
the SN technique, and can detect antibodies to the EAV before the SN. Among all the 
ELISA tests validated for the diagnosis of EVA, two have been described more 
recently and appear to be very promising (Cho et al., 2000; Nugent et al., 2000). The 
blocking ELISA validated by Cho et al. in 2000 uses monoclonal antibodies against 
the GP5 protein and has a sensitivity of 99.4% and a specificity of 97.7% with respect 
to the SN (Cho et al., 2000), while the ELISA validated by Nugent et al. in 2000 against 
a panel of 400 SN positive and 400 SN negative sera uses a synthetic peptide 
conjugated with ovalbumin and has a sensitivity and specificity of 96.75% and 
95.6% respectively (Nugent et al., 2000). 
Few of the ELISAs that have been developed have been validated as 
extensively as the SN test, although some of them have been reported to have 
comparable sensitivity and specificity to the SN (Cho et al., 2000; Hedges et al., 1998; 
Nugent et al., 2000). There are also differences in terms of the type of antibodies that 
detect both techniques; whereas SN detects neutralizing antibodies, thus being a 
reflection of the immune protection status of the horse, the ELISAs detect both 
neutralizing and non-neutralizing antibodies (OIE, 2013d). 
ELISA tests have the advantage of not being affected by cytotoxicity in serum, 
and therefore they do not have the delay and difficulties in the interpretation of 
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results that can pose a significant problem in a SN test (Newton et al., 2004). Due to 
this and other advantages ELISA tests are increasingly being used around the world 
for the diagnosis of EVA. Currently there are two commercial ELISA kits for the 
diagnosis of EVA in Spain, Ingezim Arteritis ELISA® (Ingenasa) (Duthie et al., 2008) 
and Id Screen® Equine Viral Arteritis Indirect (Id.Vet) (Legrand et al., 2007). 
Although they both have an excellent sensitivity, in one case (Id Screen® Equine 
Viral Arteritis Indirect) the specificity is higher and it also presents benefits 
associated to results being obtained faster (Legrand et al., 2007).   
 
Diagnosis by antigen detection molecular techniques 
 
Diagnosis of EVA by techniques that detect viral antigen or nucleic acid is 
most useful when an acute infection is suspected. The most suitable samples for 
diagnosis include nasopharyngeal and conjunctival swabs and also peripheral blood 
from the affected horse. In case of an EVA suspected abortion, the viral antigen can 
be detected in placental tissue and fluids, and also in fetal lung, liver and lympho-
reticular tissue (del Piero, 2000a; Higgins, 1993). Finally, these techniques are 
useful in order to confirm the carrier state in a stallion, once it has been established 
that the stallion is positive to antibodies against EVA by serology; the most 
appropriate sample for this is semen containing sperm from the ejaculate 
(Balasuriya et al., 2002; Bryans et al., 1957a; McCollum and Swerczek, 1978). 
Several RT-PCR tests, including nested RT-PCR (RT-nPCR) and real-time RT-
PCR techniques have been validated. The supernatants of cell cultures used for EVA 
virus isolation, as well as clinical samples can be used for these techniques 
(Balasuriya et al., 2002; Chirnside and Spaan, 1990; Ramina et al., 1999; Sekiguchi 
et al., 1995; St-Laurent et al., 1994; Westcott et al., 2003). RT-PCR techniques have 
many advantages over viral isolation techniques; however, a well-planned 
validation has not yet been performed for their use in the diagnosis of abortions and 
confirmation of carrier stallions (Go et al., 2008; Lu et al., 2008). 
EVA antigen can also be detected in tissues and skin biopsies using the 
immunohistochemistry, a reliable, effective and fast technique (del Piero, 2000b). 
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Staining with an avidin-biotin complex (ABC) immunoperoxidase has been used for 
the detection of the viral antigen of the EAV in formalin-fixed tissues, paraffin-
embedded tissues and frozen tissues sections (del Piero, 2000a, b; Lopez et al., 1996; 
MacLachlan et al., 1996). 
 
Diagnosis by whole virus isolation techniques 
 
As with antigen detection by RT-PCR, viral isolation techniques are used 
when an acute infection is suspected (cases of abortions, neonatal deaths, acute 
respiratory infections, confirmation of carrier stallions, etc.). The isolation of the 
EAV is carried out in a limited number of cell lines, of which the RK-13 (rabbit 
kidney) cell line is one of the most useful (OIE, 2013d). The samples used for viral 
isolation are similar to those used in RT-PCR techniques (Balasuriya et al., 2002; 
Bryans et al., 1957a; del Piero, 2000a; Higgins, 1993; McCollum and Swerczek, 
1978). Both types of techniques are complementary, have the same sensitivity and 
are often used together, although the results by RT-PCR techniques are obtained 
much faster (OIE, 2013d). 
 
 
I.3.2.5 Treatment 
 
In the absence of a specific anti-viral drug against EVA, the treatment of EVA 
cases is symptomatic, with an emphasis on controlling the fever and the oedema, 
especially in the affected stallions (Glaser et al., 1997; Timoney and McCollum, 
1993b). Breeding stallions and horses in training should be provided with adequate 
rest in order to minimize the adverse effects of the disease on performance. In foals 
with neonatal disease, the prophylactic administration of antibiotics is indicated to 
control secondary bacterial infections and always considering the risk of lateral 
spread of the virus to other foals or horses in close proximity to the affected animal. 
Safe and effective therapeutic measures to eliminate the carrier status in the stallion 
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have not been developed yet and castration is recommended when a stallion is 
found to be a carrier of the EAV (Timoney, 2003). 
 
 
I.3.2.6 Prevention and control 
 
The methods for the prevention and control of this disease in the equine 
population include on the one hand an effective diagnosis of EVA in clinical 
outbreaks of the disease, and on the other hand the identification of carriers 
(Timoney and McCollum, 1993b; Timoney et al., 1987b). 
 
The carrier stallions should be handled separately in order to ensure that 
there is no risk of unnoticed spread of the virus, especially to the pregnant mares. 
Under appropriate management conditions, carriers can continue being used for 
breeding, although it is recommended that they are only used for covering EVA 
seropositive mares (Timoney, 2003). 
 
There is currently a significant risk of introducing EVA in the equine breeding 
population through the use of fresh or frozen infective semen (Balasuriya et al., 
1998; Timoney, 2000; Timoney et al., 1987b). Therefore, it is important to 
determine the presence of the EAV in the semen used for AI, especially when it has 
been imported from abroad. When working with EVA-positive semen, appropriate 
precautions when inseminating mares should be followed to avoid the risk of 
spreading the virus to susceptible horses (Timoney, 2003). 
Finally, safe and effective vaccines against EVA have been developed (Doll et 
al., 1968; McCollum, 1970; McCollum, 1986; Timoney and McCollum, 1993b) and 
currently there are two commercially available EVA vaccines, one produced with a 
modified live virus (Arvac®, Fort Dodge Animal Health), licensed for use in the US, 
and one with an inactivated virus and adjuvants (Artervac ®, Fort Dodge Animal 
Health), licensed for use in the UK, France, Ireland and Germany, and with a special 
import permit use in Denmark (Doll et al., 1968; McCollum, 1970; McCollum, 1986; 
Timoney and McCollum, 1993b). The modified live virus vaccine is safe and 
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immunogenic in stallions, non-pregnant mares and young horses. The inactivated 
vaccine, although safe for the use in pregnant mares, is not as immunogenic as the 
modified live virus vaccine. While vaccination is part of EVA control programmes in 
some countries, there are no available vaccines in Spain and EVA vaccination is not 
currently permitted. 
 
 
 
I.3.2.7 Worldwide distribution and seroprevalence studies 
 
EVA is present in North America, South America, Europe, Africa, Asia and 
Australia (Huntington et al., 1990a; Timoney and McCollum, 1988, 1991).  Recently, 
as of May 2014, New Zealand was declared to be free from EAV infection (Herrera, 
2014). 
According to the OIE, since 2005 EVA outbreaks have occurred in the UK 
(2005, 2010, 2011, 2012), Israel (2008), Croatia (2008), and Argentina (2010) (OIE, 
2014b). 
During the first six months of 2013, the distribution of EVA in the world, 
according to the OIE, was the following:  
Figure 4 Worldwide distribution of EVA in the first six months of 2013 (OIE, 2013c). 
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This map shows that, during the first half of 2013, there were outbreaks of 
clinical disease in Canada, United States of America, France, Slovenia and 
Switzerland (OIE, 2013c). In the map Spain appears in purple colour, which 
indicates that there was clinical disease limited to one or more areas. As of April 
2013 the International Collating Centre (ICC) published a report of an outbreak of 
abortions produced by EVA in a breeding stud farm located in the South of Castilla y 
León autonomous community (ICC, 2013). This report may have been the trigger for 
the EVA situation of Spain in this map during the first half of 2013. 
Further to the confirmation of clinical EVA in outbreaks in many countries, 
seroprevalence studies have been carried out worldwide. In the American continent 
there is only one study published in 2001 in the USA (Hullinger et al., 2001). In 
Oceania two studies of EVA seroprevalence were carried out in New Zealand and 
Australia (Huntington et al., 1990b; McFadden et al., 2013). In the African continent, 
there are only two references regarding EVA seroprevalence, a study carried out in 
the North-East of Tunisia (Ghram et al., 1994) and a study conducted in France 
where horses residing in several African countries were analysed (Moraillon and 
Moraillon, 1978). Finally, Europe is the continent where most of the studies of EVA 
seroprevalence have been published; there are studies published in Poland (Rola et 
al., 2011), UK (Newton et al., 1999), Germany (Herbst et al., 1992), the Netherlands 
(de Boer et al., 1979), Austria (Kölbl et al., 1991) and France (Moraillon and 
Moraillon, 1978). Table 4 shows a summary of the characteristics and results of the 
EVA seroprevalence studies published in different countries all around the world. 
Most studies were carried out with a representative, random sample of horses; 
however some of them, such as the one published in the UK in 1999 or the one 
published in Germany in 1992 were dependent on ad hoc laboratory submissions 
and a few actively solicited samples (Herbst et al., 1992; Newton et al., 1999). 
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Table 4. Characteristics and results of the EVA seroprevalence studies published worldwide. 
Study reference Country Study period Study area Number of horses sampled Serological 
assay 
Seroprevalence estimate 
Hullinger et al., 2001 USA -- California 
364 horses residing in 
California and 226 imported 
SN 
1.9% (resident horses) 
18.6% (imported horses) 
McFadden et al., 2013 New Zealand 2001 - 2011 Whole country 7,157 SN 0% 
Huntington et al., 
1990b 
Australia 1975 - 1989 Whole country 
58 Thoroughbred and 57 
Standardbred stallions, 914 
Thoroughbred and 481 
Standardbred mares 
SN 
73% Standardbred stallions 
71% Standardbred mares 
8% Thoroughbred stallions 
1% Thoroughbred mares 
Ghram et al., 1994 Tunisia -- North-East 400 SN 8.75% 
Moraillon and 
Moraillon, 1978 
Several African 
countries 
1966 - 1974 -- 468 SN 37.1% 
Rola et al., 2011 Poland 2006 - 2008 -- 176 Hucul horses SN 
55.1% (45% of stallions virus-
positive in semen) 
Newton et al., 1999 UK 1995 - 1996 Whole country 
5,478 Standardbred and 
12,576 Thoroughbred horses 
SN 
18.5 – 24% Standardbred horses 
0-3% Thorougbred horses 
Herbst et al., 1992 Germany 1986 - 1987 Whole country 1905 SN 8.7% 
De Boer et al., 1979 Netherlands 
1963 - 1966 and 
1972 - 1979 
Whole country 283 SN 14% 
Kölbl et al., 1991 Austria 1988 - 1989 Saltzburg and Lower Austria 944 SN 10.9% 
Moraillon and 
Moraillon, 1978 
France 1966 - 1974 Whole country 3,324 SN 15.2% 
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I.3.2.8 Equine Viral Arteritis in Spain 
 
In Spain, serological evidence indicates the presence of EVA since 1978 
(Moraillon and Moraillon, 1978), and in 1992 in Barcelona the first confirmed 
outbreak of EVA clinical disease was reported (Monreal et al., 1995). 
 
According to the OIE there were serological and/or isolation findings of EVA 
in Spain in the years 2000, 2001 and 2002. Eleven years later, in April 2013 the ICC 
published a report regarding an outbreak of abortions produced by the EAV in a 
breeding stud farm located in the South of Castilla y León autonomous community 
(ICC, 2013). 
 
The majority of EAV infections in Spain are sporadic cases, which are not 
usually reported (MAPA, 2003). Despite the surveillance plan published in the 
APA/212/2003 order, which includes the communication and control of diseases 
such as EVA and the establishment of an EVA surveillance programme (BOE, 2003),  
to date there are no studies that have identified or quantified the presence of this 
disease in Spain and there has been only a preliminary, small study carried out in 
the autonomous community of Valencia (East of Spain) which determined antibody 
against EVA by SN in a population of 49 SP horses in 2010-2011. The seroprevalence 
for EVA was 12.24% in this preliminary study (Gimeno Suarep et al., 2011b). Since 
then, there have been no further studies to evaluate and quantify the presence of 
EVA in Spain. 
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I.3.2.9 Economic importance and association with 
reproductive pathologies in a breeding stud farm 
 
EVA can have very significant economic effects for the equine breeding 
(Timoney and McCollum, 1993a; Timoney and McCollum, 1993b). 
There are devastating direct and indirect consequences for the economy of a 
stud farm when an EVA outbreak occurs. The direct consequences of infection by 
EAV are related to its association with reproductive pathology in the mares 
(abortions), death or disease in the newborn foals, and a possible transient decrease 
in the fertility of the infected stallion. The indirect consequences of an EVA outbreak 
are related to the decrease in the market value and decreased demand for carrier 
stallions, the difficulty or impossibility of exporting carrier stallions, EVA positive 
semen and, in some countries, any EVA seropositive horse; and finally the costs 
related to implementation of control measures during an outbreak (i.e. the 
interruption of the training in the stallions, quarantines, restrictions of movement, 
screening tests in all the horses of the stud farm, etc. (Timoney, 2003). 
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I.3.3 Equine Herpesvirus-1 and/or -4 (EHV-1/-4) 
 
 
I.3.3.1 Aetiology 
 
EHV-1 and EHV-4, both members of the Herpesviridae family, produce a set 
of different diseases in horses, including respiratory disease, abortion, neonatal 
pneumonia, or myeloencephalopathy (Allen and Bryans, 1986; Allen, 1999; Bryans, 
1988; Crabb and Studdert, 1995). These diseases represent a challenge to the 
international equine industry.  
Until 1981, EHV-1 and EHV-4 were considered as two subtypes of the same 
virus, called EHV-1. Even though Sabine et al. and Studdert et al. showed the 
differentiation of the two viruses through their viral genomic footprint (Sabine et 
al., 1981; Studdert et al., 1981), the official recognition of distinction as two different 
viruses came a decade later, in 1992 (Roizmann et al., 1992).  
 
 
I.3.3.2 Epidemiology 
 
Herpesviruses are enzootic in the majority of the equine population. Both 
EHV-1 and EHV-4 can be highly contagious and can spread rapidly among animals. 
In an infected animal, the risk of transmitting the disease during the first 10 days is 
very high and decreases significantly after 28 days (Allen, 1999). Transmission 
occurs via the respiratory route, by direct or indirect contact with conjunctival and 
nasal secretions from infected horses. In stud farms with outbreaks of abortions or 
affected foals, transmission in mares usually occurs through contact with the 
placentas and fetal membranes, or the secretions and excretions of infected foals 
(Patel and Heldens, 2005). 
A very important characteristic of these viruses is that they can remain latent. 
Around the 80% of primary infections by EHV-1 and EHV-4 are followed by a state 
of latent viral infection in the trigeminal ganglion of the horse; in this latency state 
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horses are healthy and do not display any clinical signs (Borchers et al., 1999). In 
situations of immunosuppression or stress, viral reactivation can occur, leading to a 
release of viral particles through the nasal secretions and the transmission of the 
virus to other susceptible healthy horses (Allen, 2002). This reactivation is very 
likely to happen also in pregnant mares, resulting in an abortion and consequently 
a possible transmission to other individuals through the foetus and foetal 
membranes (Patel and Heldens, 2005). This mechanism of latency is essential for 
the survival and transmission of EHV-1 and EHV-4 in the population, since the 
horses infected with a latent virus are important reservoirs of the disease (Allen, 
2002). 
 
 
I.3.3.3 Pathogenesis and clinical signs 
 
EHV-1 was first isolated from tissues of aborted foetuses in the USA in 1933 
(Dimock et al., 1947); but retrospective studies identified the virus as a cause of 
abortion in 1921 in Australia (Gilkerson et al., 1998). The infection by EHV-1 can 
progress through the respiratory mucosae, produce a cell-associated viraemia and 
be dispersed to other systems, including the uterus resulting in abortion in the last 
trimester of gestation (Crabb and Studdert, 1995).  Foetuses infected with EHV-1 
during late pregnancy may be born alive, but they become ill one to two days after 
birth. These foals present with weakness, lethargy, fever, lymphopenia, hypoxia and 
severe respiratory problems, with a rapid clinical deterioration and a grave 
prognosis. In EHV-1 outbreaks, the infection can lead to the presentation of 
myeloencephalopathy, which can vary from ataxia accompanied by bladder 
paralysis and retention of faeces to paraplegia or quadriplegia with subsequent 
death (or more commonly slaughter on humane grounds) (Stierstorfer et al., 2002; 
van Maanen, 2001). 
Infection with EHV-4 has been associated with upper respiratory tract 
disease; it rarely produces a cell-associated viraemia and in rare occasions it can 
cause abortion or myeloencephalopathy, although understanding of the role of the 
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virus in the latter is limited (Allen, 2002; Meyer et al., 1987; Verheyan, 1988). 
Respiratory disease occurs predominantly in horses between weaning and 2-3 years 
of age. It is characterized by clinical signs such as fever, lethargy, anorexia, 
submandibular lymphadenopathy and profuse nasal discharge, which can become 
mucopurulent as a result of a secondary bacterial infection. The virus can progress 
to the lungs causing a bronchopneumonia which can be exacerbated by secondary 
bacterial infections, and with signs of lower respiratory tract disease including 
cough, abnormal sounds at auscultation and increased inspiratory effort (Allen, 
2002; Gilkerson et al., 1994). 
 
 
I.3.3.4 Diagnosis 
 
EHV-1/-4 cause a very contagious disease, with a great potential to explosive 
outbreaks with high mortality due to abortions or the sequelae of neurological cases. 
For this reasons, fast and effective methods are needed for the diagnosis of this 
disease. 
 
Clinical diagnosis 
 
As described for EVA diagnosis, in the clinical diagnosis of EHV-1/-4, several 
equine respiratory and systemic diseases may be confused given the similarity of 
their clinical signs with those produced by EHV-1/-4 (Patel and Heldens, 2005).  
Among the most significant diseases to be included in the differential diagnosis 
would be EVA, EI, leptospirosis, diseases caused by other herpesviruses such as 
equine coital exanthema, infections caused by Brucella abortus, Streptococcus 
pyogenes equi, and finally fungal infections such as those produced by fungi of the 
Mucor genus and Aspergillus genus (FAO, 2014). 
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Diagnosis by serological techniques 
 
Serology remains the most popular tool for the diagnosis of EHV-1/-4, even 
though its utility in some situations, such as abortions, is highly reduced due to the 
fact that antibody titres to these viruses are frequently already elevated at the time 
of the abortion (Allen, 1999). It is mostly used in epidemiological investigations of 
EHV-1/-4 or in the serosurveillance of equine populations (Browning et al., 1988a; 
Browning et al., 1988b; Gilkerson et al., 1999b; Singh, 1999; Yasunaga et al., 1998). 
Diagnosis of EHV-1/-4 by serology relies on the demonstration of a 
significant increase in the antibody titres (more than four times) in paired samples 
collected during the acute and convalescent phase of the disease. Serum antibodies 
against EHV-1 and EHV-4 can be detected by ELISA (Dutta et al., 1983), SN 
(Thomson et al., 1976), or CF (Thomson et al., 1976). 
In 1995 Crabb et al. validated a specific ELISA for the diagnosis of EHV-1/-4 
that discriminated EHV-1 from EHV-4, and had a sensitivity of 100% and a 
specificity of 96% (Crabb et al., 1995). More recently, Hartley et al. compared 
different techniques for detecting antibodies against EHV-1/-4 in experimentally 
and naturally infected foals (Hartley et al., 2005).  In this study SN, CF and ELISA 
were used; whereas the ELISA could clearly identify the horses infected with EHV-1 
and those infected with EHV-4, both the SN and CF showed cross-reactivity between 
both viruses (Hartley et al., 2005).  
Even though SN is a very sensitive technique and it is used worldwide, CF and 
ELISA tests have the advantage of providing results more rapidly than SN and they 
do not require facilities for cell culture (OIE, 2013d). The lack of standardised 
reagents or techniques for serological tests in the detection of antibodies against 
EHV-1/-4 often results in variations in antibody titres in the same sample between 
different laboratories. 
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Diagnosis by antigen detection molecular techniques 
 
EHV-1 and EHV-4 nucleic acid or antigen detection techniques are most 
frequently used when an acute infection is suspected.   
Detection of viral antigen by direct immunofluorescence in tissues from 
aborted foetuses is essential for the diagnosis of abortion caused by EHV-1 (Gunn, 
1992). This technique has been compared to viral isolation using cell cultures in 
more than 100 cases of equine abortion showing that both techniques are similar in 
terms of diagnostic reliability (OIE, 2013d).   
Immunohistochemistry techniques, such as the staining with 
immunoperoxidase have been validated and are useful in the detection of the EHV-
1 antigen in paraffin embedded tissues from aborted foetuses or horses affected by 
the neurological form of the disease (Schultheiss et al., 1993; Whitwell et al., 1992).  
Immunoenzymatic staining is particularly useful for the simultaneous evaluation of 
the morphologic lesions and the identification of the infectious agent when EHV-1 is 
suspected. This technique can also be used to diagnose EHV-1 or EHV-4 in a 
monolayer of infected cells (van Maanen et al., 2000).   
Several PCRs with primers specific for EHV-1 and EHV-4 have been 
developed for the detection of virus in clinical samples, paraffin embedded tissues, 
or cell cultures inoculated with the virus (Borchers and Slater, 1993; Lawrence et 
al., 1994; O'Keefe et al., 1994; Tekelioglu, 2005; Varrasso et al., 2001; Wagner et al., 
1992; Wang, 2007); There is a multiplex PCR that can simultaneously detect and 
discriminate EHV-1 and EHV-4 (Ataseven et al., 2009). There is a high correlation 
between PCR techniques and viral isolation in the diagnosis of EHV-1 and EHV-4 
(Varrasso et al., 2001) The diagnosis of EHV-1/-4 by PCR is rapid, sensitive, and does 
not depend on the presence of infectious virus in the sample, thus it has been 
included in the range of routine diagnostic tests for EHV-1 and EHV-4 (OIE, 2013d). 
The most appropriate samples for the diagnosis of an acute infection by PCR are 
samples of aborted foetuses, nasopharyngeal swabs, or peripheral blood from 
affected horses. The diagnosis by PCR may also be done in samples from the spinal 
cord, cerebrospinal fluid (CSF) and brain of horses with neurological signs (OIE, 
2013d). 
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Diagnosis by whole virus detection techniques 
 
Viral detection techniques are used in the same scenarios where antigen 
detection by PCR techniques are used (i.e. when an acute infection - neonatal deaths, 
abortions, neurological form of the disease, acute respiratory infections – is 
suspected). For the isolation of EHV-1 and EHV-4 from nasopharyngeal swabs, 
primary equine foetal kidney cells or cells derived from equine dermal or pulmonary 
tissue fibroblasts are most used, although EHV-1 can also be isolated by using a 
range of non-equine cell lines (Barrandeguy, 1999; Taouji et al., 2002).  Blood 
leukocyte cultures can be used to isolate EHV-1 in the early stages of 
myeloencephalopathy (OIE, 2013d). The basis for the identification of any viruses 
isolated from clinical samples is the immunoreactivity with specific antisera. 
Immunofluorescence techniques are used for the detection of viral antigen in 
infected cell cultures by using specific monoclonal antibodies. This technique is 
effective and very specific; in laboratories where this technique cannot be carried 
out, isolates can be identified using the SN test or a PCR (OIE, 2013d). 
 
 
I.3.3.5 Treatment 
 
Currently there is no specific treatment for EHV-1/-4. In some cases (e.g. in 
neonatal infections by EHV-1, early stages of an outbreak of abortions or 
myeloencephalopathy), antiviral drugs can be administered (Murray et al., 1998). In 
most of the cases, treatment is provided in order to alleviate clinical signs, maintain 
hydration and minimize complications such as secondary bacterial infections (Allen, 
2002). In certain cases of EHV-1 myeloencephalopathy, horses may require 
catheterization of the bladder and antibiotic treatment. The most severe cases of 
myeloencephalopathy with recumbency require intensive support measures, as 
well as lifting the horse with a crane in order to prevent decubitus ulcers; in these 
cases, several days without an improvement are often followed by euthanasia of the 
horse (Allen, 2002). 
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I.3.3.6 Prevention and control 
 
The elimination of EHV-1/-4 from an equine population is virtually 
impossible due to the state of latency of these viruses. The most effective method to 
control EHV-1/-4 relies on prevention through vaccination and the implementation 
of preventive management practices on the premises (OIE, 2013d).   
Vaccination with inactivated or live-attenuated vaccines against EHV-1/-4 is 
an important part of any programme of prevention and control of infectious 
diseases in a stud farm. Foals usually have maternal antibodies against EHV-1/-4 up 
to 5-6 months of age; therefore primary vaccination should be administered just 
before weaning. In premises with a large number of horses, vaccination of the entire 
herd can help reduce the spread of infection due to the benefits of herd immunity. 
Pregnant mares should be vaccinated according to vaccine manufacturers’ 
instructions, thus reducing the risk of abortion storms caused by EHV-1/-4. No 
vaccine to date has shown protection against myeloencephalopathy caused by EHV-
1, and vaccinating does not prevent from the state of latency (Allen, 2002). 
Preventive management strategies include segregating horses in small 
groups in the stud farm, isolating these groups and reducing stress (HBLB, 2013). 
The highest risk of infection by EHV-1/-4 lies in the introduction of new horses to 
established groups, especially new horses coming from competitions, auctions, etc. 
Any newcomers should be isolated for at least 21 days before they are introduced in 
the herd (HBLB, 2013). 
When an outbreak of EHV-1/-4 occurs, the measures already mentioned are 
essential to prevent the spread of the infection and the economic losses. Infected 
horses, as well as those in contact with affected horses should be isolated. The 
movement of horses to and from the stud farm should be restricted until 21 days 
after the last case of rhinopneumonitis. Finally, after the outbreak has been resolved, 
all facilities within the premises should be cleaned and disinfected (HBLB, 2013). 
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I.3.3.7 Worldwide distribution and serological studies 
 
EHV-1 and EHV-4 are distributed worldwide. EHV-4 is enzootic and 
wridespread in many equine populations in the world (Allen and Bryans, 1986; 
Gilkerson et al., 1999a; Matsumura et al., 1992); whereas EHV-1 infection has been 
described in the USA (Allen, 2002; Brown et al., 2007), Australia (Gilkerson et al., 
1999a), Japan (Matsumura et al., 1992), Argentina (Galosi et al., 1998), Brazil (Mori 
et al.), Egypt (Amer, 2011) and Nigeria (Ayedefa, 1992) among other countries. 
According to the OIE, since 2005, EHV-1/-4 outbreaks have occurred in Israel 
(2005, 2008, 2011, 2012), Croatia (2009), South Africa (2009), United Arab 
Emirates (2010) and Chile (2013) (OIE, 2014b). 
 During the first six months of 2013, the distribution of EHV-1/-4 in the 
world, according to the OIE, was the following:  
Figure 5. Worldwide distribution of EHV-1/-4 in the first six months of 2013 (OIE, 2013b). 
 
This map shows that, during the first half of 2013, there were outbreaks of 
clinical disease in Canada, USA, Chile, Argentina, Uruguay, Morocco, UK, France, 
Switzerland, Finland, Russia, Japan, Australia and New Zealand (OIE, 2013b). During 
this period, Spain appears in purple colour in the map, indicating that there was 
clinical disease limited to one or more areas.  
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In addition to the confirmed worldwide presence of outbreaks of EHV-1/-4, 
seroprevalence studies have been carried out in several countries of the world such 
as Colombia (Ruiz-Saenz et al., 2007, 2008), Peru (Rios, 2002), the Netherlands (de 
Boer et al., 1979), Turkey (Ataseven, 2010; Gür, 2008), Lithuania (Liutkevicien, 
2006), and in Tanzania and Namibia in zebras (Borchers and Frolich, 1997; Borchers 
et al., 2005). Table 5 shows a summary of the characteristics and results of the EHV-
1/-4 seroprevalence studies published in different countries all around the world. 
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Table 5. Characteristics and results of the EHV-1/-4 seroprevalence studies published worldwide. 
 
Study reference Country Study period Study area Number of horses 
sampled 
Serological assay Seroprevalence estimate 
Ruiz-Saenz et al., 2007 Colombia -- Region of Meta 68 Indirect ELISA 
0% (EHV-1) 
94.1% (EHV-4) 
Ruiz-Saenz et al., 2008 Colombia -- 
Region of Antioquia 
and Meta 
96 horses in 
Antioquia and 43 in 
Meta 
Indirect ELISA 
18.8% (EHV-1 in Antioquia region) 
33% (EHV-1 in Meta region) 
98.7% (EHV-4 in Antioquia region) 
96.6% (EHV-4 in Meta region) 
Rios, 2002 Peru 2000 - 2001 
Surco, Chorrillos, 
Cieneguilla, Lurín 
and Pachacamac 
448 SN test 39.6% – 48.8% (EHV-1/-4) 
Gür and Yapici, 2008 Turkey -- West and Central 188 Indirect ELISA 
3.7% (EHV-1) 
56.9% (EHV-4) 
60 % (EHV-1/-4) 
Ataseven et al., 2010 Turkey -- East 405 Indirect ELISA 
9.9% (EHV-1) 
64.7% (EHV-4) 
De Boer et al., 1979 Netherlands 
1963 – 1966 and 
1972 - 1979 
Whole country 283 SN test 76 % (EHV-1/-4) 
Liutkevicien, 2006 Lithuania -- Seven herds 114 
Indirect Fluorescent 
Antibody and SN 
86.8% (EHV-1/-4) 
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I.3.3.8 EHV-1/-4 in Spain 
 
According to the OIE,  the first report of EHV-1/-4 in Spain dates back to 1989, 
and since then there have been sporadic outbreaks reported in 2008 (two outbreaks 
with ten cases in total) and 2011 (a single case reported). In addition, according to 
the OIE, Spain reported the presence of EHV-1/-4 without specifying the number of 
outbreaks or affected horses in 2007, 2009 and 2010 (OIE, 2014a; OIE, 2014b).  
 
The only epidemiological study to evaluate the presence of EHV-1/-4 in Spain 
dates back to 1992 and was published by Martín Otero as part of his PhD Thesis 
(Martin Otero, 1992). In this study 202 samples from horses residing in different 
military horse breeding centres in Palencia, San Sebastian, Cadiz, Alcalá de Henares 
and Zaragoza were collected and analysed using an indirect ELISA and SN. The 
percentage of seropositives for EHV (EHV-1 and/or EHV-4) by ELISA was 6.9% 
while this percentage was 4.9% by SN. The indirect ELISA resulted in 2% of false 
positives (Martin Otero, 1992). Since 1992 there has only been a further, small 
preliminary study carried out in the autonomous community of Valencia (East of 
Spain) which determined antibody against EHV-1/-4 by SN in a population of 49 SP 
horses in 2010-2011. The seroprevalence for EHV-1/-4 was 100% in this 
preliminary study (Gimeno Suarep et al., 2011a). Since then, there have been no 
further studies to evaluate and quantify the presence of EHV-1/-4 in Spain.  
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I.3.3.9 Economic importance and association with 
reproductive pathologies in a breeding stud farm 
 
The consequences of an outbreak of EHV-1/-4 in the economy of a stud farm 
are mainly related to its association with reproductive pathology in the mares 
(abortions), and death or disease in the neonatal foals. Outbreaks of 
rhinopneumonitis tend to be on a larger scale than other disease outbreaks, such as 
those of EVA; therefore the economic losses due to abortions and neonatal deaths 
are often devastating. In addition, the presence of carriers with a latent virus means 
that outbreaks of EHV-1/-4 are difficult to prevent and control, since any situation 
of stress or immune suppression in a carrier can trigger an outbreak of abortions 
(HBLB, 2013). 
Even though the respiratory disease caused by EHV-1/- 4 can easily be 
controlled and does not produce sequelae, respiratory disease can spread rapidly 
amongst young horses and can result in more severe situations, such as an outbreak 
of abortions in mares or cases of myeloencephalopathy (Allen, 2002). 
Finally, other economic consequences of an EHV-1/-4 outbreak would be the 
costs related to control measures, the interruption of the stallions training, 
quarantines, movement restrictions, screening tests carried out in all horses, 
disinfection of the premises, etc. (HBLB, 2013). 
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II. RATIONALE, AIMS AND OBJECTIVES 
 
II.1 RATIONALE 
 
The equine industry continues to increase in importance in Spain, with a 
direct and indirect economic impact of more than 5,300 million euro, representing 
the 0.51% of the Gross Domestic Product (GDP) (Deloitte, 2013). 
 
Equine breeding accounts for an economic impact of nearly 543 million euro, 
with most of this impact being attributed to the breeding of SP horses, since this 
breed represents 85% of the pure breed horses in Spain and nearly 100% of 
exportations to Europe and America standing for more than 58 million euro in 2012 
(Deloitte, 2013). 
 
Even though Andalusia is the region with the largest number of registered SP 
horses in Spain, this region is quite static in terms of horse movements and the 
majority of the SP horses reside in private premises with less than 4 horses 
(MAGRAMA, 2012). The central region of Spain (Madrid, Castilla La Mancha and 
Castilla y León), although with a lower number of SP horses than Andalusia, 
accounts for the 20.4% of SP horses and represents a high risk for the introduction 
of equine infectious diseases, being a very frequent stop for horses travelling 
from/to Europe and the region where the largest number of competitions are held 
(Deloitte, 2013; MAGRAMA, 2012). 
 
Equine viral diseases such as EIA, EVA and EHV-1/-4 are important causes of 
breeding problems and economic losses in a stud farm. Most importantly, these 
diseases compromise welfare in the affected horses, causing death in some cases. 
The lack of a specific treatment for them and the speed at which they are spread 
within an equine population strengthen the need for their prevention and control in 
a breeding stud farm.  
 
In order to plan and apply measures of prevention and control against these 
diseases, it is essential to know the current scenario regarding the presence of these 
three diseases and risk factors associated with exposure to these viruses in SP stud 
farms. There are no recent studies published regarding the seroprevalence of EIA in 
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Spain and the only studies to evaluate the seroprevalence of EVA and EHV-1/-4 in 
this country are either historical or carried out in a very small sample (Gimeno 
Suarep et al., 2011a; Martin Otero, 1992). However, the situation in nearby 
European countries is of concern, with EIA outbreaks of clinical disease in Belgium 
and Germany in 2013 (OIE, 2014b) and a seroprevalence estimate of 0.44% for EIA 
in the Netherlands (de Boer et al., 1979), EVA outbreaks of clinical disease in France, 
Switzerland and Spain in 2013 (OIE, 2014b) and studies showing EVA 
seroprevalences ranging from 8.7% in Germany (Herbst et al., 1992) to 55.1% in 
Hucul horses in Poland (Rola et al., 2011), and EHV-1/-4 outbreaks of clinical 
disease in the UK, France, Switzerland, Finland and Spain in 2013 (OIE, 2014b) and 
studies showing EHV-1/-4 seroprevalence results of 76% in the Netherlands (de 
Boer et al., 1979) or 86.8% in Lithuania  (Liutkevicien, 2006). 
 
 
 
II.2 AIMS 
 
The main aim of this study was to evaluate the current situation regarding 
the presence of EIA, EVA and EHV-1/-4 in the SP breeding population in the central 
area of Spain. These results are relevant to veterinary surgeons, and those involved 
in the care of SP horses used in breeding, and they are key in order to establish the 
need for routine serosurveillance measures in SP breeding stud farms.  
 
Additionally, this study aimed to determine the most important 
characteristics and measures of prevention and control of equine infectious diseases 
to take into account when trying to lower the risk of introduction of equine viral 
diseases into SP stud farms.   
 
Finally, the study aimed to investigate whether the SP breeding stallions and 
mares residing in this area were healthy in terms of being free from reproductive 
problems which involve a lower efficiency and higher costs to the breeding.   
 
The information provided by this study will inform the SP breeding industry 
about the need for raising the awareness of the problems that can pose equine 
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infectious diseases in the people related to SP breeding stud farms (stud farm 
owners, veterinary surgeons, stud farm workers) through the implementation of 
Codes of Practice for the most important infectious diseases affecting the breeding 
stock in Spain such as the ones already implemented in other nearby European 
countries (e.g. UK, France, Italy or Germany), which would help to implement 
targeted management strategies and measures of prevention and control of equine 
infectious diseases in the Spanish SP stud farms in order to aid disease prevention 
and, consequently, the associated welfare and financial costs. 
 
 
II.3 OBJECTIVES 
 
 
The main objectives of the study were to: 
 
1. Determine the seroprevalence of EIA, EVA and EHV-1/-4 in the SP 
breeding population in the central area of Spain.  
 
2. Describe the characteristics and management practices with regards to 
the prevention and control of equine infectious diseases implemented in 
the SP breeding stud farms in the central area of Spain.  
 
3. Describe the occurrence and nature of the breeding problems in SP mares 
and stallions in the central area of Spain. 
 
 
The secondary objectives of the study were to:  
 
 Identify any potential risk factors associated with the exposure to the 
infectious diseases of interest (EIA, EVA and EHV-1/-4) within the 
characteristics and management practices regarding the prevention 
and control of equine infectious diseases in SP stud farms in central 
Spain.  
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 Evaluate associations between the exposure to the infectious 
diseases of interest (EIA, EVA and EHV-1/-4) and the occurrence of 
breeding problems in SP mares and stallions in the central area of 
Spain.  
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III. MATERIALS AND METHODS 
 
 
III.1 MATERIALS 
 
III.1.1 Study site 
  
For the purpose of this study, the central region of Spain, comprising the 
provinces of Madrid, Segovia, Ávila, Cuenca, Guadalajara and Toledo, was chosen. 
This area has a total of 67,724 km2, representing 13.4% of the total surface of Spain. 
The total number of inhabitants in this central area as of January 2012 was 
8,022,327, representing 17% of the total Spanish population. Of the provinces in this 
central area, Madrid accounts for the largest number of inhabitants (6,498,560) and 
also the highest density of population (809.5 inhabitants/km2) (INE, 2012). 
The central area of Spain has a variety of climate types, which are 
representative of the whole country. The map with the different climates present in 
Spain, according to the Köppen-Geiger Climate Classification, is shown in Figure 6. 
 
Figure 6. Distribution of the different climate types in Spain. 
 
 
 
 
 
 
 
Source: AEMET. Iberian Climate Atlas (1971-2000) (AEMET, 2011). 
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The provinces of Segovia, Ávila and the North-west (NW) of Madrid have 
similar climate types, according to the Köppen-Geiger Climate Classification, 
including a temperate with a dry season and hot summer climate (CFA), a temperate 
with a dry season and temperate summer (CFB), a temperate with dry or hot 
summer (CSA), a temperate with dry or temperate summer (CSB), a cold with 
temperate and dry summer (DSB), a cold with dry and fresh summer (DSC) and a 
cold steppe climate (BSK). The provinces of Cuenca, Guadalajara, Toledo and most 
of the surface of Madrid have CSA, BSK, CFA and CFB climate types (AEMET, 2011).   
 
Regarding the census of SP horses in the central area of Spain, 21,309 SP 
horses were registered as of 31st December 2012 in this region, accounting for the 
12.1% of the SP horses registered in Spain (MAGRAMA, 2012). Based on census data 
indicating 175,945 registered SP horses and 17,933 registered SP breeding stud 
farms in Spain, and an average of 9.8 SP horses per stud farm, the estimated number 
of SP breeding stud farms in the area of study would be 2,174 (MAGRAMA, 2012). 
 
The area studied has a similar average density of SP horse population to that 
of Spain (0.39 SP horses/km2 in the central area of Spain vs. 0.35 SP horses/km2 in 
Spain). However, within the area of study there are differences in the density of SP 
horse population between provinces; with the lowest SP horse densities observed 
in Guadalajara and Cuenca  (0.03 and 0.04 SP horses/km2 respectively) and the 
highest SP horse density observed in Madrid (0.90 SP horses/km2). SP stud farms 
densities in the area of study have a similar distribution; the central region of Spain 
has a comparable average density of SP stud farms to that of Spain (0.039 SP stud 
farms/km2 in the central area vs 0.035 SP stud farms/km2 in Spain), and the same 
differences apply to the SP stud farm densities between provinces, with the lowest 
SP stud farm densities in Guadalajara and Cuenca (0.003 and 0.004 SP stud 
farms/km2 respectively) and the highest SP stud farm density in Madrid (0.092 SP 
stud farms/km2) (INE, 2012; MAGRAMA, 2012). 
 
The data on the number of registered SP horses, calculated number of SP 
breeding stud farms, area surface and SP horse and stud farm density of population 
in each of the provinces in the central region of Spain is shown in Table 6. 
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Table 6. Distribution of SP horses and stud farms in the central region of Spain. 
Region Area Surface 
(km2) 
SP Stud 
Farms 
SP 
Horses 
SP horses 
density 
SP stud farms 
density 
ÁVILA 
SEGOVIA 
CUENCA 
GUADALAJARA 
TOLEDO 
MADRID 
TOTAL CENTRAL REGION 
8,049.92 
6,922.75 
17,141.13 
12,212.09 
15,369.69 
8,027.70 
67,723.28 
322 
400 
64 
38 
610 
740 
2,174 
3,164 
3,916 
623 
374 
5,977 
7,255 
21,309 
0.39 
0.56 
0.04 
0.03 
0.39 
0.90 
0.39 
0.040 
0.058 
0.004 
0.003 
0.040 
0.092 
0.039 
TOTAL SPAIN 505,968.36 17,933 175,945 0.35 0.035 
 
Source: Arca database, data as of 31st December 2012; Instituto Nacional de Estadística, 2012 (INE, 2012; 
MAGRAMA, 2012). 
 
Finally, the central area of Spain is also the area where the largest number of 
competitions are held, with nearly 31% of the 1616 competitions held in Spain per 
year, followed by Andalusia, with 15.6% of the total competitions held in Spain 
(Deloitte, 2013; MAGRAMA, 2012). 
 
 
 
III.1.2 Population of study 
 
The SP breeding industry differs from the other livestock sectors (such as 
porcine, poultry, bovine or ovine) as management and healthcare measures are 
often applied at individual animal level rather than to the herd as a whole. Thus, 
each horse is individually treated, and horses may enter and leave the premises for 
many reasons (competitions, morphologic shows, other stud farms). The target 
population of this study was the population of breeding SP horses in the central area 
of Spain. Considering the census of SP breeding horses registered as of 31st 
December 2012 in the central area of Spain, the reference population for this study 
were 21,309 horses (MAGRAMA, 2012). 
 
Out of these 21,309 horses in the central region, 52.7% (11,230) were mares 
and 47.3% (10,079) were stallions. Within the SP registered mares, 56.3% (6,322) 
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were registered as active breeders, whereas only the 39.8% (4,011) of all the 
registered SP stallions were active breeders (MAGRAMA, 2012). 
 
Regarding the distribution by age of the SP horse population in the central 
area of Spain, there are no data published in the census of 2012; however, the 
distribution by age within the horses of pure breed (including SP horses but also 
Arab, Thoroughbred, French trotter and other pure breeds) in Spain, in 2001, is 
shown in Figure 7. 
Figure 7. Distribution of horses of pure breed, by age, in 2001. 
Source: Study and characterisation of equine industry in Spain (MAPA, 2003). 
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III.1.2.1 Sample size  
 
Assuming a seroprevalence of 50% for any of the three diseases studied (EIA, 
EVA and EHV-1/-4), a population of 21,309 SP horses in the central area of Spain, 
with a 95% confidence and 5% precision in the determination of seroprevalence for 
these diseases, the minimum sample size was determined to be 378 horses.  The 
sample size calculation for the estimation of a proportion (seroprevalence) was 
carried out with the Win Epi software by using the formula for finite populations 
(De Blas, 2006):   
 
Z2 * p * q * N 
    n = --------------------------    
e2 (N-1) + Z2 p * q 
 
The population of SP registered horses in the central region of Spain was 
stratified by stud farms.  In order to capture the heterogeneity of the SP breeding 
stud farms, eligible premises were identified based on the number of horses and the 
population density in the stud farm, climate of the area (following the Köppen-
Geiger Climate Classification) and distribution in the central region of Spain.  From 
these premises, a convenience sample of stud farms were included following the 
methods proposed by Dohoo et al. (Dohoo et al., 2003), the inclusion criteria were 
the presence of any active SP breeders in the stud farm and the willingness of stud 
farm owner/veterinary surgeon to collaborate in the study, whereas the exclusion 
criteria were the impossibility to draw blood samples from any SP horses in the stud 
farm due to the animals presenting a risk for the person in charge of sampling, and 
the refusal of the veterinary surgeon/stud farm owner to provide the necessary data 
from the animals sampled or the stud farm. 
 
In every stud farm, 100% of the breeding SP stallions were sampled and at 
least 25% of the breeding SP mares were conveniently sampled by means of 
choosing the mares which were easiest to handle. The inclusion criteria for the 
breeding SP stallions and mares were to actively have bred in the past twelve 
months or to have been in contact with other SP breeding stallions/mares, and to be 
considered healthy by means of a clinical examination performed by the stud farm 
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veterinary surgeon, whereas the exclusion criteria were the impossibility to draw a 
blood sample due to the animal presenting a risk for the person in charge of 
sampling, and to be resident in the stud farm for a shorter time than 3 weeks.   
 
Where possible a convenience sample of at least 25% of the SP colts and fillies 
was also taken following the same method as mares; the inclusion criteria for the SP 
colts and fillies were to be older than 8 months of age and to be considered healthy 
by means of a clinical examination performed by the stud farm veterinary surgeon, 
whereas the exclusion criteria were the impossibility to draw a blood sample due to 
the animal presenting a risk for the person in charge of sampling, and to be resident 
in the stud farm for a shorter time than 3 weeks.   
 
In the case of EHV-1/-4, only the samples from horses with a history of non-
vaccination against EHV-1/-4 were analysed and used in the determination of EHV-
1/-4 seroprevalence.  
 
The inclusion of SP stud farms in the study was carried out consecutively 
until the target horse sample size was reached. Between September 2011 and 
November 2013, serum samples were obtained from 555 SP horses residing in 35 
different stud farms in the central region of Spain. 
 
 
 
III.1.2.2 Data collection from the horses included in the study.  
 
Data were collected for each horse meeting study inclusion criteria, including 
sex, age, breeding status, presence/absence of reproductive problems and 
vaccination history for EHV-1/-4.  
 
In breeding stallions and mares with a record of reproductive problems 
within 12 months prior to being sampled for the study, a sex-specific questionnaire 
of reproductive problems was completed. Both questionnaires (reproductive 
problems in the mare and reproductive problems in the stallion) were designed 
following the most typical causes for alteration in the male and female sexual 
function (Smith, 2002).  
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Both questionnaires consisted of a combination of 5 open and multiple-
choice closed ended questions. The questions covered the identification of the 
mare/stallion in the study, the age of the mare/stallion, the number of years as an 
active breeder, a multiple-choice question that included all the most typical causes 
for alteration in the female/male sexual function (as a checkbox list) (Smith, 2002) 
and two open questions in order to specify the cause and/or treatment for the 
reproductive problem. Questionnaires were pretested amongst a group of 
veterinary surgeons, who were not enrolled on the study, and were revised in 
accordance with their comments. They were then administered in a face-to-face 
format, and the veterinary surgeon´s responses were recorded on a printed copy of 
the questionnaire. If requested, the survey was sent to the veterinary surgeon prior 
to collection of data. Data were entered into MS Excel 2007 (Microsoft Corporation, 
Redmond WA, USA). 
 
The questionnaire of reproductive problems in the stallion is shown in 
Appendix 1, and the questionnaire of reproductive problems in the mare is 
presented in Appendix 2. 
 
 
 
III.1.2.3 Data collection from the stud farms included in the 
study.  
 
Once stud farms had met study inclusion criteria, veterinary surgeons 
completed a questionnaire regarding general management and health, with the help 
of the stud farm owner where required.  
 
The questionnaire of general management and health in SP breeding stud 
farms in central Spain (Appendix 3) was designed to cover the characteristics and 
management measures regarding the prevention and control of equine infectious 
diseases in a stud farm. It consisted of 8 sections and a combination of open, closed 
and multiple-choice questions with space for additional comments. The 
questionnaire sections aimed to gather information such as contact data and stud 
farm location, general farm operation size and features, number of horses in the stud 
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farm, groups established in these horses, movement of horses in the stud farm, 
health management of the horses, vaccination and worming regimes, disinfection 
measures, measures against insects and rodents, and finally the breeding 
performance of the breeding stallions and mares of the stud farm.  
 
As for the other questionnaires, it was pretested amongst a group of 
veterinary surgeons, and was revised in accordance with their comments. The 
questionnaire was then administered in a face-to-face format, and the veterinary 
surgeon´s responses with the help of the stud farm owner when necessary were 
recorded on a printed copy of the questionnaire. If requested, the survey was sent 
to the veterinary surgeon or the stud farm owner prior to collection of data. Data 
were entered into MS Excel 2007 (Microsoft Corporation, Redmond WA, USA). 
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III.2 METHODS 
 
 
III.2.1 Sampling procedures 
 
Each of the SP horses included in the study were sampled by means of jugular 
venepuncture using needles and tubes with the Vacutainer® system.  Ten millilitres 
(10 ml) of blood were collected in tubes without an anticoagulant and the tubes 
were identified with the study identification number, consisting of a letter for the 
stud farm and a number for each of the horses sampled.  
The blood samples were transported to the laboratory, where they were 
allowed to clot, and after the clot was formed the samples were centrifuged at 3000 
rpm (revolutions per minute) for 10 minutes using a KUBOTA Compact Tabletop 
2010 centrifuge (Kubota Corporation). Serum was separated using 1.5 ml Pasteur 
pipettes and aliquots of approximately 600 µl serum were placed in 1.5 ml 
Eppendorf tubes. Samples were then frozen at -400C until their analysis.  
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III.2.2 Serological analysis of the samples 
  
The samples collected in the study were analysed for antibodies against EIA 
and EVA. Only the samples from unvaccinated horses were analysed for antibodies 
against EHV-1/-4, since vaccine-induced antibodies cannot be differentiated from 
viral infection-induced antibodies (Allen, 1999). 
  
 
III.2.2.1 Equine Infectious Anaemia serology 
 
EIA serological analysis by ELISA 
 
 The serological technique used for the analysis of antibodies against EIA in 
this study was a double antigen ELISA commercial kit (ID Screen Equine Infectious 
Anaemia Double Antigen ELISA®, ID.vet Innovative Diagnostics) (Pourquier, 2010). 
 This diagnostic kit is designed to detect antibodies directed against the 
Equine Infectious Anaemia Virus (EIAV) in horse sera. It uses two fragment 
antibodies (Fab) on Immunoglobulin G (IgG) and ten Fab on Immunoglobulin M 
(IgM) which either bind the immunoglobulins to the microplate or bind a peroxidase 
antigen used as conjugate. The kit is composed of microplates coated with p26 (Gene 
GAG) recombinant antigen, positive and negative controls, dilution buffer for the 
samples, dilution buffer for the conjugate, p26 antigen-peroxydase conjugate, wash 
concentrate, substrate solution and stop solution (H2SO4 0.5M). Figure 19 shows the 
different components of the EIA ELISA kit. 
  The materials required for this technique that were not provided in the 
commercial kit were a Finnpipette® digital 12 channel 50-300 µl micropipette 
(Sigma Aldrich®, Spain), 10 µl micropipette (PIPETMAN Classic P10®, Gilson Inc.), 
100 µl micropipette (PIPETMAN Classic P100®, Gilson Inc.), disposable tips, 
disposable 300 µl 96-well microplates, distilled water, a 96-well microplate reader 
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(BioTek ELx 800 Absorbance microplate reader, BioTek®) and a printer connected 
to the microplate reader. 
Figure 8. Components of the ID Screen Equine Infectious Anaemia Double Antigen ELISA® used. 
 
 
 
 
 
 
 
 
The microplate wells are coated with p26 (gene GAG) recombinant antigen. 
If there are antibodies against the EIAV in the tested sample, antibodies against p26 
form an antibody-antigen complex. When a p26 antigen-peroxidase conjugate is 
added to the well, it fixes to the free Fab of the bound serum anti-p26 antibodies. 
After adding a substrate solution which binds to the peroxidase producing colour, 
the resulting coloration depends on the quantity of specific antibodies and can be 
measured by using a microplate reader.  
As for the testing procedure, and after all the reagents were allowed to come 
to room temperature, the first step was to prepare the serum samples for the 
analysis; samples were defrosted at 370C in a WS27 SHEL LAB Shaking Water Bath 
(Shelly Scientific®) and, in order to avoid differences in incubation times between 
specimens, a 96-well disposable microplate was prepared with 50 µl of the dilution 
buffer and 50 µl of the sample, positive or negative control. All the specimens, as 
well as the positive and negative controls, were duplicated. One hundred microliters 
(100 µl) of the sample/control dilutions were then transferred into the ELISA 
microplate with p26 coated wells included in the commercial kit using a 
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multichannel pipette, and the microplate was incubated for 30 minutes at room 
temperature (210C ± 50C).  
After the first incubation, the wells were emptied and manually washed 3 
times with approximately 300 µl of the wash solution (previously diluted with 
distilled water). The conjugate was diluted with a dilution buffer, and 100 µl 
conjugate were added to each well. The microplate was then incubated a second 
time for 30 minutes at room temperature.  
After the second incubation, the wells were emptied and manually washed 3 
times with approximately 300 µl of the wash solution (previously diluted with 
distilled water); 100 µl of the substrate solution were then added to each well, and 
the microplate was incubated a third time for 15 minutes at room temperature and 
in the dark. After the last incubation 100 µl of the stop solution were added to each 
well in order to stop the reaction. The microplate was then read at 450 nm with the 
microplate reader and the Optical Density (OD) results were printed. Figure 9 shows 
a scheme of the testing procedure of an indirect ELISA such as the one used in this 
study. 
Figure 9. Scheme of the testing procedure of an indirect ELISA. 
Source: http://www.sanidadanimal.info 
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The test was validated if the mean OD value of the positive control was 
greater than 0.350, and if the ratio of the mean values of the positive and negative 
controls was greater than 3.  For each sample, results were expressed as S/P 
(sample-to-positive control) percentage, which was calculated with the following 
formula: 
 
           ODsample - ODNC 
    S/P % = -------------------------- x 100   
           ODPC - ODNC 
ODNC: mean OD of the negative control 
ODPC: mean OD of the positive control 
ODsample: mean OD of the sample 
 
Samples with an S/P % ≤ 50% were considered negative, samples with an 
S/P % > 50% but < 60% were considered equivocal and samples with an S/P & ≥ 
60% were considered positive. 
According to the manufacturers, the ELISA kit used has a published 
sensitivity and specificity of 100% (Pourquier, 2010). However, while ELISA tests 
are more rapid and easier to interpret than the Coggins test, there are more chances 
of getting false positive results, since they have a lower specificity than the Coggins 
test (Cullinane et al., 2007; Piza et al., 2007). In a study of EIA seroprevalence in the 
Sultanate of Oman the ID Screen Equine Infectious Anaemia Double Antigen ELISA® 
used in this study was reported to have a sensitivity of 100% and a specificity of 
99.3% (Body et al., 2011). Since the Coggins test is the OIE standard confirmatory 
test for EIA, any positive or equivocal samples by ELISA would be tested by Coggins 
test. 
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III.2.2.2 Equine Viral Arteritis serology 
 
EVA serological analysis by ELISA 
 
The serological technique used for the analysis of antibodies against EVA in 
this study was an indirect confirmation ELISA commercial kit (ID Screen® Equine 
Viral Arteritis Indirect, ID.vet Innovative Diagnostics) (Legrand et al., 2009; Legrand 
et al., 2007). 
This diagnostic kit is designed to detect antibodies directed against EAV in 
horse sera. It has a bi-well format and uses specific EAV peptides which bind the 
immunoglobulins to the wells in the even columns of the microplate (the wells in 
the odd columns of the microplate are not coated). When there are antibodies 
against the EAV in the sample, the antibodies bind to the specific EAV peptides and 
these complexes bind to an anti-equine IgG-peroxydase conjugate which will 
produce colour when the substrate solution is added to the well. The resulting 
coloration depends on the quantity of specific antibodies and can be measured by 
using a microplate reader.   
The kit is composed of microplates, positive and negative controls, dilution 
buffer for the samples, dilution buffer for the conjugate, anti-equine IgG-peroxydase 
conjugate, wash concentrate, substrate solution and stop solution (H2SO4 0.5M). 
Figure 20 shows the different components of the EVA ELISA kit. 
  The materials required for this technique that were not provided in the 
commercial kit were a Finnpipette® digital 12 channel 50-300 µl micropipette 
(Sigma Aldrich®, Spain), 10 µl micropipette (PIPETMAN Classic P10®, Gilson Inc.), 
100 µl micropipette (PIPETMAN Classic P100®, Gilson Inc.), disposable tips, 
disposable 300 µl 96-well microplates, distilled water, a 96-well microplate reader 
(BioTek ELx 800 Absorbance microplate reader, BioTek®) and a printer connected 
to the microplate reader. 
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Figure 10. Components of the ID Screen® Equine Viral Arteritis Indirect ELISA used. 
 
 
 
 
 
 
 
 
 
 
As for the testing procedure already shown in Figure 9, and after all the 
reagents were allowed to come to room temperature, the first step was to prepare 
the serum samples for the analysis; samples were defrosted at 370C in a WS27 SHEL 
LAB Shaking Water Bath (Shelly Scientific®) and, in order to avoid differences in 
incubation times between specimens, a 96-well disposable microplate was prepared 
with 180 µl of the dilution buffer and 200 µl of the sample, positive or negative 
control. All the specimens, as well as the positive and negative controls, were 
duplicated. Two hundred microliters (200 µl) of the sample/control dilutions were 
then transferred into the ELISA microplate (100 µl into the even column wells 
coated with the EAV specific peptides and 100 µl into the odd column wells, not 
coated) using a multichannel pipette, and the microplate was incubated for 1 hour 
30 minutes at room temperature (210C ± 50C).  
After the first incubation, the wells were emptied and manually washed 3 
times with approximately 300 µl of the wash solution (previously diluted with 
distilled water). The conjugate was diluted with a dilution buffer, and 100 µl 
conjugate were added to each well. The microplate was then incubated a second 
time for 30 minutes at room temperature.  
After the second incubation, the wells were emptied and manually washed 3 
times with approximately 300 µl of the wash solution (previously diluted with 
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distilled water); 100 µl of the substrate solution were then added to each well, and 
the microplate was incubated a third time for 15 minutes at room temperature and 
in the dark. After the last incubation 100 µl of the stop solution were added to each 
well in order to stop the reaction. The microplate was then read at 450 nm with the 
microplate reader and the OD results were printed.  
For every sample, the mean corrected OD was calculated with the formula: 
ODcorrected sample = ODeven column – ODodd column 
The test was validated if the mean corrected OD value of the positive control 
was greater than 0.350, and if the ratio of the mean values of the positive and 
negative controls was greater than 3.  For each sample, results were expressed as an 
S/P percentage, which was calculated with the following formula: 
 
           ODcorrected sample 
    S/P % = -------------------------- x 100   
           ODcorrected PC 
ODcorrected sample: mean corrected OD of the sample 
ODcorrected PC: mean corrected OD of the positive control 
 
Samples with an S/P % ≤ 50% were considered negative, samples with an 
S/P % > 50% but < 60% were considered equivocal and samples with an S/P & ≥ 
60% were considered positive. When the OD value of the control, uncoated well 
(ODodd column) was higher than the OD value of the coated well (ODeven column), the 
result was considered not interpretable.  
According to the manufacturers, the ELISA kit used has a sensitivity of 100% 
and a specificity of 100%. However, while ELISA tests are more rapid and easier to 
interpret than the SN test, there are more chances of getting false positive results, 
since they have a lower specificity than the SN test (Legrand et al., 2009; Legrand et 
al., 2007). In a validation study carried out by the Beaufort Cottage Laboratories at 
Rossdales, Newmarket, Suffolk, the ID Screen® Equine Viral Arteritis Indirect ELISA 
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used in this study was reported to have a sensitivity of 100% and a specificity of 
96.75% (Beaufort Cottage Laboratories, 2008). Given this specificity, samples with 
a positive, equivocal or not interpretable result were retested by the SN test. 
 
 EVA serological analysis by SN test 
 
The virus SN test measures the capacity of antibody present in serum 
samples to neutralise virus infectivity. In this study, samples with a positive, 
equivocal or not interpretable result by ELISA were sent to the Diagnostic 
Laboratory Services, Animal Health Trust, Newmarket, Suffolk, United Kingdom, in 
order to be retested by SN.  
The test procedure in use was that developed by the National Veterinary 
Service Laboratories of the United States Department of Agriculture, with some 
modifications (Senne et al., 1985). The neutralisation reaction takes place in micro 
plates in which pre-diluted sera are incubated with a Standard Virus Dose in the 
presence of exogenous complement. The samples are then added to preformed 
monolayers of RK13 indicator cells grown in 96 well cell culture micro plates, these 
plates are incubated for 2 days and the wells examined for cytopathic effect (CPE) 
caused by infectious virus. The presence of neutralising antibody is indicated by the 
absence of CPE in wells containing test sera, relative to the Virus Control wells. 
The test was carried out in RK-13 cells using the approved CVL-Bucyrus 
(Weybridge) strain of EAV as reference virus (Edwards et al., 1998). Serum samples 
were inactivated for 30 minutes in a water bath at 56°C. Serial twofold dilutions of 
the inactivated test sera in cell culture medium were made in a 96-well, flat-
bottomed, cell-culture microtitre plate starting at a ½ serum dilution and using four 
rows of wells for each serum to be tested. Serum controls, together with low-, mid 
and high-titred positive control sera were included in each test. A dilution of stock 
virus made up to contain from 100 to 300 TCID50 (50% tissue culture infective dose) 
per 25 µl was prepared using as diluent, 10% cell culture medium containing 
antibiotics and fresh guinea-pig complement at a final concentration of 10%. 
Twenty-five microliters (25 µl) of the appropriate dilution of stock virus was added 
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to every well containing 25 µl of each serum dilution, except the cell control wells 
on each plate. The plates were covered and incubated for 1 hour at 37°C in a humid 
atmosphere of 5% CO2 in air. The contents of each well were then transferred to an 
identical set of plates containing a volume of 100 µl of a monolayer of cells from 1 
day-old cultures of RK-13 cells. The plates were covered with plate sealers and lids, 
incubated at 37°C in a humid atmosphere of 5% CO2 in air and read microscopically 
for non-viral CPE after 18 - 24 hours and again for viral CPE after 48–72 hours’ 
incubation.  
If the control virus titration was < 101.6 TCID50/well, then the plates were 
incubated again, until reaching this target. If the virus titration was >102.4 
TCID50/well, the test was considered invalid.  Those wells with CPE covering > 50% 
of the total monolayer were scored positive, whereas those wells with CPE covering 
≤ 50% of the monolayer were scored negative; these wells were antibody positive. 
The Karber formula [Log10 VN50 = L – d(S – 0.5), where L = negative log of the lowest 
dilution used, d = log difference between dilution steps and S = sum of the 
proportion of negative wells (those showing ≤50% CPE, i.e. neutralised)] was used 
to calculate the log10 VN50 endpoint titres for the EAV SN titrations.  Samples with 
a log10 titration of ≥0.6 were considered positive, whereas samples with a log10 
titration of <0.6 were considered negative. 
When using this technique, not infrequently, sera are encountered that give 
rise to toxic changes in the lower dilutions tested. In such cases it may not be 
possible to establish whether the sample is negative or a low-titred positive. This 
problem may be overcome by carrying out repeated freeze-thaw cycles of the serum 
samples (Geraghty et al., 2005), or by retesting the toxic sample using microtitre 
plates with confluent monolayers of RK-13 cells that had been seeded the previous 
day. Also, the toxicity in serum samples can be reduced or eliminated if the sample 
is adsorbed with a packed suspension of RK-13 cells prior to testing or by 
substituting rabbit in place of guinea-pig complement in the virus diluent (Newton 
et al., 2004). The sensitivity of the SN test for detection of antibodies to EAV can be 
significantly influenced by several factors, especially the source and passage history 
of the strain of virus used (Edwards et al., 1998). 
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III.2.2.3 EHV-1/-4 serology 
 
EHV-1/-4 analysis by ELISA 
 
The serological technique used for the analysis of antibodies against EHV-1/-
4 in this study was an indirect ELISA commercial kit (Ingezim Rinoneumonitis 
14.HVE.K1®, Ingenasa).  
This assay allows the detection of antibody against EHV-1/-4 by using a 96-
well plate coated with a soluble extract of EHV-1 proteins. When an equine serum 
sample contains antibodies against EHV-1/-4, the antibodies bind the antigen 
adsorbed on the plate. After washing to eliminate all non-fixed material from the 
serum sample, the presence of immunoglobulins can be detected by using a specific 
anti-equine IgG-peroxydase conjugate which will produce colour when the 
substrate solution is added to the well (Nakane and Kawaoi, 1974; Sanz et al., 1985). 
The resulting coloration depends on the quantity of specific antibodies against EHV-
1, EHV-4 or both (there is cross-reactivity since both viruses have epitopes in 
common) and can be measured by using a microplate reader.   
The kit is composed of microplates, positive and negative controls, dilution 
buffer for the samples, dilution buffer for the conjugate, anti-equine IgG-peroxydase 
conjugate, wash concentrate, substrate solution, dilution buffer for the substrate 
solution, stop solution (H2SO4) and microplate lids. Figure 21 shows the different 
components of the EHV ELISA kit. 
The materials required for this technique that were not provided in the 
commercial kit were a Finnpipette® digital 12 channel 50-300 µl micropipette 
(Sigma Aldrich®, Spain), 10 µl micropipette (PIPETMAN Classic P10®, Gilson Inc.), 
100 µl micropipette (PIPETMAN Classic P100®, Gilson Inc.), 1000 µl micropipette 
(PIPETMAN Classic P1000®, Gilson Inc.), disposable tips, disposable 1 ml tubes, 
distilled water, a 96-well microplate reader (BioTek ELx 800 Absorbance microplate 
reader, BioTek®) and a printer connected to the microplate reader. 
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Figure 11. Components of the Ingezim Rinoneumonitis 14.HVE.K1® Indirect ELISA used. 
 
 
 
 
 
 
 
 
 
As for the testing procedure (shown in Figure 9), and after all the reagents 
were allowed to come to room temperature, the first step was to prepare the serum 
samples for the analysis; samples were defrosted at 370C in a WS27 SHEL LAB 
Shaking Water Bath (Shelly Scientific®) and, in order to avoid differences in 
incubation times between specimens, 1 ml disposable tubes were prepared with 
495 µl of the dilution buffer and 5 µl of the sample. The positive and negative 
controls were not diluted. All the specimens, as well as the positive and negative 
controls, were duplicated. One hundred microliters (100 µl) of the sample 
dilutions/controls were then transferred into the ELISA microplate using a 
multichannel pipette, and the microplate was sealed and incubated for 1 hour at 
370C in a Memmert 854 incubator (Memmert GmbH & Co).   
After the first incubation, the wells were emptied and manually washed 4 
times with approximately 300 µl of the wash solution (previously diluted with 
distilled water). The conjugate was diluted with a dilution buffer, and 100 µl 
conjugate were added to each well. The microplate was then sealed and incubated a 
second time for 30 minutes at room temperature (250C).  
After the second incubation, the wells were emptied and manually washed 5 
times with approximately 300 µl of the wash solution (previously diluted with 
distilled water); 100 µl of the substrate solution previously diluted with a dilution 
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buffer were then added to each well, and the microplate was sealed and incubated a 
third time for 15 minutes at room temperature and in the dark. After the last 
incubation 100 µl of the stop solution were added to each well in order to stop the 
reaction. The microplate was then read at 405 nm with the microplate reader and 
the OD results were printed.  
The test was validated if the mean OD value of the positive control was 
greater than 0.8, and if the mean OD value of the negative control was lower than 
0.3. The positive and negative cut-off values for the test were calculated using the 
following formulas: 
 Positive cut-off = mean OD of negative control + 0.3 
 Negative cut-off = mean OD of negative control + 0.2 
Samples with a mean OD value higher than the Positive cut-off were 
considered positive, whereas samples with a mean OD value lower than the 
Negative cut-off were considered negative, and samples with a mean OD value 
between the positive and negative cut-off were considered equivocal. 
According to the manufacturers, the ELISA kit used has a sensitivity of 100% 
and a specificity of 67%. Given this specificity, samples with a positive or equivocal 
result were retested by the SN test. 
 
 
EHV-1/-4 serological analysis by SN test 
 
In this study, samples with a positive or equivocal result by ELISA were sent 
to the Diagnostic Laboratory Services, Animal Health Trust, Newmarket, Suffolk, 
United Kingdom, in order to be retested by SN.  
This serological test was performed in flat-bottom 96-well microtitre plates 
using a constant dose of virus and doubling dilutions of equine test sera. Ten percent 
(10%) medium was used throughout as a diluent and virus stocks of known titre 
were diluted just before use to contain 100 TCID50. Monolayers of E-Derm equine 
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embryonic cells were monodispersed with EDTA/trypsin and resuspended at a 
concentration of 5 × 105/ml for their use.  
As for the testing procedure, serum samples to be tested were inactivated for 
30 minutes in a water bath at 56°C. Twenty-five microliters (25 µl) of 10% medium 
were added to all wells of the microtitre assay plates, and 25 µl of each test serum 
were pipetted into the first wells of triplicate rows of the plate. Doubling dilutions 
of each serum were made across the plates by sequential mixing and transfer of 25 
µl to each subsequent well. Four sera were assayed in each plate per antigen.  
After that, 25 µl of the appropriately diluted EHV-1 or EHV-4 virus stock were 
added to each well (100 TCID50/well). The final serum dilutions, after addition of 
virus, ran from 1/4 to 1/256. A separate control plate included titration of a positive 
horse serum of known titre, cell control (no virus), and a virus titration to calculate 
the actual amount of virus used in the test. The plates were incubated for 1 hour at 
37°C in 5% CO2 atmosphere, and after the incubation 25ul of guinea-pig complement 
diluted 1:4 in 10% medium was added to each well. The plates were then incubated 
for a further hour at 37°C in 5% CO2 atmosphere.  150 µl of the prepared of Equine 
Embryonic cell suspension (2 × 105 cells/ml) were added to each well. Finally the 
plates were incubated for 4–7 days at 37°C in an atmosphere of 5% CO2 in air.  
The plates were microscopically examined for CPE and the results were 
recorded on a worksheet. The actual amount of virus added to each well should be 
between 101.6 and 102.4 TCID50 for the test to be validated. Wells were scored as 
positive for neutralisation of virus if 50% of the cell monolayer remained intact. The 
highest dilution of serum resulting in complete neutralisation of virus (no CPE) in 
both duplicate wells was the end-point titre for that serum. As for EHV-1, samples 
with a log10 titration of ≥2.3 were considered positive, whereas samples with a log10 
titration of <2.3 were considered negative. For EHV-4, samples with a log10 titration 
of ≥2.0 were considered positive, whereas samples with a log10 titration of <2.0 
were considered negative. 
 
 
 105 
 
III.2.3 Data analysis and statistics  
 
The apparent seroprevalence (AS) for the three diseases of study was 
estimated by the percentage of seropositive results obtained by each technique 
(ELISA and SN test) within the total number of horses sampled (555 SP horses 
sampled for EIA, EVA and 334 non-vaccinated horses for EHV-1/-4).  
 
The determination of true seroprevalence (TS) for ELISA tests used was 
carried out by using the following formula, which took into account the AS, the 
sensitivity (SE) and specificity (SP) of the test.:  
(AS + SP – 1) 
    TS = --------------------------    
(SE + SP – 1) 
The “gold standard”, reference SN tests carried out for EVA and EHV-1/-4, 
were assumed to have a perfect sensitivity and specificity and therefore the 
apparent seroprevalence was assumed to be equal to the true seroprevalence. For 
every disease analysed, 95% confidence intervals (CI) were calculated for each 
seroprevalence percentage given a sample size and a reference population size (De 
Blas, 2006). The results from EVA and EHV-1/-4 SN tests were used for further 
analysis of data with regards to the identification of risk factors for exposure to these 
equine diseases.  
As for the data from individual horses and the characteristics, management 
measures and measures of control of equine infectious diseases of each stud farm, 
the initial examination, data coding and descriptive analyses were conducted using 
Excel (Microsoft). Descriptive statistics were produced for quantitative variables 
[mean, standard deviation (SD), median, maximum and minimum, interquartile 
range (IR)] and qualitative variables (absolute and relative frequencies). All further 
analyses were conducted using SPSS® software (IBM®).  
As for individual variables (i.e. sex, age, etc.) and stud farm variables 
(variables regarding the characteristics, and management practices in the stud 
farm), an univariable analysis was made by using a Chi-squared (χ2) or Fisher´s 
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exact contingency table analysis as well as an ordinary logistic regression in order 
to obtain odds ratios (OR) with 95% CI. SPSS for Windows (SPSS Inc. version 18) 
was used for the data analysis. 
A multivariable analysis was performed on all individual and stud farm 
variables by creating a decision tree through the Chi-square automatic interaction 
detector (CHAID) (Kass, 1980), as it offered the capacity to combine categorical and 
continuous variables. This procedure is a non-parametric analysis based on 
statistically recursive partitioning algorithms that classify independent variables 
into predictor values of a dependent outcome. EVA VN status or EHV-1/-4 VN status 
in the SP horses sampled in the study was set as the dependent outcome, while 31 
independent outcomes were tested. Exhaustive CHAID analysis results were 
presented in decision trees, which provide a hierarchical visual depiction of 
predictor variables interactions. The independent variables that were significantly 
associated with the dependent outcome were classified in nodes. The variable at the 
highest level of the tree was determined to have the closest statistical association 
with the dependent outcome, and was represented as the first node. Subsequent 
associations were classified in consecutive nodes. Groups were split under the 
following criteria: tree depth was limited to three levels and the minimum number 
of cases per node for parent nodes was ten. Statistical significance was established 
at the 95% confidence level. SPSS for Windows (SPSS Inc. version 18) was used for 
the data analysis. Standard post-fit diagnostic tests were conducted to evaluate the 
decision tree model including Hosmer-Lemeshow goodness-of-fit test and a receiver 
operating characteristic (ROC) curve was generated with calculation of area under 
the curve (AUC).  
Finally, the prevalence of reproductive problems in the SP breeding horses 
(>2 years old) within the preceding 12 months was calculated and descriptive 
statistics were produced. The nature of the reproductive problems was reported 
and these data were used in order to identify any associations with the presence of 
EVA and/or EHV-1/-4 antibodies using Chi-squared (χ2) or Fisher´s exact 
contingency table analysis and also ordinary logistic regression analysis to obtain 
OR with 95% CI.  
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IV. RESULTS 
 
IV.1 CHARACTERISTICS OF THE SP HORSE POPULATION 
SAMPLED. 
 
Between September 2011 and November 2013, serum samples were 
obtained from 555 SP horses residing in 35 different stud farms in the central region 
of Spain. The percentages of the horses sampled in each province of this region 
matched that of 2012 census, as shown in Figure 12. 
 
Figure 12. Distribution by province of 555 SP horses sampled in Central Spain in comparison 
with the distribution of the general SP breeding population in central Spain published in the 
census of 2012 (n=21,309).  
Source: Arca database, data as of 31st December 2012; Instituto Nacional de 
Estadística, 2012 (INE, 2012; MAGRAMA, 2012). 
 
The subset of horses unvaccinated against EHV-1/-4 used as sample 
population for EHV-1/-4 seroprevalence (n=334 horses) had a similar distribution 
by province in central Spain than the whole sample population (n=555 horses). 
However, there were no data of the EHV-1/-4  unvaccinated horse population in 
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central Spain and therefore Figure 13 shows the distribution by province of this 
subset of horses (n=334) in comparison with the general SP breeding horse 
population in central Spain. 
 
Figure 13. Distribution by province of 334 EHV-1/-4 unvaccinated SP horses sampled in 
Central Spain in comparison with the distribution of the general SP breeding population in 
central Spain published in the census of 2012 (n=21,309). 
 
Source: Arca database, data as of 31st December 2012; Instituto Nacional de 
Estadística, 2012 (INE, 2012; MAGRAMA, 2012). 
 
Figures 14 to 19 show the stratification of the SP horses included in the study 
(n=555) and the subset used for EHV-1/-4 seroprevalence (n=334) by sex, age, and 
breeding status.  
 
Regarding the distribution of the sample by sex, mares represented a slightly 
higher proportion of the sample (Figure 14). No geldings were sampled in this study.  
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Figure 14. Distribution by sex of 555 SP horses sampled in Central Spain. 
 
 
 
 
 
 
 
 
 
 
 The distribution by sex of the subset of EHV-1/-4 unvaccinated horses used 
for EHV-1/-4 seroprevalence showed slightly changed percentages, with stallions 
being more numerous in this sample (Figure 15). 
 
Figure 15. Distribution by sex of 334 EHV-1/-4 unvaccinated SP horses sampled in Central Spain 
 
 
 
 
 
 
 
 
 
 
The ages of the horses in the sample (n=555) ranged from 0.7 to 24 years, 
with a mean age of 7.3 years ± SD 5.0 years, a median age of 6 years and interquartile 
range (IR) of 4 – 10 years. Figure 16 shows the distribution by age group of the SP 
horses included in the study.  
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Figure 16. Distribution by age group of the SP horses sampled in Central Spain (n=555). 
 
 
The ages of the horses in the subset of unvaccinated horses used for EHV-1/-
4 seroprevalence (n=334) ranged from 0.7 to 24 years, with a mean age of 6.7 years 
± SD 4.7 years, a median age of 5.5 years and interquartile range (IR) of 3 – 9 years. 
Figure 17 shows the distribution by age group of the subset of EHV-1/-4 
unvaccinated horses included in the study. 
 
Figure 17. Distribution by age group of the EHV-1/-4 unvaccinated SP horses sampled in 
Central Spain (n=334). 
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 Regarding the stratification of the sample (n=555) by breeding activity, 
Figure 18 shows that the majority (63%) of the horses were active breeders. Within 
the active breeders, nearly three quarters (74%) were mares and 26% were 
stallions. However, within the inactive breeders (horses aged ≥ 3 years old that had 
been inactive for the past 12 months) and the pre-pubertal horses (horses < 3 years 
old), the proportions of females and males were the opposite. The stratification of 
the subset of EHV-1/-4 unvaccinated horses (n=334) by breeding activity showed 
the same distribution as the general sample population (Figure 19). 
 
Figure 18. Distribution by breeding activity of the 555 SP horses sampled in Central Spain. 
 
 
Figure 19. Distribution by breeding activity of the 334 EHV-1/-4 unvaccinated SP horses 
sampled in Central Spain. 
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 Of the horses currently used for breeding in the sample of SP breeding horses 
of central Spain, 23% (n=80/348) were reported to have had at least one 
reproductive problem in the past 12 months. Out of these, 92% were mares and 8% 
were stallions (Figure 20).  Within the active breeding mares, 29% (n=74/257) had 
a history of reproductive problems, whereas within the active breeding stallions, 
only 7% (n=6/91) were reported to have reproductive problems. A similar picture 
was observed in horses used for breeding in the subset of EHV-1/-4 unvaccinated 
SP horses (n=171), which is shown in Figure 21. 
 
Figure 20. History of reproductive problems within the active SP breeders sampled in Central 
Spain (n=348, 80 SP breeders with and 268 SP breeders without reproductive problems in the 
past 12 months). 
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Figure 21 History of reproductive problems within the active EHV-1/-4 unvaccinated SP 
breeders sampled in Central Spain (n=171, 30 SP breeders with and 141 SP breeders without 
reproductive problems in the past 12 months).  
 
 
 
 
 
 
 
 
 
 
 
Figure 22 shows the proportion of horses vaccinated and unvaccinated 
against EHV-1/-4 in the sample (n=555). The majority of horses (60.2%) included 
in the sample were unvaccinated against EHV-1/-4. Within the vaccinated horses, 
the number of vaccinated mares was significantly greater than the number of 
vaccinated stallions (p<0.0001). 
  
Figure 22. Distribution of horses vaccinated and unvaccinated against EHV-1/-4 in the sample 
(n=555, 334 unvaccinated and 221 vaccinated SP horses).  
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IV.2. DISTRIBUTION OF THE SP BREEDING STUD FARMS 
SAMPLED. 
 
Regarding the distribution of the 35 SP stud farms included in this study, 16 
stud farms were located in the province of Madrid, whereas 3 were located in Ávila, 
4 were located in Segovia, 6 in Toledo, 3 in Cuenca and 3 in Guadalajara. Figure 23 
shows the study area and the distribution of the 35 stud farms sampled in the central 
area of Spain.  
Figure 23. Distribution of the SP stud farms sampled in the central area of Spain. 
 
As shown in Figure 24, the 35 stud farms included in this study had locations 
with the most representative climates of Spain: 48% of the stud farms with a 
temperate with dry or hot summer climate (CSA), this climate representing the 40% 
of the Spanish territory, 23% of the stud farms with a temperate with dry or 
temperate summer climate (CSB), 23% of the stud farms with a cold steppe climate 
(BSK), 3% of the stud farms with a cold with temperate and dry summer (DSB) and 
3% of the stud farms with a temperate with a dry season and hot summer climate 
(CFA) (Rubel and Kottek, 2010). 
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Figure 24. Köppen-Geiger climatic map with the distribution and different climates of 
the SP stud farms sampled in this study. 
 
Within the 35 SP stud farms sampled in this study, 5 had an EHV-1/-4 
vaccination regime in all the horses and therefore they were excluded from any 
further analysis related to EHV-1/-4; these stud farms were located in Cuenca (n=1), 
Madrid (n=1), Toledo (n=2) and Segovia (n=1) and had locations with CSA climate 
(n=3), BSK climate (n=1) and CSB climate (n=1). 
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IV.3 SEROPREVALENCE RESULTS 
 
 
IV.3.1 Seroprevalence of Equine Infectious Anaemia  
 
After testing the 555 serum samples for EIA antibodies by ELISA, all samples 
were identified as negative. Figure 25 shows an EIA ELISA test where wells A1 and 
A4 were positive controls, wells B1 and B4 were negative controls, and the rest of 
the wells were samples with a negative result.  
Figure 25. Example of an EIA ELISA test carried out in this study. 
 
 
 
 
 
 
 
 
Based on a census-derived population size of 21,309 SP breeding horses in 
the central area of Spain (MAGRAMA, 2012) and a sample size of 555 SP horses 
serologically screened in this study using an ELISA test with a published sensitivity 
of 100%, there was evidence with 95% confidence that the true prevalence of EIA 
among SP breeding horses in central Spain was between 0% and 0.53% (De Blas, 
2006). 
Regarding the maximum possible stud farm seroprevalence, based on a 
census-derived number of 2,174 SP stud farms registered as of 31st December 2012 
in the central area of Spain (provinces of Segovia, Ávila, Madrid, Guadalajara, Cuenca 
1 2 3 4 5 6
C+ C+ 
C- C- 
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and Toledo) (MAGRAMA, 2012) and a sample size of 35 SP stud farms serologically 
screened in this study using an ELISA test with a published sensitivity of 100%, 
there was evidence with 95% confidence that the true prevalence of EIA among SP 
stud farms in central Spain was between 0% and 8.14%.  
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IV.3.2 Seroprevalence of Equine Viral Arteritis 
  
Using an ELISA with a published sensitivity of 100% and a specificity of 
96.75% (Beaufort Cottage Laboratories, 2008), 106 out of 555 serum samples were 
positive for antibodies against EAV, whereas 8 samples gave equivocal results and 
14 were not interpretable (NI). Figure 26 shows an EVA ELISA test in a bi-well 
format where wells A1-A2 and H11-H12 were positive controls, wells B1-B2 and 
G11-G12 were negative controls, wells C7-C8 were a sample with a NI result, wells 
G3-G4 were a sample with a equivocal result, wells E1-E2 for were an example of a 
serum without antibody against EAV and wells A5-A6 were an example of a serum 
with antibody against EAV.  
Figure 26. Example of an EVA ELISA test carried out in this study. 
 
 
 
 
 
 
 
 
The true EVA seroprevalence (TS) for the ELISA test used, with a sensitivity 
of 100% and a specificity of 96.75%, for an apparent seroprevalence of 19.1% and  
95% confidence, was 16.4% (12.8% - 20%).  
 
When the positive, equivocal and NI samples were retested using the SN test, 
92 out of 106 positive samples by ELISA were positive by SN, 2 out of 8 equivocal 
samples by ELISA were positive by SN, and 2 out of 14 NI samples by ELISA were 
positive by SN. A total of 96 samples were therefore positive for EVA by SN (i.e. had 
1 2 3 4 5 6 7 8 9 10 11 12
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a log10 titre of ≥ 0.6). The results of both the EVA ELISA and EVA SN for each of the 
horses sampled in the study are shown in Appendix 4.  
 
The true seroprevalence for EVA using the SN test (gold standard test) in the 
population of this study, with 95% confidence was 17.3% (14.2% - 20.4%).  
 
Within the 96 EVA seropositive SP horses in the study, 15% had EVA SN log10 
titres ≥ 0.6 and < 2, whereas 18% had EVA SN log10 titres ≥ 2 and < 2.5, 28% had 
log10 titres ≥ 2.5 and < 3, 25% had log10 titres ≥ 3 and < 3.5, and finally 15% had 
log10 titres of ≥ 3.5. Figure 27 shows the number of seropositive SP horses 
distributed by EVA log10 titre.  
 
Figure 27. Number of seropositive SP horses distributed by EVA log10 titre (n=96). 
 
Regarding the stud farms sampled in this study, 13 out of 35 (37.1%) had 
horses which were seropositive to EAV by SN. The stud farm seroprevalence for EVA 
in the population of this study, with 95% confidence was between 21.1% and 53.1%. 
Out of the 13 EVA seropositive stud farms, 5 (38.5%) showed a seroprevalence of < 
30%, whereas 6 (46%) showed a seroprevalence between 30% and 60% and 2 
(15.5%) showed a seroprevalence of > 60%. 
 
The distribution of the EVA seropositive SP stud farms (black dots) within 
the central area of Spain is shown in Figure 28. Fifty percent (50%) of the SP stud 
farms sampled in the NW of this central area were seropositive for EVA, whereas 
0 5 10 15 20 25 30
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≥ 2 to < 2.5
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≥ 3 to < 3.5
≥ 3.5
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40% were seropositive in the South-West (SW), 25% were seropositive in the South-
East (SE) and none were seropositive in the North-East (NE).  
 
Figure 28. Distribution of EVA seropositive stud farms in the area of study. 
 
 
 
 
 
 
 
 
The distribution of the EVA seropositive SP stud farms (black dots) within 
the different climate areas in the central area of Spain is shown in Figure 29. Forty-
one percent (41%) of the SP stud farms in a location with CSA climate (temperate 
with dry or hot summer climate) were seropositive, whereas 37.5% of the stud 
farms in a location with BSK climate (cold steppe climate) were seropositive, 25% 
of the stud farms in a location with CSB climate (temperate with dry or temperate 
summer climate) were seropositive, and 100% (1 out of 1 stud farm) in a location 
with DSB or CFA climate (cold with temperate and dry summer or temperate with a 
dry season and hot summer respectively) were seropositive.  
 
Figure 29. Distribution of EVA seropositive stud farms within the different climate areas in the 
area of study (n=35). 
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IV.3.3 Seroprevalence of EHV-1/-4 
 
Using an ELISA with a sensitivity of 100% and a specificity of 67% according 
to the manufacturers, 179 out of 334 serum samples were positive for antibodies 
against EHV-1/-4, whereas 72 samples gave equivocal results. Figure 30 shows an 
EHV-1/-4 ELISA test where the well A1 is a positive control, well B1 is a negative 
control, wells A3 or D2 are examples of sera with a positive result, wells C1 or D1 
are examples of sera with a negative result and wells A2 or F1 are examples of sera 
with an equivocal result.  
Figure 30. Example of an EHV-1/-4 ELISA test carried out in this study. 
 
 
 
 
 
 
 
 
The true EHV-1/-4 seroprevalence (TS) for the ELISA test used, with a 
sensitivity of 100% and a specificity of 67%, for an apparent seroprevalence of 
53.6% and 95% confidence, was 30.7% (22.7% – 38.8%).  
 
When the positive and equivocal samples were retested using the SN test, 
141 out of 179 positive samples by ELISA were positive for either EHV-1, EHV-4 or 
both by SN, and 37 out of 72 equivocal samples by ELISA were positive for either 
EHV-1, EHV-4 or both by SN.  A total of 178 samples were therefore positive for 
either EHV-1, EHV-4 or both by SN (i.e. had a log10 titre of ≥ 2.3 for EHV-1 and/or 
≥2.0 for EHV-4).  Out of these 178 positive samples, 90 (50.6%) were positive for 
1 2 3 4 5 6 7 8 9 10 11 12 
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EHV-1 only, 80 (44.9%) were positive for both EHV-1 and EHV-4 and only 8 (4.5%) 
were positive for EHV-4 only. Figure 31 shows the percentages of horses that were 
seropositive to EHV-1, EHV-4 or both EHV-1 and EHV-4 in the VN test. 
 
Figure 31. Percentage of SP horses seropositive to EHV-1, EHV-4 or both in the VN test (n=178, 
90 SP horses seropositive to EHV-1 only, 80 SP horses seropositive to both EHV-1 and EHV-4 
and 8 SP horses seropositive to EHV-4 only) 
 
The true seroprevalence for EHV-1/-4 using the SN test (gold standard test) 
in the population of this study, with 95% confidence was 53.3% (47.9% - 58.6%). 
Since the SN test differentiates between EHV-1 and EHV-4 (although there can be a 
certain grade of cross-reactions between both viruses), individual seroprevalence 
for EHV-1 and EHV-4 could be calculated; EHV-1 seroprevalence by SN was 50.9% 
(45.5% - 56.3% with 95% confidence), whereas EHV-4 seroprevalence by SN was 
26.3% (21.6% - 31.1% with 95% confidence). The results of both the EHV-1/-4 
ELISA and EHV-1 and EHV-4 SN for each of the horses sampled in the study are 
shown in Appendix 4. 
 
Within the 178 EHV-1/-4 positive horses, 23 had a positive titre to EAV, 
therefore the seroprevalence of EVA and EHV-1/-4 in this sample was 6.9% (4.2% - 
9.6% with 95% confidence).  
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Regarding the stud farms sampled in this study where there were any horses 
non-vaccinated against EHV-1/-4, 27 out of 30 (90%) had horses which were 
seropositive to EHV-1/-4 by SN within the horses unvaccinated against EHV-1/-4. 
The stud farm seroprevalence for EHV-1/-4 in the population of this study, with 
95% confidence was between 79.3% and 100%. Out of the 27 EHV-1/-4 seropositive 
stud farms, 4 (15%) showed a seroprevalence of < 30%, whereas 9 (33%) showed a 
seroprevalence between ≥30% and <60%, 13 (48%) showed a seroprevalence 
between ≥60% and <90% and only 1 (4%) had a seroprevalence of > 90%. 
 
The three EHV-1/-4 seronegative SP stud farms sampled in this study were 
located in the NW of the central area of Spain and had different climate types; one of 
them was located in an area with CFA (temperate with dry season and hot summer) 
climate, another was located in a location with CSA (temperate with dry or hot 
summer) climate and the third was located in an area with DSB (cold with temperate 
and dry summer) climate. 
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IV.4 GENERAL MANAGEMENT AND HEALTH IN SP BREEDING 
STUD FARMS IN CENTRAL SPAIN. 
 
IV.4.1 Descriptive analysis 
 
Regarding the location of the 35 participating stud farms in the central area 
of Spain shown in Table 7, 45% of the 35 participating stud farms were located in 
the province of Madrid. Looking at the area of study as a whole (Table 8), the stud 
farms were equally distributed in the North and South of the central area of Spain. 
Table 7. Distribution by provinces of the 35 SP stud farms sampled in the central area of Spain. 
 
 
 
 
 
 
 
Table 8. Distribution by area of the 35 SP stud farms sampled in the central area of Spain. 
Province SP Stud Farms No SP Stud Farms % 
Madrid 16 45% 
Ávila 3 9% 
Segovia 4 11% 
Toledo 6 17% 
Cuenca 3 9% 
Guadalajara 3 9% 
Total 35 100% 
Area SP Stud Farms No SP Stud Farms % 
North 17 49% 
South 18 51% 
Total 35 100% 
North-West 14 40% 
North-East 3 9% 
South-West 10 29% 
South-East 8 22% 
Total 35 100% 
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Regarding the climates in the stud farms locations, 17 stud farms (48%) had 
a temperate with dry or hot summer climate (CSA), 8 stud farms (23%) had a 
temperate with dry or temperate summer climate (CSB), 8 (23%) had a cold steppe 
climate (BSK), 1 stud farm (3%) had a cold with temperate and dry summer climate 
(DSB) and 1 stud farm (3%)  had a temperate with a dry season and hot summer 
climate (CFA). 
The SP stud farms included in this study had a total area surface ranging from 
0.004 to 13 km2 (mean 0.94 km2 ± SD 2.35 km2; median 0.1 km2, IR 0.03 – 0.3). The 
number and percentage of stud farms by total area surface is shown in Table 9.  
Table 9. Distribution by total area surface of the 35 SP stud farms sampled in central Spain. 
 
 
 
 
 
Regarding the area used for breeding, the 35 SP stud farms of this study had 
a surface ranging from 0.002 to 6.5 km2 (mean 0.53 km2 ± SD 1.27 km2; median 0.07 
km2, IR 0.02 – 0.2). The number and percentage of stud farms by area surface used 
for breeding is shown in Table 10.  
Table 10. Distribution by breeding surface of the 35 SP stud farms sampled in central Spain. 
 
 
 
 
 
Area surface SP Stud Farms No SP Stud Farms % 
< 0.1 km2 16 46% 
≥0.1 to <1 km2 11 31% 
≥1 to <4  km2 7 20% 
> 4 km2 1 3% 
Total 35 100% 
Breeding surface  SP Stud Farms No SP Stud Farms % 
< 0.1 km2 21 60% 
≥0.1 to <1 km2 8 23% 
≥1 to <4  km2 5 14% 
> 4 km2 1 3% 
Total 35 100% 
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The population density on the stud farms ranged from 7 to 11000 
horses/km2 (mean 1063 horses/km2 ± SD 2077 horses/km2; median 400 
horses/km2, IR 125 – 950 horses/km2). As displayed in Table 11, 60% of the stud 
farms had ≥100 to <1000 horses/km2.  
 
Table 11. Distribution by population density of the 35 SP stud farms sampled in central Spain. 
 
Of the 35 SP stud farms, the oldest farm started its activity in 1965 and the 
newest started in 2013. Stud farms starting their activity before 1990 represented 
a quarter of the total stud farms (9 farms, 26%), same as those starting between 
1990 and 1999 (9 farms, 26%) and those starting between 2000 and 2009 (9 farms, 
26%), whereas those starting between 2010 and 1013 were represented by a 22% 
(8 farms). 
Within the stud farms sampled, 60% (21 stud farms) were linked to a 
breeders association. Of these, 18 (86%) were associated to ANCCE; other breeders 
associations were ASOCAMAN (Asociación de Castilla La Mancha de Pura Raza 
Española (P.R.E.)), CESCALE (Asociación de Criadores de Caballos P.R.E. de Castilla y 
Leon) and UCCE (Unión de Criadores de Caballos P.R.E.). 
In addition to SP breeding,  46% of stud farms sampled (16 stud farms) 
involved in other equine industry activities and the most frequently reported  
activities were dressage (n=9/16), liveries (n=6/16), and equine hospitals 
(n=2/16).  Other additional activities less frequently reported included bullfighting, 
farriers teaching, carriage driving, show jumping or hacking. 
Population density  SP Stud Farms No SP Stud Farms % 
< 100 horses/km2 6 17% 
≥100 to <500 horses/km2 13 37% 
≥500 to <1000 horses/km2 8 23% 
≥1000 to <3000 horses/km2 6 17% 
≥3000 horses/km2 2 6% 
Total 35 100% 
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All SP stud farms had animals other than horses in the premises. The most 
common were dogs (86%), and cats (40%). Other animals in the premises were 
chickens (17%), other birds (20%), goats (14%), cattle (11%), sheep (9%), donkeys 
(6%), pigs (3%), rabbits and deer (both 3%). 
The SP stud farms included in this study had a number of horses ranging 6 to 
220 (mean 48.1 ± SD 47.3 horses; median 32 horses, IR 16–61). The majority of them 
(86%, n=30/35) had ≤70 horses of all breeds and also ≤70 SP horses. The 
distributions of SP stud farms by number of horses of all breeds and number of SP 
horses are shown in Table 12 and Table 13, respectively. 
Table 12. Distribution of the 35 SP stud farms sampled in central Spain by number of horses of 
all breeds. 
 
 
 
 
 
 
Table 13. Distribution of the 35 SP stud farms sampled in central Spain by number of SP horses. 
 
The SP stud farms included in this study had a number of SP breeding mares 
ranging from 0 to 65 (mean 16.3 ± SD 15.8 mares; median 12 mares, IR 4–22). The 
distribution of SP stud farms by number of SP breeding mares is shown in Table 14. 
Number of horses of all breeds  SP Stud Farms No SP Stud Farms % 
≤15 horses 8 23% 
>15 to ≤30 horses 9 26% 
>30 to ≤70 horses 13 37% 
>70 horses 5 14% 
Total 35 100% 
Number of SP horses  SP Stud Farms No SP Stud Farms % 
≤15 horses 10 29% 
>15 to ≤30 horses 8 23% 
>30 to ≤70 horses 12 34% 
>70 horses 5 14% 
Total 35 100% 
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Most of the SP stud farms (77%) had no SP mares retired from breeding, 12% had 
only one retired mare and 11% had two retired mares.  
Table 14. Distribution of the 35 SP stud farms sampled in central Spain by number of SP 
breeding mares. 
 
The 35 SP stud farms had a number of SP breeding stallions ranging from 0 
to 15 (mean 3.0 ± SD 3.4 stallions; median 2 stallions, IR 1–3). The distribution of SP 
stud farms by number of SP breeding stallions is shown in Table 15. Most of the SP 
stud farms (71%) had no SP stallions retired from breeding, 17% had only one 
retired stallion and 12% had 2-6 retired stallions.  
Table 15. Distribution of the 35 SP stud farms sampled in central Spain by number of SP 
breeding stallions. 
 
The number of geldings and/or stallions older than 4 years old but without a 
history of covering mares ranged from 0 to 80 horses (mean 6.8 ± SD 15.6 horses; 
median 1 horse, IR 0–4). Eighty percent (80%) of the stud farms (28 farms) had ≤ 5 
and 20% had > 5 geldings and/or stallions older than 4 years old. Regarding teasers, 
94% of the stud farms had no teasers, and only 6% of farms had 1 teaser in the 
premises. 
Number of breeding mares  SP Stud Farms No SP Stud Farms % 
≤10 mares 17 49% 
>10 to ≤30 mares 12 34% 
>30 mares 6 17% 
Total 35 100% 
Number of breeding stallions  SP Stud Farms No SP Stud Farms % 
0 to ≤2 stallions 21 60% 
>2 to ≤5 stallions 8 23% 
>5 stallions 6 17% 
Total 35 100% 
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Regarding the presence of young horses in the SP stud farms sampled, the 
number of suckling foals ranged from 0 to 21 (mean 4.4 ± SD 5.7 foals; median 3 
foals, IR 0–6). The number of yearlings ranged from 0 to 22 (mean 5.6 ± SD 6.7 
yearlings; median 2 yearlings, IR 1-10). Finally, the number of 2 and 3 year-old 
horses ranged from 0 to 40 (mean 8.1 ± SD 10.3 horses; median 5 yearlings, IR 2-7).  
A total of 17 stud farms (49%) reported that they routinely grouped all 
breeding mares together with the young horses (fillies and colts < 2 years old), while 
a further 20% of stud farms (n=7) reported that they grouped all breeding mares 
together, and segregated the youngsters. Other herd management practices 
reported were grouping mares with suckling foals in one group, pregnant and 
barren mares in other group, and youngsters in other group (11% of the stud farms), 
grouping mares with suckling foals in one group, pregnant mares in other group, 
and barren mares together with youngsters in other group (6%), and finally having 
four groups: mares with suckling foals, pregnant mares, barren mares, and 
youngsters (14%). The presence of smaller groups within these categories was 
recorded only in 9 stud farms (26%).  
The majority of stud farms (74%) housed breeding stallions and colts > 2 
years old in stables, while 23% of stud farms reported that breeding stallions were 
stabled and colts > 2 years old were kept together in a large paddock. The third way 
of housing these horses, although less frequent (3% of stud farms), was to have each 
horse in an individual paddock. 
Regarding the movements to fairs and/or competitions in the SP stud farms 
of the study, most of the stud farms (19 out of 35, 54%) had not attended fairs 
and/or competitions with their horses in the past 12 months.  Of those farms that 
did report movement of horses off the premises, 10 stud farms (29%) went to <5 
fairs and/or competitions, whereas 6 (17%) went to ≥5 fairs and/or competitions 
in the past 12 months.  
Within the SP stud farms, nearly three quarters had not taken their stallions 
or mares to other studs for breeding purposes in the past 12 months (74% and 77% 
respectively). The number of new horses acquired by the owners of the stud farms 
in the past 12 months ranged from 0 to 15 (mean 3.1 ± SD 4.9 horses; median 1 
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horse, IR 0–3). The number of horses sold ranged from 0 to 40 (mean 5.1 ± SD 7.4 
horses; median 4 horses, IR 0–6). The distribution of SP stud farms by number of 
horses acquired and sold is presented in Table 16 and Table 17, respectively. 
 
Table 16. Distribution of the 35 SP stud farms sampled in central Spain by number of horses 
acquired. 
 
 
Table 17. Distribution of the 35 SP stud farms sampled in central Spain by number of horses 
sold. 
 
Regarding movement of stallions and mares onto the stud farm from other 
stud farms for breeding purposes, 80% of the stud farms reported no movements of 
stallions onto the premises for breeding purposes and within the remaining 20% 
there were 2 stud farms which were breeding and AI centres and which had 100 
stallions coming onto the premises for semen extraction in the past 12 months. 
Regarding visitor mares, 20 out of 35 stud farms (57%) had no visitor mares coming 
into the premises for breeding purposes in the past 12 months and within the 
remaining 43% there were 4 stud farms which had 30 to 100 mares coming into the 
Number of horses acquired  SP Stud Farms No SP Stud Farms % 
0 horses 16 46% 
>0 to ≤5 horses 12 34% 
>5 horses 7 20% 
Total 35 100% 
Number of horses sold  SP Stud Farms No SP Stud Farms % 
0 horses 10 29% 
>0 to ≤5 horses 14 40% 
>5 horses 11 31% 
Total 35 100% 
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premises for being covered/inseminated with any of the stallions owned by the stud 
farm. 
Finally, the visits from people not belonging to the stud farm into the 
premises per month ranged from 1 to 1500 (mean 114.5 ± SD 272.8 visits from 
people; median 15 visits from people, IR 5–80). The distribution of SP stud farms by 
number of visits from people coming into the premises per month is presented in 
Table 18.   
 
Table 18. Distribution of the 35 SP stud farms sampled in central Spain by number of people 
coming into the premises per month.  
 
Regarding the implementation of vaccination regimes for several equine 
diseases, the distributions of SP stud farms by presence of vaccination regimes 
following the manufacturer instructions for Tetanus, Equine Influenza, EHV-1/-4 
and West Nile Virus (WNV) are shown in Table 19. 
 
 
 
 
 
 
Number of visits from people per month  SP Stud Farms No SP Stud Farms % 
≤10 people 14 40% 
>10 to ≤50 people 10 29% 
>50 people 11 31% 
Total 35 100% 
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Table 19. Distribution of the 35 SP stud farms sampled in central Spain by presence of a 
vaccination regime for Tetanus, Equine Influenza, EHV-1/-4 and WNV. 
 
 Within the 35 SP stud farms, a worming regime was implemented in all 
horses in 32 stud farms (91%), whereas the regime was implemented in active 
breeders in 2 farms (6%) and no worming regime was implemented in one stud 
farm (3%). Within the stud farms which had a worming regime (n=34), most of them 
wormed their horses twice a year (76%), whereas the rest wormed their horses 3 
or 4 times a year (24%). The anthelmintic products used in the 34 SP stud farms 
with a worming regime is shown in Figure 32. 
 
Vaccination regime  SP Stud Farms No SP Stud Farms % 
Tetanus  
Yes, in all horses 25 71% 
No 10 29% 
Total 35 100% 
Equine Influenza  
Yes, in all horses 25 71% 
No 10 29% 
Total 35 100% 
EHV-1/-4  
Yes, in all horses 5 14% 
No 16 46% 
Active breeders/Pregnant mares only 14 40% 
Total 35 100% 
West Nile Virus   
Yes, in all horses 1 3% 
No 34 97% 
Total 35 100% 
 135 
 
Figure 32. Percentages of the different wormers used in the 35 SP stud farms sampled 
in central Spain  
 
Regarding the implementation of disinfection regimes, and preventive 
measures against insects and rodents in the premises, distributions of SP stud farms 
by presence of these regimes are shown in Table 20, Table 22 and Table 23 
respectively, whereas the products or measures used in the disinfection of the SP 
stud farms of this study are presented in Table 21. 
Table 20. Distribution of the 35 SP stud farms sampled in central Spain by presence of 
a disinfection regime. 
 
 
Presence of disinfection regime  SP Stud Farms No SP Stud Farms % 
Yes 29 83% 
No 6 17% 
Total 35 100% 
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Table 21. Distribution of the 35 SP stud farms sampled in central Spain by use of different 
products and regimes for disinfection. 
Zotal: 4-cloro-3-metilphenol 0,8% - 4-cloro-2-bencilphenol 0,4% - 2-fenilphenol 1,5%. Despadac: 
quarternary amonium and aldehides 
The areas in the SP stud farms most commonly disinfected were the stables 
(disinfected in 100% of stud farms), corridors (disinfected in 24% of stud farms), 
sand paddocks (disinfected in 14% of stud farms) and the areas where the feed was 
kept (disinfected in 10% of the stud farms). 
 
Table 22. Distribution of the 35 SP stud farms sampled in central Spain by presence of 
measures against insects. 
 
Within the 29 stud farms which had measures against insects, Agita 
(Tiametoxam 10%; 9-tricosene 0,05%) was used in the surfaces of 38% of stud 
farms, whereas cypermethrin was applied topically for  horses on 48% of stud 
farms, deltamethrin was applied topically for the horses on 7% of stud farms, Zotal 
Products  and regimes used for disinfection SP Stud Farms No SP Stud Farms % 
Zotal daily 11 38% 
Zotal once a week 4 14% 
Zotal twice a month 3 11% 
Zotal once a month 4 14% 
Zotal twice a year 1 3% 
Despadac once a week 3 11% 
Zotal + Despadac once a week 1 3% 
Zotal + Limestone once a month 1 3% 
Bleach once a week 1 3% 
Total 29 100% 
Presence of measures against insects  SP Stud Farms No SP Stud Farms % 
Yes 29 83% 
No 6 17% 
Total 35 100% 
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(4-cloro-3-metilphenol 0,8% - 4-cloro-2-bencilphenol 0,4% - 2-fenilphenol 1,5%) 
was used in 7% of stud farms and other measures such as ultraviolet lamps, nets, 
fly-capture sticks, or garlic in feed were implemented in 14% of stud farms. 
 
Table 23. Distribution of the 35 SP stud farms sampled in central Spain by presence of 
measures against rodents. 
 
Within the 28 stud farms that had measures implemented against rodents, 
cats were used in 39% of the stud farms, dogs were used in 21% of farms, poison 
boxes were used in 29% of stud farms, traps were used in 21% of stud farms and 
other measures such as electronic devices or hiring a company to treat rodents in 
the farm were used in 7% of the stud farms. 
Regarding the use of natural cover (NC) and artificial insemination (AI) in the 
stallions of the SP stud farms of this study (n= 29 stud farms with presence of 
breeding stallions), the distribution of stud farms by the  use of NC and AI is shown 
in Table 24. 
Table 24. Distribution of the 35 SP stud farms sampled in central Spain by % use of 
Natural cover (NC) and Artificial Insemination (AI) in their stallions. 
 
Presence of measures against rodents SP Stud Farms No SP Stud Farms % 
Yes 28 80% 
No 7 20% 
Total 35 100% 
% use of NC / % use of AI in the stallions  SP Stud Farms No SP Stud Farms % 
0% NC / 100% AI 6 21% 
10 – 50% NC / 50 - 90% AI 4 14% 
60 – 90% NC / 10 – 40% AI 5 17% 
100% NC / 0% AI 14 48% 
Total 29 100% 
 138 
 
Out of the 29 stud farms with presence of breeding stallions, only 5 (18%) 
reported having stallions with reproductive problems. The percentage of stallions 
with reproductive problems in the 29 stud farms ranged from 0% to 100% (mean 
7.2% ± SD 21.9%, median 0, IR 0 – 0).  
Regarding the use of NC and AI in the mares of the SP stud farms of this study 
(n= 34 stud farms with presence of breeding mares), the distribution of stud farms 
by the use of NC and AI is shown in Table 25.  
Table 25. Distribution of the 35 SP stud farms sampled in central Spain by % use of 
Natural cover (NC) and Artificial Insemination (AI) in their mares. 
 
The percentage of  mares with reproductive problems in the 34 stud farms of 
this study ranged 0 to 100 (mean 24.8% ± SD 26.4%, median 15, IR 4.5 – 35.2). The 
distribution of stud farms by % mares with reproductive problems is shown in Table 
26. 
Table 26. Distribution of the 35 SP stud farms sampled in central Spain by % mares 
with reproductive problems. 
      
 
% use of NC / % use of AI in the mares  SP Stud Farms No SP Stud Farms % 
0% NC / 100% AI 9 26% 
10 – 50% NC / 50 - 90% AI 9 26% 
60 – 90% NC / 10 – 40% AI 7 22% 
100% NC / 0% AI 9 26% 
Total 34 100% 
% mares with reproductive problems  SP Stud Farms No SP Stud Farms % 
0%  4 12% 
>0 to ≤10% 10 29% 
>10 to ≤20% 7 21% 
>20 to ≤50% 9 26% 
>50% 4 12% 
Total 34 100% 
 139 
 
Within the stud farms which had mares with reproductive problems, repeat 
breeding was reported in 21% of the stud farms, early abortions were reported in 
29% of the stud farms, late abortions in 32% of the stud farms, stillbirths in 9% of 
the stud farms, the presence of neonatal deaths or weak foals at birth was reported 
in 32% of the stud farms, and barren mares (mares which were 
covered/inseminated several times and did not manage to conceive) were reported 
in 65% of the stud farms. 
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IV.5 ASSOCIATION OF EVA STATUS WITH INDIVIDUAL AND 
STUD FARM RISK FACTORS. 
 
In order to find associations between the different individual and stud farm 
risk factors and the seropositivity to EVA, a Chi squared and a univariable ordinary 
logistic regression analysis was carried out in the SP horses sampled in this study 
(n=555). The results for the Chi squared analysis, as well as the ordinary logistic 
regression between the different individual and stud farm variables and EVA status 
in the 555 SP horses of this study are shown in Table 28 and Table 29, respectively.   
Individual risk factors associated a priori with EVA seropositivity included 
sex, age, breeding activity and reproductive problems and EHV-1/-4 vaccination 
(Table 27), whereas stud farm factors associated a priori with EVA seropositivity 
included the stud farm location and climate, the total area and the area used for 
breeding in the stud farm, the stud farm horse density of population, the stud farm 
association to a Breeders´ association, the presence of dogs and cats in the stud farm, 
the number of SP breeding stallions in the stud farm, the outings to 
fairs/competitions and to other stud farms with breeding purposes in the past 12 
months, the average number of visits from people coming into the stud farm 
monthly in the past 12 months, the presence of an Equine Influenza + Tetanus 
vaccination regime in the stud farm, the presence of a EHV-1/-4 vaccination regime 
in the stud farm, the presence of measures against insects implemented in the stud 
farm and the percentage of reproductive problems in the mares of the stud farm 
(Table 28). 
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Table 27. Chi squared analysis and univariable logistic regression of risk factors related to individual characteristics for EVA seropositivity in 555 SP horses in 
the central region of Spain. 
 
 
 
 
Variable Category Frequency % 
EVA positives 
Frequency % 
EVA negatives 
Odds ratio 95% CI χ2 p value 
Sex (n=555) Stallion 
Mare 
26 (11%) 
70 (22%) 
211 (89%) 
248 (78%) 
Reference 
0.001 
2.29 1.41 - 3.72 
Age (n=555) < 3 years 
3 - 6 years 
7 - 9 years 
10 - 14 years 
≥ 15 years 
9 (10.8%) 
17 (10.7%) 
24 (17.6%) 
33 (27.5%) 
13 (22.8%) 
74 (89.2%) 
142 (89.3%) 
112 (82.4%) 
87 (72.5%) 
44 (77.2%) 
1.02 0.43 -2.39 
0.002 
Reference 
1.79 0.92 - 3.49 
3.17 1.67 - 6.03 
2.47 1.11 -5.45 
Age (n=555)    1.07 1.03 - 1.11 0.002 
Breeding activity and 
reproductive problems (n=555) 
Non breeding 
Breeding-No reproductive problems 
Breeding-Reproductive problems 
18 (8.7%) 
44 (16.4%) 
34 (42.5%) 
189 (91.3%) 
224 (83.6%) 
46 (57.5%) 
Reference 
<0.001 2.06 1.15 - 3.69 
7.76 4.03 - 14.95 
EHV-1/-4 vaccination (n=555) No 
Yes 
38 (11.3%) 
58 (26.5%) 
298 (88.7%) 
161 (73.5%) 
Reference 
<0.001 
2.82 1.80 - 4.44 
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Table 28. Univariable logistic regression of risk factors for EVA seropositivity related to stud farm characteristics, general management and measures of 
prevention and control of infectious diseases in 555 SP horses in the central region of Spain. 
 
 
 
Variable Category Frequency % 
EVA positives 
Frequency % 
EVA negatives 
Odds 
ratio 
95% CI p value 
Stud farm location in central area of 
Spain (n=555) 
North 
South 
61 (25.3%) 
35 (11.1%) 
180 (74.7%) 
279 (88.9%) 
2.70 1.71 - 4.26 
<0.001 
Reference 
Stud farm climate (n=555) temperate with dry or hot summer 
(CSA + CFA) 
temperate/cold with temperate 
and dry summer (CSB + DSB) 
cold steppe (BSK) 
37 (14.0%) 
 
42 (32.6%) 
 
17 (10.6%) 
228 (86.0%) 
 
87 (67.4%) 
 
144 (89.4%) 
Reference 
 
<0.001 2.97 
 
1.79 - 4.93 
 
0.73 0.39 - 1.34 
Total area of the stud farm (n=555) < 1 km2 
≥ 1 km2 
94 (25.2%) 
2 (1.1%) 
279 (74.8%) 
180 (98.9%) 
Reference 
<0.001 
0.03 0.01 – 0.13 
Area used for breeding in the stud 
farm (n=555) 
< 1 km2 
≥ 1 km2 
31 (30.4%) 
65 (14.4%) 
71 (69.6%) 
388 (85.6%) 
Reference 
<0.001 
0.38 0.23 – 0.63 
Stud farm density of population 
(n=555) 
≤ 500 horses/km2 24 (7.5%) 296 (92.5%) Reference 
<0.001 
> 500 horses/km2 72 (30.6%) 163 (69.4%) 5.45 3.30 – 8.98 
Stud farm onset year (n=555) ≤ 2000 53 (15.8%) 283 (84.2%) Reference 
0.240 
> 2000 43 (19.6%) 176 (80.4%) 1.30 0.84 – 2.03 
Stud farm association to Breeders´ 
association (n=555) 
no 15 (9.2%) 148 (90.8%) Reference 
0.001 
yes 81 (20.7%) 311 (79.3%) 2.57 1.43 - 4.61 
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Table 28 (cont). Univariable logistic regression of risk factors for EVA seropositivity related to stud farm characteristics, general management and measures 
of prevention and control of infectious diseases in 555 SP horses in the central region of Spain. 
 
Variable Category Frequency % 
EVA positives 
Frequency % 
EVA negatives 
Odds 
ratio 
95% CI p value 
Other equine activities in the stud farm 
(n=555) 
no 60 (19.2%) 253 (80.8%) Reference 
0.185 
yes 36 (14.9%) 206 (85.1%) 0.74 0.47 - 1.16 
Dogs in stud farm (n=555) no 44 (52.4%) 40 (47.6%) Reference 
< 0.001 
yes 52 (11.0%) 419 (89.0%) 0.11 0.07 – 0.19 
Cats in stud farm (n=555) no 84 (28.3%) 213 (71.7%) Reference 
< 0.001 
yes 12 (4.7%) 246 (95.3%) 0.12 0.06 – 0.23 
Number of SP breeding mares in stud farm 
(n=555) 
≤ 10 SP Breeding mares 23 (13.1%) 153 (86.9%) Reference 
0.073 
> 10 SP Breeding mares 73 (19.3%) 306 (80.7%) 1.59 0.96 - 2.63 
Number of SP breeding stallions in stud farm 
(n=555) 
≤ 2 SP Breeding stallions 29 (10.7%) 241 (89.3%) Reference 
< 0.001 
> 2 SP Breeding stallions 67 (23.5%) 218 (76.5%) 2.55 1.59 – 4.10 
Breeding mares separated from young horses 
(n=555) 
no 50 (20.6%) 193 (79.4%) 1.50 0.94 - 2.33 
0.071 
yes 46 (14.7%) 266 (85.3%) Reference 
Groups within breeding mares and young 
horses (n=555) 
no 67 (19.3%) 280 (80.7%) 1.48 0.92 - 2.37 
0.106 
yes 29 (13.9%) 179 (86.1%) Reference 
Outings to fairs/competitions in the past 12 
months (n=555) 
no 32 (11.1%) 255 (88.9%) Reference 
< 0.001 
yes 64 (23.9%) 204 (76.1%) 2.50 1.57 - 3.97 
Outings to other stud farms with breeding 
purposes in the past 12 months (n=555) 
no 77 (22.0%) 273 (78.0%) Reference 
< 0.001 
yes 19 (9.3%) 186 (90.7%) 0.36 0.21 - 0.62 
Acquired horses in the past 12 months 
(n=555) 
no 9 (10.3%) 78 (89.7%) Reference  
0.062 
yes 87 (18.6%) 381 (81.4%) 1.98 0.95 - 4.10 
 144 
 
Table 28 (cont). Univariable logistic regression of risk factors for EVA seropositivity related to stud farm characteristics, general management and measures 
of prevention and control of infectious diseases in 555 SP horses in the central region of Spain. 
 
Variable Category Frequency % 
EVA positives 
Frequency % 
EVA negatives 
Odds 
ratio 
95% CI p value 
Average number of visits from people coming into the 
stud farm monthly in the past 12 months (n=555) 
≤ 50 people 52 (13.8%) 326 (86.2%) Reference 
0.001 
> 50 people 44 (24.9%) 133 (75.1%) 2.07 1.32 - 3.25 
Equine Influenza + Tetanus vaccination regime in the 
stud farm (n=555) 
no 43 (25.6%) 125 (74.4%) 2.17 1.38 - 3.41 
0.001 
yes 53 (13.7%) 334 (86.3%) Reference 
Equine Rhinopneumonitis vaccination regime in the 
stud farm (n=555) 
no 16 (7.8%) 188 (92.2%) 0.29 0.16 - 0.51 
< 0.001 
yes 80 (22.8%) 271 (77.2%) Reference 
Disinfection regime in the stud farm (n=555) no 14 (15.7%) 75 (84.3%) 0.87 0.47 - 1.62 
0.670 
yes 82 (17.6%) 384 (82.4%) Reference 
Measures against insects implemented in the stud farm 
(n=555) 
no 46 (43.0%) 61 (57.0%) 6.00 3.70 - 9.73 
< 0.001 
yes 50 (11.2%) 398 (88.8%) Reference 
Measures against rodents implemented in the stud farm 
(n=555) 
no 21 (18.9%) 90 (81.1%) 1.15 0.67 - 1.96 
0.614 
yes 75 (16.9%) 369 (83.1%) Reference 
Breeding by natural covering in the stallions of the stud 
farm (n=501) 
no 19 (17.6%) 89 (82.4%) 0.95 0.54 - 1.66 
0.862 
yes 72 (18.3%) 321 (81.7%) Reference 
Breeding by natural covering in the mares of the stud 
farm (n=548) 
no 19 (13.2%) 125 (86.8%) 0.66 0.38 - 1.13 
0.126 
yes 76 (18.8%) 328 (81.2%) Reference 
Percentage of reproductive problems in the mares of the 
stud farm (n=548) 
<50% 58 (12.8%) 397 (87.2%) Reference 
< 0.001 
≥50% 37 (39.8%) 56 (60.2%) 4.52 2.75 – 7.44 
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Following the Chi squared and the univariable logistic regression analysis of 
the association between the EVA status in the horses sampled and individual and 
stud farm risk factors, and given the complex and clustered nature of the data which 
impeded a multivariable analysis by ordinary logistic regression at this stage, a non-
parametric, multivariable analysis by the construction of a decision tree using the 
CHAID algorithm was carried out.   
The decision tree, which included both individual and stud farm variables 
(variables related to the characteristics, general management and measures of 
prevention and control of infectious diseases in the SP stud farms) is shown in 
Figure 33. 
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Figure 33. Decision tree for variables associated with seropositivity to EAV in the study population of SP breeding horses sampled in central Spain (n=555). 
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 The tree had 17 nodes and 10 terminal nodes, therefore there would be 10 
different probabilities for EVA infection in the horses sampled in this study.  The 
first branch would be the variable “Density of population in the stud farm”; horses 
in stud farms with ≤125 horses/km2 were all negative for EVA VN in our sample and 
would be expected to be negative in the SP breeding horse population in central 
Spain. Horses living in stud farms with >125 and <800 horses/km2 would have a 
probability of 0.167 for being seropositive to EVA. Within these, the next branch 
would be the variable “average number of visits from people coming monthly into 
the stud farm in the past 12 months”. Horses in stud farms with >50 visits from 
people coming monthly into the premises would have a probability of being EVA 
seropositive of 0.337, and within these and in a final branch, horses ≤4 years old 
would all be negative for EVA VN, whereas horses between 4 and 8 years old would 
have a probability of being EVA positives of 0.26 and horses >8 years old would have 
a probability of 0.524 of being EVA positives.  Horses in stud farms with ≤50 visits 
from people coming monthly into the premises would have a probability of being 
EVA seropositive of 0.03, and within these and in a final branch, horses in stud farms 
where more than 8 horses were acquired or visited the premises had a probability 
of being EVA seropositive of 0.20 whereas horses in stud farms where ≤8 horses 
were acquired or visited the premises had a very low probability of being EVA 
seropositive (0.01).  
 Horses living in premises with more than 800 horses/km2 would have a 
probability of being infected by EAV of 0.36, and the next branch would divide this 
group in two by the climate of the area where the stud farm was located. Horses 
living in an area with a temperate with dry or hot summer (CFA or CSA) and those 
living in an area with a cold steppe climate (BSK) had a smaller probability of being 
infected by EAV (0.21) than horses living in an area with a temperate/cold with dry 
or temperate summer climate (CSB or DSB) (0.74). The group of horses in stud farms 
with a CFA, CSA or BSK climate, was divided in three final nodes by number of horses 
that were acquired or visited the premises; within these the highest probability of 
being EVA seropositive was in the group of horses living in premises where between 
2 and 8 horses were acquired or visited the premises (0.56). Finally, the group of 
horses in stud farms with a CSB or DSB climate was divided in two final nodes by the 
presence of a physical separation between breeding mares and youngsters in the 
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stud farm. Interestingly, the highest probability of being EVA seropositive was that 
in the group of horses living in premises where broodmares and youngsters were 
segregated (0.92). 
Regarding the predictive power of the tree model, the area under the ROC 
curve was 0.94 (95% CI 0.92 – 0.96), indicating that the model had good overall 
predictive power. The ROC curve is shown in Figure 34. 
 
Figure 34. ROC curve for the decision tree model for variables associated with seropositivity to 
EAV in the study population of 555 SP breeding horses in central Spain (AUC = 0.94). 
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IV.6 ASSOCIATION OF EHV-1/-4 STATUS WITH INDIVIDUAL 
AND STUD FARM RISK FACTORS. 
 
In order to find associations between the different individual and stud farm 
risk factors and the seropositivity to EHV-1/-4, a Chi squared and a univariable 
ordinary logistic regression analysis was carried out in the unvaccinated SP horses 
sampled in this study (n=334). The results for the Chi squared analysis, as well as 
the ordinary logistic regression between the different individual and stud farm 
variables and EHV-1/-4 status in the 334 unvaccinated SP horses of this study are 
shown in Table 29 and Table 30, respectively.   
Individual risk factors associated a priori with EHV-1/-4 seropositivity 
included the age and the breeding activity and reproductive problems (Table 30), 
whereas stud farm factors associated a priori with EHV-1/-4 seropositivity included 
the stud farm location, the total area of the stud farm, the segregation in small 
groups within the mares and the young horses in the stud farm, the average number 
of visits from people coming into the stud farm monthly in the past 12 months, and 
the presence of a EHV-1/-4 vaccination regime in the stud farm (Table 30). 
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Table 29. Chi squared analysis and univariable logistic regression of risk factors related to individual characteristics for EHV-1/-4 seropositivity in 334 
unvaccinated SP horses in the central region of Spain. 
 
Variable Category Frequency (%) 
EHV-1/-4 positives 
Frequency (%) 
EHV-1/-4 negatives 
Odds ratio 95% CI p value 
Sex (n=334) Stallion 86 (48.6%) 91 (51.4%) Reference 
0.067 
Mare 92 (58.6%) 65 (41.4%) 1.50 0.97 - 2.31 
Age (n=334) < 3 years 15 (26.3%) 42 (73.7%) 0.47 0.23 - 0.96 
< 0.001 
3 - 6 years 51 (46.4%) 59 (53.6%) Reference 
7 - 9 years 35 (47.9%) 38 (52.1%) 1.06 0.59 - 1.93 
10 - 14 years 54 (79.4%) 14 (20.6%) 4.46 2.22 - 8.96 
≥ 15 years 23 (88.5%) 3 (11.5%) 8.87 2.51 - 31.27 
Age (n=334)    1.20 1.13 - 1.28 <0.001 
Breeding activity and 
reproductive problems 
(n=334) 
Non breeding 68 (41.7%) 95 (58.3%) Reference 
<0.001 
Breeding-No reproductive 
problems 
89 (63.1%) 52 (36.9%) 2.39 1.50 - 3.80 
Breeding-Reproductive 
problems 
21 (70.0%) 9 (30.0%) 3.26 1.41 - 7.56 
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Table 30. Univariable logistic regression of risk factors for EHV-1/-4 seropositivity related to stud farm characteristics, general management and measures of 
prevention and control of infectious diseases in 334 SP horses in the central region of Spain. 
Variable Category Frequency (%) 
EHV-1/-4 positives 
Frequency (%) 
EHV-1/-4 negatives 
Odds 
ratio 
95% CI p value 
Stud farm location in central 
area of Spain (n=334) 
North 78 (44.8%) 96 (55.2%) reference 
0.001 
South 100 (62.5%) 60 (37.5%) 2.05 1.32 - 3.18 
Stud farm climate (n=334) temperate with dry or hot summer 
(CSA + CFA) 
80 (47.9%) 87 (52.1%) reference 
0.109 temperate/cold with temperate 
and dry summer (CSB + DSB) 
54 (61.4%) 34 (38.6%) 1.73 1.02 - 2.92 
cold steppe (BSK) 44 (55.7%) 35 (44.3%) 1.34 0.80 - 2.34 
Total area of the stud farm 
(n=334) 
< 1 km2 150 (56.6%) 115 (43.4%) reference 
0.017 
≥ 1 km2 28 (40.6%) 41 (59.4%) 0.52 0.30 - 0.90 
Area used for breeding in the 
stud farm (n=334) 
< 1 km2 155 (55.0%) 127 (45.0%) reference 
0.154 
≥ 1 km2 23 (44.2%) 29 (55.8%) 0.65 0.36 - 1.18 
Stud farm density of population 
(n=334) 
≤ 500 horses/km2 88 (54.7%) 73 (45.3%) reference 
0.630 
> 500 horses/km2 90 (52.0%) 83 (48.0%) 0.90 0.58 - 1.38 
Stud farm onset year (n=334) ≤ 2000 103 (55.1%) 84 (44.9%) reference 
0.460 
>2000 75 (51.0%) 72 (49.0%) 0.85 0.55 - 1.31 
Stud farm association to 
Breeders´ association (n=334) 
no 73 (51.0%) 70 (49.0%) reference 
0.477 
yes 105 (55.0%) 86 (45.0%) 1.17 0.76 - 1.81 
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Table 30 (cont). Univariable logistic regression of risk factors for EHV-1/-4 seropositivity related to stud farm characteristics, general management and 
measures of prevention and control of infectious diseases in 334 SP horses in the central region of Spain. 
Variable Category Frequency (%) 
EHV-1/-4 positives 
Frequency (%) 
EHV-1/-4 negatives 
Odds 
ratio 
95% CI p value 
Other equine activities in the stud farm 
(n=334) 
no 103 (50.2%) 102 (49.8%) reference 
0.159 
yes 75 (58.1%) 54 (41.9%) 1.37 0.88 - 2.14 
Dogs in stud farm (n=334) no 24 (64.9%) 13 (35.1%) reference 
0.135 
yes 154 (51.8%) 143 (48.2%) 0.58 0.29 - 1.19 
Cats in stud farm (n=334) no 104 (52.8%) 93 (47.2%) reference 
0.826 
yes 74 (54.1%) 63 (46.0%) 1.05 0.68 - 1.63 
Number of SP breeding mares in stud 
farm (n=334) 
≤ 10 SP breeding mares 64 (53.3%) 56 (46.7%) reference 
0.991 
> 10 SP breeding mares 114 (53.3%) 100 (46.7%) 1.00 0.64 - 1.56 
Number of SP breeding stallions in stud 
farm (n=334) 
≤ 2 SP breeding stallions 110 (51.9%) 102 (48.1%) reference 
0.497 
> 2 SP breeding stallions 68 (55.7%) 54 (44.3%) 1.17 0.75 - 1.83 
Breeding mares separated from young 
horses (n=334) 
no 93 (55.0%) 76 (45.0%) 1.15 0.75 - 1.77 
0.520 
yes 85 (51.5%) 80 (48.5%) reference 
Groups within breeding mares and 
young horses (n=334) 
no 141 (56.8%) 107 (43.1%) 1.74 1.06 - 2.86 
0.027 
yes 37 (43.0%) 49 (57.0%) reference 
Outings to fairs/competitions in the 
past 12 months (n=334) 
no 103 (55.7%) 82 (44.3%) reference 
0.331 
yes 75 (50.3%) 74 (49.7%) 0.81 0.52 - 1.24 
Outings to other stud farms with 
breeding purposes in the past 12 
months (n=334) 
no 114 (51.6%) 107 (48.4%) reference 
0.381 
yes 64 (56.6%) 49 (43.4%) 1.22 0.78 - 1.93 
Acquired horses in the past 12 months 
(n=334) 
no 32 (47.8%) 35 (52.2%) reference 
0.310 
yes 146 (54.7%) 121 (45.3%) 1.32 0.77 - 2.26 
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Table 30 (cont). Univariable logistic regression of risk factors for EHV-1/-4 seropositivity related to stud farm characteristics, general management and 
measures of prevention and control of infectious diseases in 334 SP horses in the central region of Spain. 
Variable Category Frequency (%) 
EHV-1/-4 positives 
Frequency (%) 
EHV-1/-4 negatives 
Odds 
ratio 
95% CI p value 
Average number of visits from people coming 
into the stud farm monthly in the past 12 
months (n=334) 
≤ 50 people 132 (61.1%) 84 (38.9%) reference 
<0.001 
> 50 people 46 (39.0%) 72 (61.0%) 0.41 0.26 - 0.64 
Equine Influenza + Tetanus vaccination regime 
in the stud farm (n=334) 
no 74 (51.8%) 69 (48.2%) 0.90 0.58 - 1.38 
0.624 
yes 104 (54.4%) 87 (45.5%) reference 
Equine Rhinopneumonitis vaccination regime 
in the stud farm (n=334) 
no 120 (58.8%) 84 (41.2%) 1.77 1.14 - 2.76 
0.011 
yes 58 (44.6%) 72 (55.4%) reference 
Disinfection regime in the stud farm (n=334) no 44 (55.0%) 36 (45.0%) 1.09 0.66 - 1.81 
0.726 
yes 134 (52.8%) 120 (47.2%) reference 
Measures against insects implemented in the 
stud farm (n=334) 
no 46 (57.5%) 34 (42.5%) 1.25 0.75 - 2.08 
0.387 
yes 132 (52.0%) 122 (48.0%) reference 
Measures against rodents implemented in the 
stud farm (n=334) 
no 54 (57.4%) 40 (42.6%) 1.26 0.78 - 2.04 
0.341 
yes 124 (51.7%) 116 (48.3%) reference 
Breeding by natural covering in the stallions of 
the stud farm (n=265) 
no 25 (50.0%) 25 (50.0%) 0.81 0.43 - 1.49 
0.494 
yes 119 (55.3%) 96 (44.7%) reference 
Breeding by natural covering in the mares of 
the stud farm (n=327) 
no 51 (53.7%) 44 (46.3%) 1.03 0.64 - 1.66 
0.913 
yes 123 (53.0%) 109 (47.0%) reference 
Percentage of reproductive problems in the 
mares of the stud farm (n=327) 
<50% 148 (54.0%) 126 (46.0%) reference 
0.508 
≥50% 26 (49.1%) 27 (50.9%) 0.82 0.45 - 1.48 
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Following the Chi squared and the univariable logistic regression analysis of 
the association between the EHV-1/-4 status in the unvaccinated SP horses sampled 
and individual and stud farm risk factors, and given the complex and clustered 
nature of the data which impeded a multivariable analysis by ordinary logistic 
regression at this stage, a non-parametric, multivariable analysis by the 
construction of a decision tree using the CHAID algorithm was carried out.   
The decision tree, which included both individual and stud farm variables 
(variables related to the characteristics, general management and measures of 
prevention and control of infectious diseases in the SP stud farms) is shown in 
Figure 35. 
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Figure 35. Decision tree for variables associated with seropositivity to EHV-1/-4 in the 334 unvaccinated SP breeding horses sampled in central Spain. 
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The tree had 19 nodes and 10 terminal nodes, therefore there would be 10 
different probabilities for EHV-1/-4 infection in the horses sampled in this study. 
The first branch would be the variable “age”; horses ≤3.5 years of age would have 
the lowest probability of being seropositive to EHV-1/-4 (0.33), followed by horses 
between 3.5 and 7 years of age (0.48) and horses >7 years (0.75).  
Within the group of horses ≤3.5 years of age, those living in stud farms with 
>50 visits from people coming into the premises monthly had a probability of being 
EHV-1/-4 seropositive of 0.15, whereas those living in premises where ≤50 people 
came in monthly had a probability of 0.43. Within these and in a final node, horses 
living in stud farms where mares and young horses were segregated into small 
groups had a lower probability of being EHV-1/-4 positive than those living in stud 
farms where this segregation did not occur (0.21 vs 0.52 respectively). 
Within the group of horses between 3.5 and 7 years of age, there was a higher 
probability of EHV-1/-4 infection in those living in stud farms that were associated 
to a breeders association (0.81) and within these, there was a higher probability in 
horses that lived in premises where there had been more than 2 outings to fairs or 
competitions (0.82 vs 0.50 respectively). Within the horses living in stud farms that 
were not associated to a breeders association (probability of EHV-1/-4 infection of 
0.32), mares were at a higher risk of being EHV-1/-4 infected (0.46 vs 0.10 in 
stallions).  
Regarding horses with more than 7 years of age, those living in stud farms in 
the South of the central region of Spain were at a higher risk of being EHV-1/-4 
positive (0.83 vs 0.65 in the North). Within the group of horses living in the North, 
and in a final branch, those living in premises where there were more than 50 visits 
from people into the stud farm monthly had a probability of being EHV-1/-4 positive 
of 0.36, whereas those living in premises where there were ≤50 visits from people 
coming in monthly had a higher probability (0.78). Finally, within the group of 
horses living in the South of the central region of Spain and in a final branch, those 
horses living in premises where mares and young horses were segregated into small 
groups had a lower probability than those living in premises where this segregation 
did not occur (0.65 vs 0.88 respectively).  
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Regarding the predictive power of the tree model, the area under the ROC 
curve was 0.79 (95% CI 0.74 – 0.84), indicating that the model had acceptable 
overall predictive power. The ROC curve is shown in Figure 36. 
 
 Figure 36. ROC curve for the decision tree model for variables associated with seropositivity to 
EHV-1/-4 in the study population of SP breeding horses in central Spain (AUC = 0.79). 
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IV.7 PRESENCE OF REPRODUCTIVE PROBLEMS IN THE SP 
MARES AND STALLIONS OF THE STUDY. 
 
 
IV.7.1 Descriptive analysis 
 
 Within the 257 active breeding mares sampled, 74 mares [29% (23%-34%)] 
were reported to have had at least one reproductive problem in the past 12 months. 
The mean age of these mares was 10.3 ± 4.5 years (range 4 - 21), median age was 9 
years (IR 7 – 14). The mean age of these mares was significantly different (p= 0.02) 
from the mean age of the breeding mares without reproductive problems (8.9 ± 4.5 
years). The mean number of years breeding was 3.4 years ± SD, (range 1 – 17), 
median was 5 years, IR 3 – 9 years. The number and percentage of the SP mares 
sampled in this study showing different reproductive problems is shown in Table 
31. Several mares (10) showed more than one reproductive problem. 
Table 31. Number and percentage of the SP mares sampled in central Spain showing different 
reproductive problems (n=74). 
 
Within the SP mares of this study, gestation loss was the most frequent 
problem, reported in 38 mares [51% (40.0% - 62.7%)]. Out of these mares, 14 had 
early abortions (abortions occurring before day 150), whereas 20 had late abortions 
(abortions occurring from day 150 to day 300) and 4 had stillbirths (abortions 
Reproductive problem  SP breeding mares No SP breeding mares % 
Repeat breeding 21 28% 
Cyclic irregularities 7 9% 
Early abortion 14 19% 
Late abortion 20 27% 
Stillbirth 4 5% 
Problems with neonate 16 22% 
Retained membranes 2 3% 
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occurring from day 300 onwards). Repeat breeding was the second most frequent 
reproductive problem, with 21 of the 74 mares [28.4% (18.1%-38.6%)] suffering 
from this problem. Out of the 74 mares, 16 [21.6% (12.2%-31.0%)] had problems 
with the neonate,  with 4 giving birth to immature foals, 3 having sick or weak foals, 
and 9 mares suffering from neonatal death. Cyclic irregularities were reported in 7 
of the 74 mares [9.5% (2.8% - 16.1%)]; within these, repeat breeding had occurred 
in 4 mares and early abortions had occurred in 2 mares. Finally, 2.7% (0%-6.4%) of 
mares (n=2/74) were reported to have had retained membranes after foaling. 
The suspected cause of the reproductive problem/s was specified in 21 
mares (28.4%). Old age, chronic joint pain, endometriosis, haemorrhagic follicles 
and endotoxaemia due to a severe mastitis was considered to be the cause for cyclic 
irregularities with/without repeat breeding in 5 mares. Treatments with NSAID 
(Non-Steroidal Anti-inflammatory Drugs) for chronic joint pain, prostaglandin for 
haemorrhagic follicles and systemic oxytocin for mastitis were implemented in 3 of 
these 5 mares. The suspected cause for repeat breeding was reported in only 10 out 
of 21 mares; chronic joint pain, haemorrhagic follicles, endometriosis, myometrial 
fibrosis, endometritis, subclinical infection of the uterus, bad vulval conformation, 
lack of uterine defences, uterine infection with E. coli and Staphylococcus were the 
specified causes. Treatments with NSAID for chronic joint pain, Caslick and uterine 
post AI lavages with antibiotics and oxytocin in the mares with bad vulval 
conformation, endometritis and subclinical infection of the uterus, oxytocin and 
antibiotics (gentamicin intra-uterine, enrofloxacin orally) for uterine infections 
were implemented in 6 of these 10 mares. The suspected cause for gestation loss 
was specified in 4 out of 38 mares; causes were negative energy balance due to 
lactation, uterine infection with Staphylococcus, endotoxemia due to a severe 
mastitis and bad vulval conformation. Only the uterine infection and the severe 
mastitis were treated with antibiotics and oxytocin respectively. Finally, out of the 
mares with problems in the neonate, the cause of the problem was specified only in 
5 of them; causes were pneumonia due to meconium aspiration, pneumonia, 
placentitis (2 cases), perinatal asphyxia and immaturity in the foal. Neonatal 
pneumonia was treated with cephalosporin and NSAID in one case and 
oxytetracyclin, cephalosporin and NSAID in the other case, whereas placentitis in 
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two mares was treated with Altrenogest and TMS (trimethoprim and sulfadiazine) 
in both cases. 
Within the 91 active breeding stallions sampled, only 6 stallions [7% (1.5%-
11.7%)] had shown reproductive problems in the past 12 months. The mean age of 
these stallions was 11.8 years ±SD (range 9 - 20), median age was 12 years (IR 9 – 
15). The mean number of years breeding was 7.4 years, ±SD (range 5 – 15), and 
median was 8.5 years, (IR 5 – 10 years). 
Of the SP stallions with reproductive problems, 3 stallions [50% (10%-
90%)]) had lack of libido, while the other 3 stallions [50% (10%-90%)] had 
problems in the semen. Suspected causes for lack of libido were specified in 2 cases, 
one of them had a lack of experience covering mares which was managed with 
freedom teasing, and the other had a subclinical infection by amoebas which had not 
been treated.  Causes for the problems in semen were specified in two cases: an 
intermittent haemospermia in one case (which was minimised by diluting the 
semen) and periods of low fertility and seropositivity to EVA in the other case.  
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IV.7.2 Analysis of the association of EVA status and 
reproductive problems 
 
In order to find associations between seropositivity to EVA and different 
reproductive problems, a Chi squared analysis was carried out in the SP mares with 
reproductive problems. The association between seropositivity to EVA and the 
different reproductive problems in the SP stallions could not be done, since the 
number of stallions presenting with reproductive problems was too low (6 
stallions). The results for the Chi squared analysis for the association between EVA 
status and the different reproductive problems occurring in the 74 SP mares of this 
study are shown in Table 32.  
When comparing EVA status in the SP breeding mares which showed 
reproductive problems in our study (n=74) to that in the active breeding mares with 
no reproductive problems (n=183), EVA seropositivity was associated with all the 
reproductive problems except for early abortion in the 74 SP mares, indicating that 
EVA seropositivity was linked to the presence of cyclic irregularities/repeat 
breeding, late abortion and problems with the neonate occurring in the past 12 
months in the SP mares of the study. 
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Table 32. Chi squared analysis of the association between EVA status and specific reproductive problems in the SP mares with reproductive problems 
compared to the active breeding SP mares with no reproductive problems (n=183)  in the central region of Spain. 
 
 
 
 
 
 
 
 
 
 
Reproductive problems Category 
Frequency % EVA 
positives 
Frequency % EVA 
negatives 
χ 2 p value 
Cyclic irregularities/repeat 
breeding (n=207) 
No reproductive problems 
yes 
33 (18.0%) 
11 (45.8%) 
150 (82.0%) 
13 (54.2%) 
0.006 
Early abortion (n=197) No reproductive problems 
yes 
33 (18.0%) 
4 (28.6%) 
150 (82.0%) 
10 (71.4%) 
0.304 
Late abortion (n=207) No reproductive problems 
yes 
33 (18.0%) 
11 (45.8%) 
150 (82.0%) 
13 (54.2%) 
0.006 
Problem with neonate (n=199) No reproductive problems 
yes 
33 (18.0%) 
8 (50%) 
150 (82.0%) 
8 (50%) 
0.006 
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V. DISCUSSION 
 
V.1 REPRESENTATION OF THE SP BREEDING HORSE 
POPULATION IN CENTRAL SPAIN BY THE HORSES SAMPLED 
IN THIS STUDY  
 
The characteristics of the equine population (n = 555 horses) sampled on the 
35 SP stud farms in this study were considered highly representative of the wider 
SP breeding horse population in central Spain. Regarding the percentages of the 
horses sampled in each province, the situation matched that published in the census 
of 2012, with the highest percentages of horses sampled in the provinces with a 
larger SP breeding population (Madrid, followed by Toledo and Segovia) 
(MAGRAMA, 2012).   
The distribution by sex of the sample was similar to that described in the 
census of 2012 for the SP breeding population in the central area of Spain (57% of 
mares in this study vs. 53% in the census and 43% of stallions in this study vs. 47% 
in the census) (MAGRAMA, 2012). Within the mares of our sample, a high 
percentage (74%) were active breeders whereas only the 26% of stallions were 
active breeders; this differed slightly from the data in the census, as 56% of mares 
and 40% of the stallions were active breeders (MAGRAMA, 2012). The differences 
in the percentages of the stallions may have been due to many stud farm owners 
registering their stallions but then not breeding with them, whereas the differences 
in the mares could be caused by a high representation of the breeding mares with 
respect to non-breeding and pre-pubertal mares in the sample.  
Regarding the age of the horses, both the population of SP horses sampled in 
this study and the population of horses of pure breed (including SP horses but also 
Arab, Thoroughbred, French trotter and other pure breeds) collected in the census 
of 2001 had a very similar distribution (MAPA, 2003), except that in our sample 
horses younger than 4 years could have been slightly misrepresented due to 
difficulties in their handling that made sampling impossible in some stud farms 
(these animals could not be caught or restrained in order to draw a blood sample 
from them).  
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V.2    SEROPREVALENCE 
 
V.2.1 Seroprevalence of Equine Infectious Anaemia  
 
Spain has never been surveyed in order to determine EIA seroprevalence. 
The central region of Spain that was sampled in this study is considered to represent 
a high risk area for the potential introduction of equine infectious diseases, as horses 
travelling from/to Europe frequently stop in this area and it is the region where the 
largest number of competitions are held (Deloitte, 2013).  Additionally, the most 
recent Spanish EIA outbreaks occurred predominantly in the province of Madrid, 
consequently this region is likely to reflect the highest risk of EIAV persistence since 
1983, although no clinical cases of EIA have been detected and reported through 
passive surveillance (samples from horses tested prior to exportation to other 
countries) in Spain since 1983 (OIE, 2014a; OIE, 2014b). 
After testing the 555 serum samples for EIA antibodies by ELISA, the absence 
of any EIA seropositive animals detected in the sample population using a highly 
sensitive ELISA provided 95% confidence that the true prevalence of EIA in the SP 
breeding population in central Spain is ≤0.53%. Given the excellent representation 
of the SP breeding horse population in central Spain in the sample population of this 
study in terms of location, sex, age and breeding activity and also the variety of SP 
breeding stud farms sampled in terms of size, density of population and climate, EIA 
results in this study can be considered highly representative of the SP breeding 
population in central Spain and could well be representative of the SP breeding 
population throughout Spain.  
Even though the double antigen ELISA technique used to detect antibodies 
against EIAV was not the reference or “gold standard” technique according to the 
OIE (which is the Coggins test), ELISA techniques can detect antibodies before the 
Coggins test and they are more sensitive (Reis et al., 2012; Soutullo et al., 2001). The 
reason why the Coggins test is the gold standard technique for EIA diagnosis is that 
it is more specific (Cullinane et al., 2007; Piza et al., 2007); that is, ELISA techniques 
can result in false positives and therefore any positive results to EIA by ELISA must 
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be confirmed by using the Coggins test (OIE, 2013d).  In this study there were no 
positives to EIA by ELISA and therefore there was no need to retest any samples by 
Coggins given the excellent sensitivity of the ELISA used (100%) (Body et al., 2011). 
Given the recent situation in Europe regarding the presence of EIAV in 
countries such as Belgium, Germany or Russia during the first six months of 2013 
(OIE, 2013a), the results of this study are good news for the SP breeding industry. 
Despite the absence of EIA testing prior to importation of horses into Spain from 
other EU member states and the fact that this area would have a high risk for the 
introduction of equine infectious diseases due to holding the largest number of 
national and international competitions in Spain (Deloitte, 2013; MAGRAMA, 2012), 
the SP breeding population in central Spain has remained free of EIA infection since 
the last outbreak in 1983 (Galaz, 1978).  The situation in Spain can then be compared 
to the situation in Switzerland, where the absence of EIA was confirmed in a 
seroprevalence study published in 2009 (Kaiser et al., 2009). 
The breeding of SP horses is crucial for the Spanish horse industry, with this 
breed representing 85% of pure bred horses in Spain and nearly 100% of horse 
exports to Europe and America. As this export trade had a monetary value of more 
than 58 million Euros in 2012 (Deloitte, 2013), the evidence for freedom from EIA 
provided by this study in SP horses in stud farms in central Spain may offer 
increased confidence when exporting SP horses to other countries. However, 
judicious biosecurity that includes both pre-export as well as post-arrival EIA 
testing should be implemented to prevent the movement of subclinically EIA 
infected horses within Europe. 
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V.2.2 Seroprevalence of Equine Viral Arteritis  
 
 There is serological evidence that demonstrates the presence of EAV in Spain 
since 1978 (Moraillon and Moraillon, 1978), and the first outbreak of EVA clinical 
disease was confirmed in Barcelona in 1992 (Monreal et al., 1995). However, up to 
present the only information regarding the serological presence of this disease in 
Spain was published in a preliminary, small study carried out in the autonomous 
community of Valencia (east of Spain) in 2010-2011 and which determined 
antibody against EVA by SN in the 12.24% of a population of 49 SP horses (Gimeno 
Suarep et al., 2011b). 
The seroprevalence of EVA in the population of this study was 17.3% (14.2% 
- 20.4%) and this figure is consistent with the data provided by Gimeno Suarep et al. 
in Valencia, therefore providing evidence of the actual presence of EVA in Spanish 
SP stud farms where it had always been considered a sporadic disease (MAPA, 
2003). Within the 96 EVA seropositive SP horses in the study, the majority (53%) 
had high EVA SN titres (log10 titres ≥ 2.5 and < 3) and 15% had very high EVA SN 
titres (log10 titres of ≥ 3.5); most of these results were from active breeders and 
these represented the 63% of the sample therefore explaining the high percentage 
of samples with a high titre. Many of these horses with a high EVA SN titre were 
mares having continuous contact with the same EVA seropositive stallions, and 
suggesting the presence of EVA carriers in our study (Rola et al., 2011). 
Even though this study was not designed to determine the SP stud farm 
seroprevalence, 37.1% (21.1% - 53.1%) of the stud farms in this study had horses 
which were seropositive to EVA VN test. Within these, the highest percentage of stud 
farms (46%) had a seroprevalence of EVA between 30% and 60%, again suggesting 
the presence of a high viral activity in the stud farm in the form of outbreaks which 
are not always attributed to EVA and which could be caused by carrier stallions or 
introduced in the stud farm by horses that go to competitions or to other stud farms 
(Holyoak et al., 2008).   
The results of this study confirm the presence of EAV in the SP horse 
population in central Spain, similar to that in other European countries where EVA 
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seroprevalence studies have been carried out, such as France (15.2% of horses of 
various breeds) (Moraillon and Moraillon, 1978), Netherlands (14% of horses of 
various breeds) (de Boer et al., 1979), Austria (10.9% of horses of various breeds) 
(Kölbl et al., 1991) and the UK (18.5% – 24% of Standardbred horses)(Newton et al., 
1999). 
 
While the SN test is the reference or “gold standard” technique for the 
diagnosis of EVA according to the OIE (OIE, 2013d), the indirect confirmation ELISA 
used in this study (ID Screen® Equine Viral Arteritis Indirect, ID.vet Innovative 
Diagnostics) (Legrand et al., 2009; Legrand et al., 2007) performed well as an initial 
screening test. Although this study was not designed to assess the sensitivity and 
specificity of this ELISA test, the specificity of the ELISA when used to test the 
samples in this study (87%) was lower than that published in their validation study 
(96.75%) (Beaufort Cottage Laboratories, 2008). Therefore the ELISA used in this 
study would be valid as a screening test although SN would be needed in order to 
confirm positive and equivocal results (OIE, 2013d).   
 
Given the fact that EVA outbreaks of clinical disease resemble those caused 
by EHV-1/-4 (del Piero, 2000b), EVA may be misdiagnosed and there is a low 
awareness of the disease in the Spanish equine breeding industry (MAPA, 2003). 
Despite the surveillance plan published in the APA/212/2003 order, which included 
the communication and control of diseases such as EVA and the establishment of an 
EVA surveillance programme (BOE, 2003), and the occasional OIE reports showing 
serological and/or isolation findings of EVA in Spain (OIE, 2013c), the perceptions 
drawn from the present study are that many stud farm owners ignore the existence 
and implications of this disease. Furthermore, the outbreak of abortions caused by 
EAV reported in April 2013 in a breeding stud farm located in the South of Castilla y 
León (ICC, 2013) was brought to light due to the veterinary surgeon of the affected 
stud farm being enrolled in this study. A better understanding and awareness of EVA 
disease in the equine breeding industry in Spain would probably be key in order to 
apply measures of prevention and control for this disease; the work carried out in 
other European countries with the publishing of a Codes of Practice which covers 
the most important equine infectious diseases for the equine breeding supports this 
fact (HBLB, 2013). 
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Even though the identification of carrier stallions was not included in the 
aims of this study, as published elsewhere the presence of carriers in stud farms 
where there was a high seroprevalence of EVA suggests the same phenomenon 
within the breeding stallions of these stud farms (Hullinger et al., 1998; Rola et al., 
2011). Although annual semen testing for EAV in active breeding stallions was a 
measure specified in the Royal Decree published in 2011 (BOE, 2011), this is actually 
not being done in the majority of the small, private stud farms where the stallions 
do natural coverings; however this is not the case when the semen is due to be 
exported as the semen needs to be certified free of EIA, CEM and EVA (BOE, 2011). 
The identification of carrier stallions is key in order to prevent and control EVA 
transmission within the population of a SP stud farm, but also to prevent the 
transmission between SP stud farms as there is a high number of SP breeding 
stallions and mares that move to other stud farms with breeding purposes or go to 
fairs and competitions where there is a high density of other SP breeding horses 
(Deloitte, 2013). 
Although vaccination against EVA has been successfully implemented in 
several European countries (e.g. UK and France), there are no available vaccines in 
Spain and EVA vaccination is not currently permitted. Regarding the situation in the 
UK, vaccination is carried out mostly in the Thoroughbred horse population, which 
has a lower EVA seroprevalence than that reported in this Study for SP horses in 
central Spain (<3% vs. 17.3%, respectively) (Newton et al., 1999); Thoroughbred 
horses are routinely screened for antibodies against EAV every year and they are 
tested in order to confirm they are seronegative to EVA before being vaccinated. As 
drawn from the Codes of Practice for Equine Infectious Diseases adopted in the UK 
and several European countries, the first step in order to implement a vaccination 
scheme for EVA in Spain would be to increase the awareness of the disease within 
the Spanish equine breeding industry and to encourage annual serological testing of 
the breeding stallions and mares (HBLB, 2013). 
 
The excellent representation of the SP breeding horse population in central 
Spain in the sample population of this study and also the variety of SP breeding stud 
farms sampled make possible to extrapolate EVA results in this study to the whole 
SP breeding population in central Spain and also possibly throughout Spain. 
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However, several authors have reported differences in the seroprevalence of EVA 
within breeds: EVA seroprevalence was significantly higher in Standardbred horses 
compared to Thoroughbreds in the UK (18.5%-24% vs. <3% respectively) (Newton 
et al., 1999) and the same happened in Australia where the differences were even 
greater (72% in Standardbred horses vs. 4.5% in Thoroughbreds) (Huntington et 
al., 1990b); it has also been suggested that certain breeds could be more susceptible 
to EAV infection (e.g. Hucul horses in Poland which showed a seroprevalence of 
55.1% with 45% of stallions being positive to EAV in semen (Rola et al., 2011)). 
Although breed-specific differences might reflect inherent genetic differences that 
confer resistance to infection, they are more likely reflective of different cultural and 
management factors and different perceptions and attitudes towards infectious 
diseases and their control of the horse owners within the different horse 
populations and breeds (Holyoak et al., 2008) Therefore these results may not be 
directly applicable to other equine breeds in Spain. 
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V.2.3 Seroprevalence of EHV-1/-4  
 
The first report of EHV-1/-4 in Spain dates back from 1989 (OIE, 2013b), and 
since then there have been sporadic outbreaks reported. There are only two 
references about the serological presence of EHV-1/-4 in Spain; both studies 
reported very different seroprevalence estimates although they were carried out 
with a time lapse of 18 years (Gimeno Suarep et al., 2011a; Martin Otero, 1992) and 
sampled a different horse population. While Martin Otero reported a seroprevalence 
of EHV-1/-4 of 4.9% by SN, Gimeno Suarep et al. reported a seroprevalence of EHV-
1/-4 of 100% using the same technique (Gimeno Suarep et al., 2011a; Martin Otero, 
1992). The results of the present study lie in between these, as the seroprevalence 
for EHV-1/-4 in the SP breeding horse population in central Spain was deemed to be 
53.3% (47.9% - 58.6%). The population sampled in this study would be more similar 
to the one sampled by Gimeno Suarep et al. in Valencia than the one sampled by 
Martin Otero in 1992; the seroprevalence published by Martin Otero could be low 
due to this study sampling a population of horses from the Military stud farms that 
were very static (did not move from their premises) and very controlled by the 
military. On the other hand, the seroprevalence reported by Gimeno Suarep et al. 
could be high due to this study being small and preliminary; it included only 49 SP 
horses from 5 stud farms in Valencia and their seroprevalence result would 
probably change if the study was extended to other stud farms.   
The overall EHV-1/-4 seroprevalence in SP horses in central Spain is similar 
to that published using the same technique in other countries, such as the 
Netherlands (76%) or Peru (39.6% – 48.8%) (de Boer et al., 1979; Rios, 2002). 
However, the specific seroprevalences for EHV-1 and EHV-4 in the population 
sampled in this study are different from those published elsewhere. While the 
seroprevalence of EHV-1 [50.9% (45.5% - 56.3% with 95% confidence)] was higher 
than the seroprevalence of EHV-4 [26.3% (21.6% - 31.1% with 95% confidence)] in 
this study, EHV-4 was more prevalent than EHV-1 in other countries such as 
Colombia and Turkey (Ataseven, 2010; Gür, 2008; Ruiz-Saenz et al., 2007, 2008). 
Interestingly, all four studies carried out in these countries used the same technique, 
(Svanovir® EHV1/ EHV4-Ab ELISA, Svanova Biotech AB, Sweden); this ELISA 
seemed to always detect EHV-4 and much less frequently EHV-1 and it failed to stack 
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up against known positive and negative control sera when used at the Animal Health 
Trust diagnostic laboratories (Newton, R., personal communication). However, our 
results should be considered with caution since the SN test shows a certain amount 
of cross-reactivity between the two subtypes of the virus (OIE, 2013d; Wagner et al., 
1992). 
The results of this study show that EHV-1/-4 was highly extended in the 
central area of Spain. Out of the 30 SP stud farms sampled for EHV-1/-4, 90% (79.3% 
– 100%) had at least one EHV-1/-4 seropositive horse and within these, 48% 
showed a seroprevalence between 60% and 90% in the horses sampled. Due to the 
long-term nature of neutralising antibodies tested in the horses of this cross-
sectional study, the circulation of EHV-1/-4 in SP stud farms (due to horses having 
the virus latent and it reactivating from time to time, or due to horses moving in and 
out of the premises and having contact with other potentially infected horses) 
(Allen, 2002) could not be confirmed, although the presence in our study of EHV-1/-
4 seropositive horses in horses with different ages and from different groups within 
the same stud farm would suggest this idea. In order to confirm the circulation of 
EHV-1/-4 in the SP stud farms of our study different techniques should be used 
(such as CF test which determines short-term antibodies) and/or several samples 
should be taken from the horses in a stud farm in order to evaluate any changes in 
the antibody titres (Gilkerson et al., 1999b; Patel and Heldens, 2005). 
While the SN test is a reference or “gold standard” technique for the diagnosis 
of EHV-1/-4 according to the OIE (OIE, 2013d), the indirect confirmation ELISA used 
in this study (Ingezim Rinoneumonitis 14.HVE.K1®, Ingenasa) performed well as an 
initial screening test. Although this study was not designed to assess the sensitivity 
and specificity of this ELISA test, the specificity of the ELISA when used to test the 
samples in this study (78.8%) was higher than that published in their validation 
study (67%). The ELISA used in this study would be valid as a screening test 
although SN would be needed in order to confirm positive and equivocal results 
(OIE, 2013d).   
 
Even though the awareness of EHV-1/-4 by the veterinary surgeons is higher 
than that of EVA mainly due to the neurological form of the disease, many stud farm 
owners from the present study ignored the implications of this disease. The 
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surveillance plan published in the APA/212/2003 order did not include EHV-1/-4 
(BOE, 2003) even when the outbreaks of EHV-1/-4 tend to be on a larger scale than 
other disease outbreaks, such as EVA, and the economic losses due to abortions and 
neonatal deaths in a stud farm are often devastating (Allen, 2002). 
 
The high seroprevalence of EHV-1/-4 within some of the SP stud farms 
sampled suggests either the presence of carriers with a latent virus that reactivates 
and triggers outbreaks from time to time or the periodic introduction of EHV-1/-4 
into the SP stud farms through horses that move in and out the premises (HBLB, 
2013). The presence of carriers of latent EHV-1/-4 in a breeding stud farm means 
that outbreaks of EHV-1/-4 are difficult to prevent and control, since any situation 
of stress or immune suppression in a carrier can trigger an outbreak of abortions 
(HBLB, 2013). 
In order to apply measures of prevention and control for this disease, 
increased awareness of EHV-1/-4 in the equine breeding industry in Spain would be 
essential and published Codes of Practice including this disease would be beneficial 
to both veterinary surgeons and stud farm owners (HBLB, 2013). Given the high 
seroprevalence of EHV-1/-4 in the SP horses sampled in central Spain and the 
impossibility of diagnosing horses with a latent virus by serology, there would be 
two important measures which should be put in place in SP stud farms in Spain: the 
first one would be a vaccination regime against EHV-1/-4; 54% of the SP stud farms 
sampled in this study had it already and it has been shown that vaccination 
contributes to herd immunity and, together with good management practices, 
lowers the probabilities of abortion storms in a stud farm (Allen, 2002; Mayr, 1987). 
The second measure would be to educate and increase the awareness regarding 
management and control measures against an outbreak of EHV-1/-4 in a breeding 
stud farm in order to minimize the consequences (HBLB, 2013). 
The subset of EHV-1/-4 unvaccinated horses sampled in this study and used 
for the analysis of EHV-1/-4 (n=334) could not be compared with a reference 
population of EHV-1/-4 unvaccinated horses due to data from this reference 
population not being available. However, since there was an excellent 
representation of the SP breeding horse population in central Spain in the sample 
population of this study and the percentage of EHV-1/-4 unvaccinated horses in the 
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sample of this study is likely to be similar to that in the wider population in central 
Spain, EHV-1/-4 results in this study may well be extrapolated to the whole SP 
breeding population in central Spain and also possibly throughout Spain. However, 
given the differences in the management of a breeding stud farm and the 
management of livery yards or other types of premises within the equine industry 
in Spain (MAPA, 2003), these results could probably not be extended to the whole 
equine population in this country. 
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V.3 CHARACTERISTICS, GENERAL MANAGEMENT AND 
HEALTH IN SP BREEDING STUD FARMS IN CENTRAL SPAIN. 
 
Information is scarce as to how SP horses are kept and managed in Spain and, 
data regarding demographics and management have not previously been available 
exclusively for this breed in Spain. There are only two studies carried out and 
focused on this subject: the first study dates back to 2003 and collected data from 
breeding stud farms (including those breeding SP horses but also other breeds) 
(MAPA, 2003), and the second was published recently and provided information 
regarding all types of equine premises and all breeds (including stud farms but also 
livery yards, racetracks, private yards, etc.) (Deloitte, 2013). The results of our study 
provide a detailed description of the demographic characteristics, general 
management and health measures implemented in SP stud farms in the central area 
of Spain. 
The SP stud farms in this study were chosen using non-random methods. 
While random sampling from all SP stud farms in the central area of Spain may have 
resulted in a more representative sample, this was considered to be impractical and 
would have posed logistical difficulties. However, the variety of SP breeding stud 
farms sampled in this study in terms of size, density of population and climate were 
considered to be representative of the common practices on SP breeding farms in 
central Spain at the time of the survey.  
Regarding the questionnaire of general management and health conducted 
in the SP stud farms, it is possible that where stud farm owners assisted in 
questionnaire completion, they may have provided answers that they believed were 
“correct” (social acceptability bias), but this was considered unlikely as a number of 
them actually indicated that they had limited or no protocols in place to prevent the 
spread of disease. It should also be noted that none of the SP stud farms had had a 
very recent disease outbreak so the questionnaires were conducted in a relatively 
disease-free environment, which may have influenced their responses since some 
studies published following the 2007 EI outbreak in Australia have shown that 
disease outbreak experiences can influence owner perceptions about disease 
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control (e.g. owners that had no long-term impacts resulting from the 2007 EI 
outbreak were more likely to have lower biosecurity compliance (Schemann et al., 
2011) whereas managers of horse premises that experienced EI infection in their 
horses in 2007 reported increased levels of perceived vulnerability to a future 
outbreak (Schemann et al., 2013). Memory decay in responders may have 
introduced error, as they were asked to provide details regarding characteristics of 
the stud farm within the previous 12 months; however, most veterinary surgeons 
and stud farm owners kept data in a stud farm diary which was checked in case of 
doubts.  
The 35 SP breeding stud farms sampled in this study were considered 
representative of the whole population of SP stud farms in the central area of Spain 
in terms of location, climate, area size and number of horses. Regarding location, the 
greatest proportion of stud farms sampled were located in Madrid, Toledo and 
Segovia. Stud farms in these locations accounted for the 73% of the total, compared 
to 80.5% of SP stud farms in these locations registered in the census of 2012 
(MAGRAMA, 2012). The distribution by area followed this demographic pattern and 
most of the SP stud farms were located in the NW and SW of the central area (69% 
in total). The SP stud farms sampled covered locations with all the climate types in 
central Spain, and 48% of the stud farms had CSA climate, which is the most 
prevalent in Spain being present in 40% of the country (Rubel and Kottek, 2010). 
The sample of SP stud farms in this study had slightly larger total surface area than 
the ones included in the census of 2001 (mean 0.53 km2 vs. 0.35 km2 respectively); 
although the median would have been a better figure to make the comparison, this 
data was not available in the census (MAPA, 2003). The census of 2001 also reported 
a lower number of horses per stud farm (30 horses vs. 48.1 horses in the SP stud 
farms of this study). The differences in these figures could have been due to the 
present study sampling a small number of SP stud farms compared to the census of 
2001, but they could also be due to the increased confidence of stud farm owners in 
the period of economic growth in Spain from 2001-2007 which could have made 
that the inversion in land and horses was higher than in the previous years (MAPA, 
2003). 
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Within the 35 SP stud farms sampled, 60% were associated to a Breeder´s 
association, most of them associated to ANCCE. This association has 541 members 
up to date, which represents nearly the 25% of the SP stud farms in Spain and 
focuses on the improvement of the SP breed and its promotion through the 
organisation of competitions (ANCCE, 2014). A higher level of associations within 
the SP stud farms or the creation of an industry institution such as the HBLB in the 
UK would involve an easier way to educate stud farm owners with regards to the 
communication, prevention and control of equine infectious diseases (HBLB, 2013). 
Nearly half of the SP stud farms sampled (46%, n= 16/35) were involved in 
equine activities other than the breeding of SP horses, most commonly dressage or 
liveries; these activities increase the risk of introduction of equine infectious 
diseases since they involve more movements in and out of the premises and more 
contact with horses from other premises (Ather and Greene, 2005). 
Regarding the horses living in the SP stud farms of this study, a typical SP 
stud farm in our sample would have 16 breeding mares, no mares retired from 
breeding, 3 breeding stallions, 7 geldings and/or stallions older than 4 years old but 
without a history of covering mares, no teasers, 4 suckling foals, 6 yearlings and 8 2-
3 year-old horses. This distribution reflects a lower use of the SP breeding stallions 
compared to other breeds using natural covering such as the Thoroughbred (8 
mares bred by a stallion in the SP stud farms of this study vs. 20 mares bred by a 
stallion in the Thoroughbred breed in America)(The Jockey Club, 2013). It also 
reflects the difficulties that SP stud farm owners have to sell their products as there 
were a considerable number of horses that could not be sold at an early age and 
were trained in order to be sold as riding horses; only an average of 5 horses had 
been sold in the past 12 months. 
Nearly half of the SP stud farms sampled (49%, n= 17/35) did not have any 
segregation between breeding mares and young horses and only the 26% of stud 
farm owners (n=9/35) segregated their mares and young horses in small groups. 
This demonstrates that groups in the SP stud farms were selected in order to ease 
management and decrease the costs whereas stud farm owners should be 
encouraged to consider reducing the consequences of an infectious disease 
outbreak when devising their management strategies (HBLB, 2013). 
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Regarding the movements of horses in the SP stud farms of this study, 54% 
of the SP stud farms did not attend any fairs/competitions in the past 12 months, 
but the elevated costs of attending a competition (e.g. an average of 582 euro per 
competition in Madrid (Deloitte, 2013)) could have had an influence on this. Stud 
farm owners were reticent to move their SP stallions and mares to other stud farms 
for breeding purposes (only 26% moved their stallions and 23% moved their mares 
to other SP stud farms); however the percentage of stud farm owners accepting 
visiting mares into their premises was higher (43%, n=15/35). There are no data 
regarding movement of horses in SP stud farms, and the only study to evaluate the 
percentage of horses regularly travelling off their premises was published in the UK 
and reported that only the 13% of horses never left their premises (Mellor et al., 
2001). The harsh economic situation in Spain could have decreased the number of 
movements to fairs, competitions or other stud farms with breeding purposes due 
to the associated costs.  
According to the results of our survey, the number of visits from people 
coming into the premises varied within the SP stud farms of our study; the high 
average of 114 visits from people coming into the premises monthly was influenced 
by the existence of some stud farms that had other activities such as liveries and 
stud farms with a large number of horses which were trained and sold. Therefore 
the median of 15 visits from people may represent realistic figure when 
representing the set of SP stud farms in this study. 
Regarding the implementation of vaccination regimes in the SP stud farms of 
this study, 71% did vaccinate all horses against EI and the same percentage 
vaccinated against Tetanus. Even though there are no data regarding the use of EI 
and Tetanus vaccination in SP horses, these data have been published in the UK 
general horse population (78.8% - 90.5% vaccinated against EI and 81.9% - 95.3% 
vaccinated against Tetanus) (Boden et al., 2013; Hotchkiss et al., 2007; Ireland et al., 
2013), and also in the population of geriatric horses of the UK (66.3% vaccinated 
against EI and 82.8% vaccinated against Tetanus) (Ireland et al., 2011); the reasons 
for the differences between these figures could be due to differences between both 
populations, the desire of some stud farm owners to decrease costs the belief that if 
horses don´t move out of the premises there is no risk of EI infection and the lower 
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perception of EI risk in Spain where the stud farm owners do not hear of any EI 
outbreaks reported compared to UK horse owners who have a higher awareness of 
the disease due to EI outbreaks being sporadically reported. This could have also 
been the reason of the low percentage of SP stud farms that vaccinated against WNV 
(3%, n=1/35), since even when there were outbreaks of WNV reported in the South 
of Spain in 2011, this information somehow does not reach to the stud farm owners 
(OIE, 2014b). 
The use of EHV-1/-4 vaccination in SP breeding horses has not been reviewed 
in the literature and the studies that have evaluated the use of this vaccine in horses 
showed large differences in the figures (90.6% of the horse owners in the UK 
vaccinated their horses against EHV-1/-4 in a study (Boden et al., 2013) compared 
to 4.1% - 20.6% in other studies using the same population (Hotchkiss et al., 2007; 
Ireland et al., 2013). These figures are different to the 40% vaccinated SP horses in 
our study and the 54% SP stud farms with an EHV-1/-4 vaccination regime, but the 
population used in our study is completely different than that in the UK (horses in 
riding clubs and livery yards), and the figures provided by Boden et al. seem to high 
compared to the rest of the studies carried out in the UK (Boden et al., 2013; 
Hotchkiss et al., 2007; Ireland et al., 2013), suggesting the presence of a bias in the 
responders of their survey. 
Within the SP stud farms sampled, the implementation of a worming regime 
was widespread, and only 1/35 SP stud farms did not have a worming regime. Most 
veterinary surgeons wormed 2 times a year (76%), a regime which differs greatly to 
the horse population in other countries, such as the UK, where most of the horses 
are wormed more than 2 times per year (Hotchkiss et al., 2007; Ireland et al., 2013; 
Lloyd et al., 2000; Mellor et al., 2001). Veterinary surgeons used a variety of 
products, although ivermectin was present in most worming regimes, same as in the 
UK horse population (Hotchkiss et al., 2007; Ireland et al., 2013). This is of some 
concern considering the recent reports of ivermectin resistance in horses (Kaplan 
and Nielsen, 2012; Nielsen et al., 2013) and the seroprevalence of cestodes of 18-
24% reported in 2005 in slaughtered horses in central Spain (Meana et al., 2005). 
A high percentage of the SP stud farms included in this study had disinfection 
measures (83%, n=29/35), measures against insects (83%, n=29/35) and rodents 
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(80%, n=28/35). The high percentages of stud farms having these measures 
implemented in the premises could have been due to the respondents giving the 
answers that they believed were correct; and while this could be true with the 
disinfection, the economic implications and disadvantages of having insects and 
rodents in the premises could have made that stud farm owners actually applied 
these measures.  
Regarding the breeding in the SP farms of this study, 48% bred their stallions 
by natural covering while only 26% bred their mares exclusively by natural 
covering. The differences in the breeding protocols between sexes are probably due 
to the introduction of AI techniques that are often used to breed the SP mares with 
stallions of other SP stud farms. There are no data published on the use of natural 
covering and AI in SP breeding horses, therefore these figures could not be 
contrasted. 
Of the SP breeding stud farms sampled, only 18% reported having at least a 
stallion with reproductive problems, while 88% reported having at least one mare 
with reproductive problems. The differences in number of breeding mares and 
breeding stallions in the SP stud farms may have influenced this since the mean 
number of breeding mares was 8 times higher than the mean number of breeding 
stallions in our study. Within the stud farms that had mares with reproductive 
problems, the mean percentage of these mares in the stud farms was very similar to 
the percentage of mares with reproductive problems in the sample (24.8% vs. 29% 
respectively); therefore the percentage of mares with reproductive problems 
sampled would be representative of the SP stud farms sampled in central Spain. The 
most worrying data pertained to late abortions, since 29% of all SP stud farms 
sampled reported at least one late abortion in the past 12 months. This would 
involve a high economic loss for the owner of the stud farm, since the breeding of 
each horse involves a major investment of time and money (Schulman et al., 2013). 
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V.4 ASSOCIATION OF EIA, EVA AND EHV-1/-4 STATUS WITH 
INDIVIDUAL OR STUD FARM RISK FACTORS  
 
V.4.1 Association of Equine Infectious Anaemia status with 
individual or stud farm risk factors  
 
Given the lack of seropositive results for EIA in the population sampled in this 
study, it was not possible to analyse the data in order to find any significant 
statistical associations between EIA positive status and individual horse level risk 
factors or with factors related to management practices regarding the prevention 
and control of equine infectious diseases implemented in the SP breeding stud 
farms.  
It should be noted that the 83% of the SP breeding stud farms sampled in this 
study had routine measures against insects implemented in the premises. While 
most of the stud farms where these measures were implemented used chemicals, 
interestingly 14% used a more natural approach, by installing ultraviolet lamps, 
nets, fly-capture sticks, or providing garlic in the horses feed. The presence of any 
measures, whether chemicals or natural approaches, against insects is important 
considering that the major route for EIA transmission are biting insects. Even 
though these measures were probably not implemented due to the fear of an EIA 
outbreak in the stud farms but most likely to make the horses more comfortable and 
ease the management in the stud farm, these measures should be implemented in 
every stud farm, since they can help prevent EIA infection and transmission (Issel 
and Foil, 1984). 
Given the situation in nearby European countries with regards to EIA, other 
measures for the prevention of EIA to be implemented in order to keep Spanish SP 
stud farms free from EIA infection would be routine testing of the horses prior to 
importation into Spain and after their arrival; these measures have already been 
implemented in other countries (such as the UK) when importing horses from 
countries where EIA cases have been confirmed (such as Romania) and would be of 
extreme importance in Spain (HBLB, 2013). 
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V.4.2 Association of Equine Viral Arteritis status with 
individual or stud farm risk factors  
 
The results of the analyses presented in this study did highlight several 
established as well as some apparently previously unrecognised risk factors for the 
individual seropositivity to EVA in the SP horses sampled.  
Among the individual risk factors identified in the univariable analysis (sex, 
age, breeding activity and reproductive problems, and EHV-1/-4 vaccination), the 
only factor that was included in the multivariable analysis (decision tree) was the 
age (p<0.001). According to the decision tree analysis, horses older than 8 years 
would have the highest probability of being EVA seropositive (52%) in the 83 horses 
living in premises where more than 50 people came in monthly to the premises and 
where there was a density of population of 125 – 800 horses/km2. Previous studies 
have shown that the age was a risk factor for seropositivity to EVA (Gimeno Suarep 
et al., 2011b; Rola et al., 2011); given that horses only need one encounter with EAV 
to be seropositive for life (Timoney, 2003), the increased risk of EVA seropositivity 
with age in the population of our study would be due to an increased risk of 
encountering at least one exposure to EAV within the history of the horse up to the 
time of the cross sectional sampling of this study.  
Some seroprevalence studies showed that there was a significantly higher 
proportion of seropositive mares compared to stallions (Gimeno Suarep et al., 
2011a; Hullinger et al., 1998; Rola et al., 2011). Even when sex was associated to 
EVA seropositivity in the univariable analysis (mares were 2.3 times more likely to 
be EVA positive than stallions), sex was not pointed out as a potential risk factor by 
the decision tree analysis due to other factors deemed stronger and, in order to 
confirm the association shown by the univariable analysis, a multivariable, mixed 
logistic regression analysis (including the stud farm factor as a random effect) 
should be carried out.  
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According to the decision tree analysis, within the SP horses sampled in this 
study (n=555), the stud farm factor highlighted as potentially most influential on the 
EVA seropositivity of the horses was the density of horse population in the stud farm 
(p<0.001), followed by the average number of visits from people coming monthly 
into the stud farm (p<0.001) and the climate of the location where the stud farm was 
situated (p<0.001). Other stud farm risk factors that were associated to but had less 
influence on the EVA seropositivity were the number of acquired and/or visiting 
horses (p=0.001), and the segregation of breeding mares from youngsters in the 
stud farm (p<0.001).  
Within the 555 SP horses sampled, 100% of those living in premises with 
≤125 horses/km2 were negative to the EVA VN, whereas 16.7% of horses living in 
premises with >125 and ≤ 800 horses/km2 were positive and this percentage was 
even higher (36%) in those horses living in premises with > 800 horses/km2. Even 
though a multivariable, mixed logistic regression analysis (including the stud farm 
factor as a random effect) should be carried out in order to confirm this risk factor 
in the population of SP horses of this study, this variable had also been found to be 
significant in the univariable analysis; horses living in stud farms with more than 
500 horses/km2 were 5.45 times more likely to be EVA seropositive. There are no 
data in the literature that associates horse density of population to a higher 
probability of being EVA seropositive, but McCollum and Swerczek reported higher 
morbidity rates in EVA outbreaks occurring in large concentrations of horses such 
as racetracks (McCollum and Swerczek, 1978), and some studies focused in other 
equine diseases did show that a high density of population in a stud farm does 
increase the risk of transmission of infectious diseases (Backer and Nodelijk, 2011; 
Glass and Barnes, 2013). Therefore in the SP stud farms with a high density of horse 
population, measures of prevention and control of EVA related to the detection and 
isolation of possible carriers or acutely infected horses would be strongly advised 
(HBLB, 2013; Holyoak et al., 2008). Semen shedding stallions should be identified in 
these stud farms and only previously EVA seropositive mares should be bred with 
them in order to reduce the burden of infection within the population; in time (as 
the shedding stallions retire) SP stud farms should look to eradicate EAV from the 
SP breeding herd and implement an annual testing routine to make the possibility 
of vaccinating all seronegative stallions and new stallions worthwhile.  
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Among the risk factors highlighted by the decision tree and within the group 
of SP horses that lived in premises with >125 and ≤ 800 horses/km2, the average 
number of visits from people coming monthly into the stud farm in the past 12 
months was significantly associated to EVA status. Thirty-four percent (34%) of the 
horses living in stud farms where there were more than 50 visits from people 
coming monthly into the premises were seropositive to EVA vs. only the 3% in stud 
farms where there were ≤50 visits from people. Again this factor had also been 
found to be significant in the univariable analysis comprising the 555 SP horses of 
the study; horses living in stud farms where there were more than 50 visits from 
people coming monthly into the premises were 2 times more likely to be positive to 
EVA. This could be due to a possible EVA iatrogenic transmission by fomites used by 
vets or people from the equine industry that visited the stud farms which has 
previously been reported elsewhere (Timoney and McCollum, 1993b), or it could be 
due to the fact that most of the SP stud farms with more human visitors did have 
regular horse movements into the yard such as acquired horses, or mares/stallions 
visiting the premises with breeding purposes; the number of acquired horses was 
also a variable associated to EVA status in two of the groups of SP horses in which 
the decision tree divided the sample population. Therefore biosecurity measures 
should be extreme in the SP stud farms where there are regular human or horse 
movements (Ather and Greene, 2005). 
Regarding the climate of the locations where the SP stud farms of this study 
were situated, EVA was more prevalent in locations with a temperate with dry or 
temperate summer (CSB) and cold with temperate and dry summer (DSB) climate, 
present in some areas of Segovia, Ávila and the NW of Madrid. Even though the 
climate has not yet been considered a risk factor for the transmission of EVA, it has 
been associated to the transmission of other diseases such as EIA due to the 
association of warm and humid climates to the presence of the vector (Bicout et al., 
2006; Borges et al., 2013). The locations with both of these climates are the ones 
where the temperature during the summer is the lowest of all, and this could have 
an influence on the virus survival outside the horse (e.g. in fomites), since the 
survival of EAV has been found to be temperature dependant (it may survive only 
20-30 minutes at 560C, from 2 to 3 days at 370C and up to 75 days at 40C (Holyoak 
et al., 2008; Timoney, 2003). There would also be differences in the management of 
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the horses which would depend on the climate; during the colder months of the year, 
stud farms in a location with a colder climate tend to keep horses in larger groups 
and indoor, whereas stud farms in a location with a milder climate tend to leave 
horses outside in paddocks where the density of population is lower.  
Interestingly, within the population of horses living in locations with a 
temperate/cold with dry or temperate summer climate (CSB or DSB) of our sample 
(n=43), 100% of the horses living in stud farms where breeding mares and 
youngsters were not segregated were negative for EVA VN whereas those living in 
premises that did segregate these two groups had a probability of being EVA 
seropositive of 92%. The reasons for this association could be that the SP stud farms 
where mares were separated from youngsters had a large number of breeding 
mares, which could increase the chances of EVA respiratory transmission in the 
event of an outbreak (del Piero, 2000b; Monreal et al., 1995). 
To summarise, within the SP horses sampled in this study, those residing in 
stud farms where there was a high horse density of population would benefit from 
a solid implementation of measures of prevention and control of EVA related to the 
detection and isolation of possible carriers or acutely infected horses (HBLB, 2013; 
Holyoak et al., 2008), SP horses from stud farms with a large number of visits from 
people or a large number of horses moving in and off the premises would benefit 
from the implementation of biosecurity measures and routine EVA testing prior to 
the introduction of new horses to the stud farm (Ather and Greene, 2005; HBLB, 
2013), and finally stud farm owners in locations with a cold/temperate with dry and 
temperate summer should be especially careful during the colder months and a 
thorough disinfection scheme should be in place in order to get rid of viruses (such 
as EVA) persisting in the environment and causing further infections in the event of 
an outbreak (Holyoak et al., 2008; Mumford et al., 1987). 
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V.4.3 Analysis of the association of EHV-1/-4 status with 
individual or stud farm risk factors in the SP horses sampled. 
 
Among the individual risk factors identified in the univariable analysis (age, 
and breeding activity and reproductive problems), the only of these factors included 
in the multivariable analysis (decision tree) was the age (p<0.001) in the 334 horses 
of the study.  
The association between age and EHV-1/-4 seropositivity has been studied 
in the past and a gradual increase in the risk of exposure to EHV-1/-4 was observed 
in several studies (Allen, 2002; Liutkevicien et al., 2006; Ruiz-Saenz et al., 2008). 
According to the univariable analysis carried out in the 334 unvaccinated SP horses 
of this study, the increase in the risk of exposure to EHV-1/-4 was of 1.2 times for 
every year of age. Even though a multivariable, mixed logistic regression analysis 
(including the stud farm factor as a random effect) should be carried out in order to 
confirm this association, age was found to be he variable with more influence on 
EVA seropositivity of the EHV-1/-4 unvaccinated horses sampled (n=334), 
according to the results of the decision tree analysis (p<0.001). 
Even though sex was not considered a risk factor in the whole population of 
unvaccinated SP horses of this study (n=334) according to the univariable analysis 
(p=0.067), it was in a small group of horses (n=55) according to the decision tree 
(p=0.007). In this group, mares were more likely to be seropositive than stallions 
(46% vs. 10%). This has been seen by other authors (Liutkevicien et al., 2006), 
although it would have to be interpreted with caution in this study due to this risk 
factor not being significantly associated in the wider population of SP horses 
sampled and it should be confirmed by a multivariable, mixed logistic regression 
analysis.   
Other risk factors identified in this analysis were the average number of visits 
from people coming monthly into the stud farm (p=0.006), whether the stud farm 
was associated to a Breeder´s association (p=0.002), the location of the SP stud farm 
in the central area of Spain (p=0.026), the segregation of mares from youngsters in 
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the stud farm (p=0.02) and the outings to fairs and/or competitions in the previous 
12 months (p=0.013).  
Within the group of SP horses younger than 3.5 years sampled (n=96), those 
living in premises where more than 50 visits from people coming in monthly had a 
lower probability of being EHV-1/-4 positive and this association had also been 
found in the univariable analysis carried out in the whole population of 
unvaccinated SP horses of the study (n=334). The stud farms with more human 
visits would also have had more movements of horses into the premises (p<0.001) 
and therefore the owners and/or veterinary surgeons could have been more aware 
of the risks of introduction of EHV-1/-4 by the horses coming into the premises, 
implementing an EHV-1/-4 vaccination regime (p<0.001). Therefore and in the SP 
stud farms with a large number of visits from people or a large number of horses 
moving in and off the premises, the implementation of biosecurity measures and the 
routine EHV-1/-4 vaccination of the horses is key in order to lower the risk of 
introducing EHV-1/-4 into the stud farm (Ather and Greene, 2005 ; Glass and Barnes, 
2013). 
Interestingly and even though this factor was not considered significant in 
the univariable analysis carried out in the 334 unvaccinated SP horses, according to 
the decision tree the association of the SP stud farm to a Breeders´ association would 
be a risk factor for EHV-1/-4 seropositivity in the group of horses between 3.5 and 
7 years (n=121); those horses living in SP stud farms that were associated to a 
Breeders´ association had a higher probability of being EHV-1/-4 seropositive (61% 
vs. 33%) (p=0.002). The reason for this could be that the different SP Breeders´ 
associations in Spain promote the SP breed by organising fairs, competitions, sales, 
etc. (ANCCE, 2014). Therefore the real risk factor, which was also highlighted by the 
decision tree in a group of 66 SP horses and has been associated with a higher risk 
of EHV-1/-4 infection in the literature, would be the number of horse movements in 
the premises (Lunn et al., 2009; Mumford et al., 1987). Again, these SP stud farms 
with a high number of horses moving in and off the premises would benefit from the 
implementation of biosecurity measures and a routine EHV-1/-4 vaccination of the 
horses in the stud farm (Ather and Greene, 2005 ; Glass and Barnes, 2013). 
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Within the group of horses older than 7 years of age (n= 117), which was the 
group with the highest percentage of EHV-1/-4 seropositives, location was 
pinpointed as a risk factor. Horses living in SP stud farms located in the South of the 
central region were 1.3 times more likely to seropositive to EHV-1/-4 than those 
living in the North (83% vs. 65% respectively); the same relationship had been 
found in the univariable analysis comprising the 334 SP horses sampled (OR= 2.05). 
Whereas some studies have found differences in the seroprevalence of EHV-1/-4 
between areas of the same country (Ataseven, 2010; Ataseven et al., 2009), other 
studies revealed no differences between areas (Ruiz-Saenz et al., 2007, 2008). In our 
study, most of the SP stud farms located in the South of the central region had other 
equine activities in the premises (dressage, liveries, etc.) (p<0.001) and the horses 
in these stud farms went out to more fairs and competitions than the horses in SP 
stud farm in the North of the central region (p<0.001). These factors have previously 
been related to the presence of EHV-1/-4 and other viral infections in horse 
premises and could have had an influence in this study (Lunn et al., 2009; Mumford 
et al., 1987). Therefore the number of human and horse movements in and off the 
premises would have an influence in SP stud farms, where the implementation of 
biosecurity measures (e.g. the isolation and quarantine of new horses) and a routine 
EHV-1/-4 vaccination of the horses would be benefitial (Ather and Greene, 2005 ; 
Glass and Barnes, 2013). 
Even when not considered significant in the univariable analysis comprising 
the whole population of unvaccinated horses of this study (n=334), according to the 
decision tree analysis and in two groups of horses (n=69 and n=63 respectively), 
separating the breeding mares from the young horses in the stud farm was 
protective against EHV-1/-4 infection; in both groups horses living in stud farms 
where mares were not separated from youngsters had twice the probability of being 
EHV-1/-4 seropositive than those living in stud farms where this segregation 
existed. It has been published that the mare and foal population is 
a reservoir of EHV-1, from which new cases of infection propagate through the foal 
population both before and after weaning; the long standing management practices 
of separating pregnant mares from other groups of horses have demonstrated to 
reduce the incidence of EHV-1 abortion (Gilkerson et al., 1999a) and this measure 
would be of much benefit in the SP stud farms in central Spain. 
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To summarise, within the SP horses sampled in this study, the 
implementation of biosecurity measures and a routine EHV-1/-4 vaccination regime 
in the horses of the stud farm would be key in order to reduce the risk of the 
introduction of EHV-1/-4 into the stud farm (Ather and Greene, 2005 ; Glass and 
Barnes, 2013), and this would be especially important in those horses residing in 
stud farms with a large number of visits from people, a large number of horses 
moving in and off the premises, stud farms with other equine activities in the 
premises and those where the horses go out to fairs and/or competitions (Lunn et 
al., 2009; Mumford et al., 1987). All SP stud farms would also benefit from the long 
standing management practices of separating pregnant mares from other groups 
of horses, which have demonstrated to reduce the incidence of EHV-1 abortion 
(Gilkerson et al., 1999a). 
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V.5 OCCURRENCE OF REPRODUCTIVE PROBLEMS IN THE SP 
MARES AND STALLIONS OF THE STUDY. 
 
Of the SP breeding mares sampled in the study, 29% (23%-34%) were 
reported to have had at least one reproductive problem in the past 12 months. There 
are no data published regarding the prevalence of reproductive problems in SP 
mares or stallions; the only studies that have been published on this subject were 
carried out either in Lusitano mares (a breed that has plenty of genetic similarities 
to the SP horse (Lopes et al., 2005)) or in Standardbred mares. Lusitano mares had 
a foaling rate (percentage of foalings in the mares within the covered or inseminated 
mares) of 74.5%, which means that, similarly to our study, 25.5% of mares had a 
problem that impeded foaling (Fradinho et al., 2014), whereas Standardbred mares 
had a foaling rate of 71% and therefore a 29% of mares with a reproductive 
problem, same as the mares in our study (Katila et al., 2010). In our study, the mean 
age of the SP breeding mares with reproductive problems was significantly higher 
than that in the SP breeding mares without reproductive problems (p=0.02); the 
association between age and the occurrence of reproductive problems has already 
been shown in a study where foaling rates decreased with age (Katila et al., 2010) 
and a study where mare age had a significant impact on efficiency of becoming 
pregnant, maintaining pregnancy and producing a live foal (Bosh et al., 2009). 
In the SP mares with reproductive problems of this study (n=74), gestation 
loss was the most frequent problem [n=38/74, 51% (40% - 62.7%)], and the 
suspected cause for gestation loss was identified only in 4 out of these 38 mares 
[10.5% (0%-18%)], which is quite low compared to other study where the cause 
was found in 58.7% of the cases (Marenzoni et al., 2013). Within the mares with 
gestation loss of our study, most had late abortions [n=20/38 mares, 53% (37%-
68%)], which is a cause for concern due to the high economic costs associated to a 
late abortion (Allen, 2002, 1999; de Mestre, 2013; Schulman et al., 2013). In our 
study and within the few cases that were investigated by the veterinary surgeon of 
the stud farm, no viral infections were reported to be the cause for gestation loss or 
neonatal disease. This is in contrast to other study where EHV was found to be the 
causing agent for 40% of fetal loss (Marenzoni et al., 2013), showing that EHV-1/-4 
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was probably not even considered as a cause of abortion in many of the mares of 
this study. Therefore an effort should be made to increase the awareness of 
veterinary surgeons and stud farm owners about the investigation of the cause of 
abortions and the need to analyse the foetus and/or placenta and also to make them 
consider viral diseases (such as EHV-1/-4 and EVA) as one of the main causes for 
abortion and neonatal disease (HBLB, 2013; Marenzoni et al., 2013; Timoney and 
McCollum, 1993b). 
Of the SP breeding stallions sampled in the study, only 7% (1.5%-11-7%) 
were reported to have reproductive problems during the past 12 months, and out of 
these horses, 50% showed a lack of libido. There are no data published regarding 
the prevalence of reproductive problems in SP stallions or stallions of other breeds, 
however, in a study that evaluated the behaviour of SP stallions during mating, 
13.8% showed no erection and 17.2% showed no ejaculation (Hernández et al., 
2000). 
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V.5.1 Association of reproductive problems with EVA status 
 
Even though EVA infection has only been associated to abortions in mares, 
death or disease in the newborn foals and a possible transient decrease in the 
fertility in the infected stallion and that no signs of a decrease in problems or fertility 
have been demonstrated in the infected mare further to the elimination of the virus 
(Huntington et al., 1990a; Timoney, 2003; Timoney and McCollum, 1993b), when 
the association between EVA seropositivity and the presence of specific 
reproductive problems in the past 12 months was analysed in the SP mares sampled 
showing reproductive problems (n=74) compared to the active breeding mares with 
no reproductive problems (n=183), significant associations were found for some 
problems such as cyclic irregularities/repeat breeding (p=0.006), late abortions 
(p=0.006) and problems with the neonate (p=0.006).  
Interestingly, even though EVA has previously been isolated from abortions 
that occurred from 3 to 10 months (Timoney and McCollum, 1993b), EVA 
seropositivity was not associated with the occurrence of early abortions in the SP 
mares of this study. 
Since EVA antibodies remain in serum for a long time (even for life) in 
infected horses (Timoney, 2003; Timoney and McCollum, 1993b), it would be 
difficult to ascertain whether EVA infections happened in the past 12 months, 
explaining the presence of reproductive problems in these mares, or if EVA 
infections happened long prior to the past 12 months, leaving these mares with 
reproductive sequelae which could have predisposed to  cyclic irregularities, late 
abortions or problems with their neonate. Another reason could be the fact that 
active breeding mares with reproductive problems would have had an increased 
number of exposures to several stallions and therefore to possible carriers of the 
EAV.  
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VI. FUTURE WORK 
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VI. FUTURE WORK 
 
 
In addition to providing valuable information, relevant to both veterinary 
surgeons and SP stud farm owners, regarding the current situation of EIA, EVA and 
EHV-1/-4 in SP stud farms in central Spain, this work has also described the 
characteristics and management measures with regards to the prevention and 
control of equine infectious diseases in this population of stud farms.  Within these 
characteristics and management measures, this study has identified several 
potential risk factors associated with EVA and EHV-1/-4 seropositivity in the SP 
horses in central Spain. The potential risk factors highlighted by this study are areas 
that would require targeted research and further academic study.  
Given the highly complex and clustered nature of the data gathered during 
this study, additional analysis of the variables presented within this thesis by means 
of a multivariable mixed logistic regression will take into account a possibly 
associated stud farm factor and will provide more reliable results regarding risk 
factors associated with EVA and EHV-1/-4 seropositivity. The model obtained in 
future work would aid predicting which horses are more likely to be seropositive to 
EVA and/or EHV-1/-4 and it will be validated in horses different to those sampled 
in this study but from the same reference population. A predictive model would be 
of invaluable help, for example when trying to implement a routine testing scheme 
for EVA and introduce EVA vaccination in Spain. 
 
 
 
 
 
 198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 199 
 
 
 
 
 
 
 
 
 
 
 
VII. CONCLUSIONS 
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VII. CONCLUSIONS 
 
1. The absence of EIA seropositive animals in our study provided evidence of 
freedom from EIA infection in the SP breeding horse population in central 
Spain, despite the recent EIA outbreaks in nearby European countries and 
the frequent national and international horse movements in this area.  
 
2. The seroprevalence of EVA in the horse population [17.3% (14.2% - 
20.4%)] and in the SP stud farm population [37.1% (21.1% - 53.1%)] of 
this study was highly relevant; therefore EVA should not be considered a 
sporadic disease in the SP stud farms in central Spain.  
 
3. Within the unvaccinated population of this study, EHV-1/-4 seroprevalence 
in the horses [53.3% (47.9% - 58.6%)] and in the SP stud farms [90% 
(79.3% - 100%)] demonstrated that this disease is widely spread in the SP 
breeding horse population in central Spain.  
 
4. Nearly half of the SP stud farms sampled in this study (46%) reported having 
equine activities other than breeding in the premises, the same percentage 
(46%) reported outings to fairs and competitions with their horse and 54% 
acquired new horses in the past 12 months, demonstrating that horse 
movements are frequent in the SP stud farms in central Spain.  
 
5. Most of the SP stud farms sampled had basic measures of prevention and 
control of equine infectious diseases, such as a worming regime (97%), a 
disinfection regime (83%), measures against insects (83%) and rodents 
(80%). However, nearly half of the SP stud farms showed an absence of 
specific measures, such as an EHV-1/-4 vaccination regime (46%) and 
segregating breeding mares from young horses (49%).   
 
6. In our study, 29% (23%-34%) of active breeding SP mares in central Spain 
showed reproductive problems in the past 12 months, of which gestation loss 
was the most frequent problem, and only 7% (2-12%) of active breeding SP 
stallions showed reproductive problems related to a lack of libido or 
abnormalities in the semen.  
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7. In order to maintain the SP breeding horse population in central Spain free 
from EIA infection, measures against insects should be implemented in 
every stud farm and judicious biosecurity that includes routine EIA testing 
of the horses prior to importation into Spain and after their arrival should be 
established to prevent the introduction of subclinically EIA infected horses 
from Europe. 
 
8. Within the SP horses of this study, those residing in stud farms where there 
was a high horse density of population, or had a large number of visits 
from people or frequent movements of horses were more likely to be EVA 
seropositive; these stud farms should establish good biosecurity measures 
in the premises as well as a prompt detection and isolation of possible 
carriers or acutely infected horses and routine EVA testing prior to the 
introduction of new horses.  
 
9. Older SP horses, and those residing in stud farms with a large number of 
visits from people, frequent movements of horses and other equine 
activities in the premises were more likely to be EHV-1/-4 seropositive; 
the implementation of biosecurity measures, routine EHV-1/-4 vaccination 
and specific measures such as separating pregnant mares from other horses 
would be key in order to reduce the risk of the introduction of EHV-1/-4 into 
these stud farms.  
 
10. In our study, EVA seropositivity was associated to the occurrence of cyclic 
irregularities/repeat breeding (p=0.006), late abortions (p=0.006) and 
problems with the neonate (p=0.006), suggesting that EVA should be 
considered when investigating the cause for reproductive problems in the SP 
mares in central Spain.  
 
11. In our opinion, the data obtained in the present study should encourage the 
Administration, the different Breeders´ associations and veterinary surgeons 
to pursuit the education and awareness of stud farm owners regarding the 
presence, prevention and control of equine infectious diseases in a breeding 
stud farm.  
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VIII. APPENDIXES 
 
APPENDIX 1. Questionnaire of reproductive problems in the SP stallion. 
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APPENDIX 2. Questionnaire of reproductive problems in the SP mare.  
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APPENDIX 3. Questionnaire of general management and health in SP 
breeding stud farms in central Spain.  
 
 210 
 
 
 
 211 
 
 
 
 
 212 
 
 
 
 213 
 
 
 
 214 
 
 
 
 215 
 
 
 
 216 
 
 
 
 217 
 
 
 
 218 
 
 
 219 
 
APPENDIX 4. Individual characteristics and EVA ELISA, EVA SN, EHV-1/-4 ELISA, EHV-1 and EHV-4 SN results of the SP horses included in the study. 
No ID SEX AGE 
ACTIVE 
BREEDER 
REPRODUCTIVE 
PROBLEMS 
EHV-1/-4 
VACCINATION 
SAMPLING 
DATE 
EVA 
ELISA 
EVA 
SN 
EHV 
ELISA 
EHV-1 
SN 
EHV-4 
SN 
1 A1 Stallion 13 yes no no 28/09/2011 Negative  Negative   
2 A2 Stallion 6 yes no no 28/09/2011 Negative  Negative   
3 A3 Stallion 4 yes no no 28/09/2011 Negative  Positive 2.3 1.5 
4 A4 Mare 21 yes yes yes 28/09/2011 Negative     
5 A5 Mare 6 yes no yes 28/09/2011 Negative     
6 A6 Mare 9 yes no yes 28/09/2011 Negative     
7 A7 Mare 10 no n/a no 28/09/2011 Negative  Positive 2.6 2 
8 B1 Stallion 5 no n/a no 06/10/2011 Positive 3.2 Positive 1.5 1.2 
9 B2 Stallion 7 no n/a no 06/10/2011 Positive 3.5 Positive 1.8 1.7 
10 B3 Stallion 12 no n/a no 06/10/2011 Negative  Positive 1.4 1.7 
11 B4 Stallion 9 no n/a no 06/10/2011 Positive 3.1 Positive 2.4 1.4 
12 B5 Stallion 6 no n/a no 06/10/2011 Positive 2.4 Negative   
13 B6 Stallion 4 no n/a no 06/10/2011 Negative  Negative   
14 B7 Mare 2,5 no n/a no 06/10/2011 Negative  Negative   
15 B8 Mare 14 yes yes no 06/10/2011 Negative  Positive >2.6 1.8 
16 B9 Stallion 4 no n/a no 06/10/2011 Negative  Positive 1.2 1.4 
17 B10 Stallion 4 no n/a no 06/10/2011 Negative  Equivocal 2 1.5 
18 B11 Stallion 8 no n/a no 06/10/2011 Positive 3.5 Positive 1.7 0.9 
19 C1 Stallion 9 yes yes no 07/10/2011 Negative  Positive >2.6 2 
20 C2 Stallion 15 yes yes no 07/10/2011 Positive 1.7 Positive >2.6 2 
21 C3 Stallion 24 no n/a no 07/10/2011 Positive < 0.6 Positive 2.1 1.5 
22 C4 Stallion 6 no n/a no 07/10/2011 N.I. < 0.6 Positive 2.6 1.4 
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No ID SEX AGE 
ACTIVE 
BREEDER 
REPRODUCTIVE 
PROBLEMS 
EHV-1/-4 
VACCINATION 
SAMPLING 
DATE 
EVA 
ELISA 
EVA 
SN 
EHV 
ELISA 
EHV-1 
SN 
EHV-4 
SN 
23 C5 Stallion 13 yes no no 07/10/2011 Negative  Positive 2.6 2.3 
24 C6 Stallion 15 no n/a no 07/10/2011 Negative  Positive 2.4 1.5 
25 C7 Mare 14 yes yes yes 07/10/2011 Positive 2.3    
26 C8 Mare 14 yes yes yes 07/10/2011 Positive 2.3    
27 C9 Mare 17 yes no yes 07/10/2011 Negative     
28 C10 Mare 13 yes yes yes 07/10/2011 Positive 1.7    
29 C11 Mare 8 yes yes yes 07/10/2011 Equivocal 2.3    
30 C12 Mare 19 yes yes yes 07/10/2011 Positive 3    
31 C13 Mare 18 yes yes yes 07/10/2011 Positive 3.4    
32 C14 Mare 13 yes no yes 07/10/2011 Negative     
33 C15 Mare 5 yes no yes 07/10/2011 Negative     
34 C16 Mare 4 yes no yes 07/10/2011 Negative     
35 C17 Mare 4 yes no yes 07/10/2011 Negative     
36 C18 Mare 4 yes no yes 07/10/2011 Negative     
37 C19 Mare 6 yes yes yes 07/10/2011 Negative     
38 D1 Mare 9 yes no no 20/06/2012 Negative  Negative   
39 D2 Mare 7 yes no no 20/06/2012 Negative  Positive 2.3 2 
40 D3 Mare 4 yes no no 20/06/2012 Negative  Positive >2.6 1.8 
41 D4 Mare 18 yes no no 20/06/2012 Negative  Positive >2.6 1.8 
42 D5 Stallion 11 no n/a no 20/06/2012 Negative  Positive 2.4 2 
43 D6 Stallion 8 no n/a no 20/06/2012 Negative  Positive 1.8 1.5 
44 D7 Stallion 6 no n/a no 20/06/2012 Negative  Negative   
45 D8 Stallion 10 no n/a no 20/06/2012 Positive 2.9 Positive 2.3 2 
46 D9 Stallion 10 no n/a no 20/06/2012 Negative  Positive 2.4 1.7 
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No ID SEX AGE 
ACTIVE 
BREEDER 
REPRODUCTIVE 
PROBLEMS 
EHV-1/-4 
VACCINATION 
SAMPLING 
DATE 
EVA 
ELISA 
EVA 
SN 
EHV 
ELISA 
EHV-1 
SN 
EHV-4 
SN 
47 D10 Stallion 7 no n/a no 20/06/2012 Negative  Negative   
48 D11 Mare 6 yes no no 20/06/2012 Negative  Positive 2.6 1.4 
49 D12 Mare 5 yes yes no 20/06/2012 Negative  Positive 2.3 2.3 
50 D13 Mare 8 yes no no 20/06/2012 Negative  Negative   
51 D14 Mare 12 yes no no 20/06/2012 Negative  Positive 2 1.5 
52 D15 Mare 9 yes no no 20/06/2012 Negative  Positive 2.6 2.1 
53 D16 Mare 6 yes yes no 20/06/2012 Negative  Positive 2 1.7 
54 D17 Mare 3 yes no no 20/06/2012 Negative  Positive 2 1.7 
55 D18 Stallion 16 yes no no 20/06/2012 Negative  Positive 2.6 2.3 
56 D19 Mare 8 yes yes no 20/06/2012 Negative  Positive 2.1 1.5 
57 E1 Mare 6 yes no yes 10/10/2011 Positive 2.5    
58 E2 Stallion 7 no n/a no 10/10/2011 Negative  Equivocal 1.1 0.5 
59 E3 Stallion 8 no n/a no 10/10/2011 Negative  Positive 1.7 0.9 
60 E4 Stallion 6 no n/a no 10/10/2011 Negative  Positive 2.6 2.1 
61 E5 Stallion 6 yes no no 10/10/2011 Positive 3.4 Positive 1.4 0.8 
62 E6 Stallion 5 no n/a no 10/10/2011 Positive 2.5 Positive 2.3 1.2 
63 E7 Stallion 4 no n/a no 10/10/2011 Negative  Positive 2.4 2 
64 E8 Stallion 4 no n/a no 10/10/2011 Negative  Positive 1.5 0.8 
65 E9 Mare 17 yes yes no 10/10/2011 Positive 2.9 Positive >2.6 >2.6 
66 E10 Mare 7 yes yes yes 10/10/2011 Positive 3.5    
67 E11 Mare 6 yes yes yes 10/10/2011 Positive 3.2    
68 E12 Mare 8 yes no yes 10/10/2011 Positive 2.6    
69 E13 Mare 9 yes no yes 10/10/2011 Positive 2.7    
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70 E14 Mare 12 yes yes yes 10/10/2011 Positive 3.6    
71 E15 Mare 19 yes no yes 10/10/2011 Positive 3.2    
72 E16 Stallion 2 no n/a no 10/05/2012 Negative  Equivocal 0.8 0.9 
73 E17 Mare 1 no n/a no 10/05/2012 Equivocal 1.4 Equivocal 2.4 2 
74 E18 Mare 1 no n/a no 10/05/2012 Positive 2.6 Positive 2.1 1.8 
75 E19 Stallion 2 no n/a no 10/05/2012 Negative  Positive 2 1.7 
76 E20 Stallion 1 no n/a no 10/05/2012 Positive 3 Positive >2.6 2.7 
77 E21 Stallion 1 no n/a no 10/05/2012 Positive 3.2 Equivocal 1.1 1.8 
78 E22 Stallion 1 no n/a no 10/05/2012 Positive 2.6 Negative   
79 E23 Stallion 2 no n/a no 10/05/2012 Negative  Equivocal 1.4 1.4 
80 E24 Stallion 2 no n/a no 10/05/2012 Negative  Negative   
81 E25 Stallion 2 no n/a no 10/05/2012 Negative  Positive 2 1.7 
82 E26 Stallion 1 no n/a no 10/05/2012 Negative  Negative   
83 E27 Stallion 2 no n/a no 18/03/2012 Negative  Negative   
84 F1 Stallion 2,5 no n/a no 11/10/2011 Negative  Negative   
85 F2 Stallion 10 yes no no 11/10/2011 Negative  Negative   
86 F3 Mare 9 yes yes no 11/10/2011 Negative  Negative   
87 F4 Mare 5 yes n/a no 11/10/2011 Negative  Negative   
88 F5 Mare 6 yes n/a no 11/10/2011 Positive < 0.6 Equivocal 1.4 1.4 
89 F6 Mare 8 yes no no 11/10/2011 Negative  Equivocal 1.7 1.2 
90 F7 Mare 8 yes n/a no 11/10/2011 Negative  Positive >2.6 1.5 
91 F8 Mare 4 yes no no 11/10/2011 Negative  Negative   
92 F9 Stallion 2,5 no n/a no 11/10/2011 N.I. < 0.6 Negative   
93 F10 Mare 8 yes n/a no 11/10/2011 Negative  Negative   
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94 F11 Mare 5 yes n/a no 11/10/2011 Negative  Equivocal 1.7 1.1 
95 G1 Mare 5 yes no no 21/12/2011 Negative  Positive 2 2 
96 G2 Mare 5 yes no no 21/12/2011 Negative  Positive 2 0.5 
97 G3 Mare 5 yes no no 21/12/2011 Negative  Positive 1.7 0.8 
98 G4 Mare 4 yes no no 21/12/2011 Negative  Positive 2.4 1.4 
99 G5 Mare 6 yes no no 21/12/2011 Negative  Positive 2.6 2.3 
100 G6 Mare 8 yes no no 21/12/2011 Negative  Equivocal 1.1 0.8 
101 G7 Mare 8 yes no no 21/12/2011 Negative  Positive 2.4 1.7 
102 G8 Mare 15 yes yes no 21/12/2011 Negative  Positive 2.6 1.8 
103 G9 Mare 11 yes no no 21/12/2011 Negative  Positive >2.6 2 
104 G10 Mare 9 yes no no 21/12/2011 Negative  Positive 2.6 2.3 
105 G11 Mare 4 yes no no 21/12/2011 Negative  Positive 2.6 2 
106 G12 Mare 7 yes no no 21/12/2011 Equivocal < 0.6 Positive 2.1 1.4 
107 G13 Mare 11 yes no no 21/12/2011 Negative  Positive 2.6 1.7 
108 G14 Stallion 11 yes no no 21/12/2011 Negative  Positive >2.6 1.7 
109 G15 Stallion 15 yes no no 21/12/2011 Negative  Positive >2.6 1.7 
110 H1 Mare 8 yes no no 26/12/2011 Equivocal < 0.6 Positive 2.6 >2.6 
111 H2 Mare 3 yes no no 26/12/2011 Negative  Equivocal 1.7 >2.6 
112 H3 Mare 7 yes no no 26/12/2011 Negative  Positive >2.6 >2.6 
113 H4 Mare 3 yes no no 26/12/2011 Negative  Positive 2 >2.6 
114 H5 Mare 7 yes no no 26/12/2011 Negative  Positive 2.1 1.7 
115 H6 Mare 4 yes yes no 26/12/2011 Negative  Positive >2.6 2 
116 H7 Mare 4 yes no no 26/12/2011 Negative  Positive 2.3 2.1 
117 H8 Mare 3 yes no no 26/12/2011 Negative  Negative   
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118 H9 Mare 4 yes no no 26/12/2011 Negative  Equivocal 1.4 0.9 
119 H10 Mare 3 yes no no 26/12/2011 Negative  Equivocal 1.5 1.5 
120 H11 Mare 3 yes no no 26/12/2011 Negative  Positive 1.7 1.4 
121 H12 Mare 3 yes no no 26/12/2011 Negative  Equivocal 1.5 1.2 
122 H13 Stallion 6 yes no no 26/12/2011 Negative  Positive 1.7 1.4 
123 H14 Mare 4 yes no no 26/12/2011 Negative  Positive 1.5 1.7 
124 H15 Mare 3 yes no no 26/12/2011 Negative  Positive 2.6 1.8 
125 H16 Mare 3 yes no no 26/12/2011 N.I. < 0.6 Positive 1.4 1.7 
126 H17 Mare 2 yes no no 26/12/2011 Negative  Positive 2.3 1.5 
127 H18 Mare 11 yes no no 26/12/2011 Negative  Positive >2.6 1.8 
128 H19 Mare 6 yes no no 26/12/2011 Negative  Negative   
129 H20 Mare 4 yes no no 26/12/2011 Negative  Positive 1.7 1.5 
130 H21 Mare 4 yes no no 26/12/2011 Negative  Positive 1.7 2 
131 H22 Mare 6 yes no no 26/12/2011 Negative  Equivocal 1.4 1.4 
132 H23 Mare 4 yes no no 26/12/2011 Negative  Positive 2.6 1.1 
133 I1 Mare 12 yes no yes 26/12/2011 Negative     
134 I2 Mare 16 yes no yes 26/12/2011 Negative     
135 I3 Mare 4 yes no no 26/12/2011 Negative  Negative   
136 I4 Mare 10 yes no yes 26/12/2011 Negative     
137 I5 Mare 4 yes yes no 26/12/2011 Negative  Positive 1.8 1.4 
138 I6 Mare 4 yes yes no 26/12/2011 Negative  Negative   
139 I7 Mare 6 yes no yes 26/12/2011 Negative     
140 I8 Mare 5 yes yes yes 26/12/2011 Negative     
141 I9 Stallion 8 yes no no 26/12/2011 Negative  Negative   
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142 I10 Stallion 17 yes no no 26/12/2011 Negative  Positive >2.6 1.2 
143 I11 Stallion 10 yes no no 12/04/2012 Negative  Positive 2 1.4 
144 I12 Mare 3 no n/a no 12/04/2012 Negative  Equivocal 2.3 1.4 
145 I13 Stallion 9 no n/a no 12/04/2012 Negative  Positive 1.8 1.1 
146 I14 Stallion 3 no n/a no 12/04/2012 Negative  Negative   
147 I15 Stallion 3 no n/a no 12/04/2012 Negative  Negative   
148 I16 Mare 4 no n/a no 12/04/2012 Negative  Negative   
149 I17 Stallion 3 no n/a no 12/04/2012 Negative  Equivocal 1.7 1.7 
150 I18 Stallion 4 no n/a no 12/04/2012 Negative  Equivocal 1.1 0.8 
151 I19 Stallion 3 no n/a no 12/04/2012 Negative  Equivocal 2 1.8 
152 I20 Stallion 3 no n/a no 12/04/2012 Negative  Negative   
153 I21 Stallion 4 no n/a no 12/04/2012 Negative  Equivocal 0.8 1.5 
154 I22 Stallion 4 no n/a no 12/04/2012 Negative  Negative   
155 J1 Mare 9 yes no yes 17/01/2012 Negative     
156 J2 Mare 6 yes no yes 17/01/2012 Negative     
157 J3 Mare 8 yes no yes 17/01/2012 Negative     
158 J4 Stallion 8 yes no no 17/01/2012 Negative  Positive >2.6 2 
159 K1 Stallion 3 no n/a no 17/10/2011 Negative  Negative   
160 K2 Stallion 2,5 no n/a no 17/10/2011 Negative  Negative   
161 K3 Mare 6 yes no yes 17/10/2011 Negative     
162 K4 Mare 6 yes no yes 17/10/2011 Negative     
163 K5 Mare 2,5 no n/a no 17/10/2011 Negative  Negative   
164 K6 Mare 6 yes no yes 17/10/2011 Negative     
165 K7 Mare 6 yes yes yes 17/10/2011 Negative     
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166 L1 Stallion 8 yes no yes 12/04/2012 Negative     
167 L2 Stallion 10 yes no yes 12/04/2012 Negative     
168 L3 Stallion 7 yes no yes 12/04/2012 Negative     
169 L4 Stallion 11 yes no no 12/04/2012 Negative  Positive 2.6 1.4 
170 L5 Stallion 4 yes no yes 12/04/2012 Negative     
171 L6 Stallion 18 yes no yes 12/04/2012 Positive 1.5    
172 L7 Stallion 16 yes no yes 12/04/2012 N.I. < 0.6    
173 L8 Stallion 7 yes no yes 12/04/2012 Negative     
174 L9 Stallion 6 yes no yes 12/04/2012 N.I. < 0.6    
175 L10 Stallion 14 yes no yes 12/04/2012 Positive 2.6    
176 L11 Mare 21 yes yes yes 12/04/2012 Positive 2.8    
177 L12 Mare 13 yes yes yes 12/04/2012 Positive 1.8    
178 L13 Mare 7 yes no yes 12/04/2012 Positive 3    
179 L14 Mare 11 yes yes yes 12/04/2012 Positive 2.6    
180 M1 Mare 9 yes yes no 12/07/2012 Positive 1.7 Positive 2.3 1.8 
181 M2 Stallion 11 yes yes no 12/07/2012 Positive 2.8 Positive >2.6 1.4 
182 M3 Mare 8 yes no no 12/07/2012 Positive 3.6 Positive >2.6 1.2 
183 M4 Mare 9 yes yes no 12/07/2012 Negative  Positive 2.3 1.1 
184 M6 Mare 10 yes no no 12/07/2012 Negative  Equivocal 2.1 1.1 
185 M7 Mare 12 yes no no 12/07/2012 Positive 3.2 Positive 2.4 1.4 
186 M8 Mare 12 yes yes no 12/07/2012 Positive 1.4 Positive >2.6 1.8 
187 M9 Mare 7 yes no no 12/07/2012 Negative  Negative   
188 M10 Stallion 13 yes no no 12/07/2012 Positive < 0.6 Positive 2.6 1.1 
189 M11 Stallion 3 no n/a no 12/07/2012 Negative  Equivocal 2.6 0.9 
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190 M12 Mare 11 yes no no 12/07/2012 Positive 2.6 Positive 2.3 1.7 
191 M13 Stallion 8 yes no no 12/07/2012 Negative  Equivocal 2.6 1.7 
192 M14 Mare 10 yes yes no 12/07/2012 Positive 3.6 Positive 1.4 0.8 
193 M15 Stallion 9 yes no no 12/07/2012 Positive 3.4 Positive 1.5 1.1 
194 M16 Stallion 12 yes no no 12/07/2012 Negative  Positive >2.6 1.7 
195 M17 Mare 13 yes yes no 12/07/2012 Positive 3.5 Positive >2.6 1.7 
196 N1 Mare 2 no n/a no 29/10/2012 Negative  Equivocal 1.8 1.7 
197 N2 Mare 14 yes yes no 29/10/2012 Negative  Positive >2.6 1.7 
198 N3 Mare 12 no n/a no 29/10/2012 Negative  Positive >2.6 1.5 
199 N4 Mare 7 yes no no 29/10/2012 Negative  Positive >2.6 1.4 
200 N5 Mare 7 no n/a no 29/10/2012 Negative  Positive 2.6 1.5 
201 N6 Mare 2 no n/a no 29/10/2012 Negative  Negative   
202 N7 Mare 4 no n/a no 29/10/2012 Negative  Negative   
203 N8 Stallion 16 no n/a no 20/06/2012 Negative  Positive 2.6 2.3 
204 O1 Mare 12 yes no no 06/11/2012 Negative  Positive >2.6 1.7 
205 O2 Mare 8 yes no no 06/11/2012 Negative  Negative   
206 O3 Stallion 5 yes no no 06/11/2012 Negative  Negative   
207 O4 Stallion 1 no n/a no 06/11/2012 Negative  Negative   
208 O5 Stallion 2 no n/a no 06/11/2012 Negative  Positive 1.4 1.4 
209 O6 Mare 3 yes no no 06/11/2012 Negative  Equivocal 1.8 1.4 
210 O7 Mare 6 yes no no 06/11/2012 Negative  Negative   
211 O8 Stallion 8 no n/a no 06/11/2012 Positive < 0.6 Negative   
212 O9 Mare 9 yes no no 06/11/2012 Negative  Positive 2.6 1.2 
213 O10 Mare 7 yes yes no 06/11/2012 Negative  Equivocal 1.5 1.7 
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214 O11 Mare 14 yes yes no 20/04/2013 Positive < 0.6 Positive >2.6 2.3 
215 O12 Stallion 6 yes no no 20/04/2013 Negative  Equivocal >2.6 2.3 
216 P1 Stallion 4 yes no no 13/12/2012 Negative  Negative   
217 P2 Stallion 4 no n/a no 13/12/2012 Negative  Negative   
218 P3 Stallion 8 no n/a no 13/12/2012 Positive < 0.6 Equivocal 1.5 0.9 
219 P4 Stallion 6 no n/a no 13/12/2012 Negative  Negative   
220 P5 Stallion 5 no n/a no 13/12/2012 Negative  Equivocal 2 1.7 
221 P6 Stallion 1,5 no n/a no 13/12/2012 Negative  Negative   
222 P7 Mare 2 yes no yes 13/12/2012 Negative     
223 P8 Mare 6 yes yes yes 13/12/2012 Positive 2.9    
224 P9 Mare 13 yes no yes 13/12/2012 Negative     
225 P10 Mare 6 yes yes yes 13/12/2012 Negative     
226 P11 Mare 2 no n/a no 13/12/2012 Negative  Negative   
227 P12 Mare 2 no n/a no 13/12/2012 Negative  Equivocal 2 < 0.5 
228 Q1 Mare 17 yes yes yes 21/02/2013 Negative     
229 Q2 Mare 10 yes yes yes 21/02/2013 Negative     
230 Q3 Mare 7 yes yes yes 21/02/2013 Negative     
231 Q4 Mare 13 yes yes yes 21/02/2013 Negative     
232 Q5 Mare 18 yes yes yes 21/02/2013 Negative     
233 Q6 Mare 20 yes yes yes 21/02/2013 Negative     
234 Q7 Mare 7 yes yes yes 21/02/2013 Negative     
235 Q8 Mare 22 yes no yes 21/02/2013 Negative     
236 Q9 Mare 4 yes no yes 21/02/2013 Negative     
237 Q10 Mare 20 yes no yes 21/02/2013 Negative     
 229 
 
No ID SEX AGE 
ACTIVE 
BREEDER 
REPRODUCTIVE 
PROBLEMS 
EHV-1/-4 
VACCINATION 
SAMPLING 
DATE 
EVA 
ELISA 
EVA 
SN 
EHV 
ELISA 
EHV-1 
SN 
EHV-4 
SN 
238 Q11 Mare 4 yes no yes 21/02/2013 Negative     
239 Q12 Mare 4 yes no yes 21/02/2013 Negative     
240 Q13 Mare 18 yes no yes 21/02/2013 Negative     
241 Q14 Mare 18 yes no yes 21/02/2013 Negative     
242 Q15 Mare 13 yes no yes 21/02/2013 Negative     
243 Q16 Mare 6 yes no yes 21/02/2013 Negative     
244 Q17 Mare 17 yes no yes 21/02/2013 Negative     
245 Q18 Mare 15 yes no yes 21/02/2013 Negative     
246 Q19 Stallion 20 yes yes yes 21/02/2013 Negative     
247 Q20 Stallion 10 yes no yes 21/02/2013 Negative     
248 Q21 Stallion 7 yes no yes 21/02/2013 Negative     
249 Q22 Stallion 4 yes no yes 21/02/2013 Negative     
250 Q23 Stallion 9 yes no yes 21/02/2013 Negative     
251 Q24 Stallion 7 yes no yes 21/02/2013 Negative     
252 Q25 Stallion 5 yes no yes 21/02/2013 Negative     
253 Q26 Stallion 22 yes no yes 21/02/2013 Negative     
254 Q27 Stallion 21 yes no yes 21/02/2013 N.I. < 0.6    
255 Q28 Stallion 7 yes no yes 21/02/2013 Equivocal < 0.6    
256 Q29 Mare 1 no n/a yes 21/02/2013 Negative     
257 Q30 Mare 1,1 no n/a yes 21/02/2013 Negative     
258 Q31 Stallion 1,1 no n/a yes 21/02/2013 Negative     
259 Q32 Stallion 1,2 no n/a yes 21/02/2013 Negative     
260 Q33 Stallion 1 no n/a yes 21/02/2013 Negative     
261 Q34 Stallion 1,25 no n/a yes 21/02/2013 Negative     
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262 Q35 Stallion 1,25 no n/a yes 21/02/2013 Negative     
263 Q36 Stallion 0,9 no n/a yes 21/02/2013 Negative     
264 Q37 Stallion 1,25 no n/a yes 21/02/2013 Negative     
265 Q38 Stallion 1,1 no n/a yes 21/02/2013 Negative     
266 Q39 Stallion 1 no n/a yes 21/02/2013 Negative     
267 Q40 Mare 10 yes no yes 20/03/2013 Negative     
268 Q41 Mare 7 yes no yes 20/03/2013 Positive < 0.6    
269 Q42 Mare 7 yes no yes 20/03/2013 Negative     
270 R1 Mare 6 yes yes yes 16/03/2013 Positive 2.3    
271 R2 Mare 8 yes yes yes 16/03/2013 Positive 1.4    
272 R3 Mare 6 yes no yes 16/03/2013 Positive 2.6    
273 R4 Mare 7 yes yes yes 16/03/2013 Positive 1.7    
274 R5 Mare 5 yes yes yes 16/03/2013 Positive 2.5    
275 R6 Mare 7 yes yes yes 16/03/2013 Positive 2.4    
276 R7 Mare 7 yes no yes 16/03/2013 Positive 2.5    
277 R8 Mare 6 yes yes yes 16/03/2013 Positive 2.6    
278 R9 Mare 3 yes no yes 16/03/2013 Positive 2.3    
279 R10 Stallion 1,3 no n/a no 16/03/2013 Negative  Negative   
280 R11 Mare 0,7 no n/a no 16/03/2013 N.I. < 0.6 Negative   
281 S1 Mare 1,3 no n/a yes 20/04/2013 Negative     
282 S2 Mare 1,3 no n/a yes 20/04/2013 Negative     
283 S3 Mare 2,2 no n/a yes 20/04/2013 Negative     
284 S4 Mare 1,6 no n/a yes 20/04/2013 Negative     
285 S5 Mare 2,2 no n/a yes 20/04/2013 Negative     
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286 S6 Mare 2,9 no n/a yes 20/04/2013 Negative     
287 S7 Mare 2,2 no n/a yes 20/04/2013 Negative     
288 S8 Mare 2,2 no n/a yes 20/04/2013 Negative     
289 S9 Mare 3,2 no n/a yes 20/04/2013 Negative     
290 S10 Mare 3,1 no n/a yes 20/04/2013 Negative     
291 S11 Mare 3,2 no n/a yes 20/04/2013 Negative     
292 S12 Mare 3 no n/a yes 20/04/2013 Negative     
293 S13 Stallion 1,2 no n/a yes 20/04/2013 Negative     
294 S14 Stallion 1,2 no n/a yes 20/04/2013 Negative     
295 S15 Stallion 1,2 no n/a yes 20/04/2013 Negative     
296 S16 Stallion 1,2 no n/a yes 20/04/2013 Negative     
297 S17 Stallion 1,4 no n/a yes 20/04/2013 Negative     
298 S18 Stallion 3,2 no n/a yes 20/04/2013 Negative     
299 S19 Stallion 3 no n/a yes 20/04/2013 Negative     
300 S20 Stallion 2,2 no n/a yes 20/04/2013 Negative     
301 S21 Mare 8 yes no yes 20/04/2013 Negative     
302 S22 Mare 4 no n/a yes 20/04/2013 Negative     
303 S23 Mare 4 no n/a yes 20/04/2013 Negative     
304 S24 Mare 4 no n/a yes 20/04/2013 Negative     
305 S25 Mare 4 no n/a yes 20/04/2013 Negative     
306 S26 Mare 9 yes no yes 20/04/2013 Negative     
307 S27 Mare 5 yes no yes 20/04/2013 Negative     
308 S28 Mare 16 yes no yes 20/04/2013 Negative     
309 S29 Mare 11 yes no yes 20/04/2013 Negative     
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310 S30 Mare 8 yes no yes 20/04/2013 Negative     
311 S31 Mare 10 yes no yes 20/04/2013 Negative     
312 S32 Mare 11 yes yes yes 20/04/2013 Negative     
313 S33 Mare 14 yes no yes 20/04/2013 Negative     
314 S34 Mare 13 yes no yes 20/04/2013 Negative     
315 S35 Mare 9 yes no yes 20/04/2013 Negative     
316 S36 Mare 8 yes no yes 20/04/2013 Negative     
317 S37 Mare 9 yes no yes 20/04/2013 Negative     
318 S38 Mare 13 yes no yes 20/04/2013 Negative     
319 S39 Mare 11 yes no yes 20/04/2013 Negative     
320 S40 Mare 10 yes yes yes 20/04/2013 Negative     
321 S41 Stallion 4 yes no yes 20/04/2013 Negative     
322 S42 Stallion 13 yes no yes 20/04/2013 Negative     
323 S43 Stallion 5 yes no yes 20/04/2013 Negative     
324 S44 Stallion 4 yes no yes 20/04/2013 Negative     
325 S45 Stallion 4 yes no yes 20/04/2013 Negative     
326 S46 Stallion 13 yes yes yes 20/04/2013 Negative     
327 S47 Stallion 5 yes no yes 20/04/2013 Negative     
328 S48 Stallion 5 yes no yes 20/04/2013 Negative     
329 S49 Stallion 5 yes no yes 20/04/2013 Negative     
330 S50 Stallion 7 yes no yes 20/04/2013 Negative     
331 S51 Stallion 0,7 no n/a no 16/11/2013 Negative  Negative   
332 S52 Stallion 0,7 no n/a no 16/11/2013 Negative  Equivocal 2.3 2.3 
333 S53 Stallion 0,7 no n/a no 16/11/2013 Positive < 0.6 Negative   
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334 S54 Stallion 0,7 no n/a no 16/11/2013 Negative  Negative   
335 S55 Mare 0,7 no n/a no 16/11/2013 Negative  Negative   
336 S56 Mare 0,7 no n/a no 16/11/2013 Negative  Negative   
337 S57 Mare 0,7 no n/a no 16/11/2013 Negative  Negative   
338 S58 Stallion 0,7 no n/a no 16/11/2013 Positive < 0.6 Equivocal 2.4 2.2 
339 T1 Mare 8 yes yes no 20/04/2013 Negative  Equivocal 2.5 1.6 
340 T2 Mare 12 yes no no 20/04/2013 Negative  Positive >2.6 2.5 
341 T3 Mare 7 yes yes no 20/04/2013 Negative  Negative   
342 T4 Mare 18 yes yes no 20/04/2013 Negative  Negative   
343 T5 Mare 9 yes no no 20/04/2013 Negative  Positive >2.6 >2.6 
344 T6 Mare 8 yes no no 20/04/2013 Negative  Positive >2.6 >2.6 
345 T7 Stallion 12 no n/a no 20/04/2013 Negative  Positive >2.6 2 
346 T8 Mare 2 no n/a no 20/04/2013 Negative  Negative   
347 T9 Stallion 23 yes no no 20/04/2013 Negative  Positive >2.6 2.2 
348 T10 Stallion 8 yes no no 20/04/2013 Negative  Equivocal 2.3 2.1 
349 U1 Stallion 16 yes no yes 13/07/2013 Negative     
350 U2 Stallion 5 yes no yes 13/07/2013 Negative     
351 U3 Stallion 8 yes no yes 13/07/2013 Negative     
352 U4 Stallion 7 no n/a yes 13/07/2013 Negative     
353 U5 Stallion 4 no n/a yes 13/07/2013 Negative     
354 U6 Stallion 4 no n/a yes 13/07/2013 Negative     
355 U7 Stallion 8 no n/a yes 13/07/2013 Negative     
356 U8 Stallion 12 no n/a yes 13/07/2013 Negative     
357 U9 Stallion 8 no n/a yes 13/07/2013 Negative     
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358 U10 Stallion 14 no n/a yes 13/07/2013 Negative     
359 V1 Mare 14 yes no yes 18/08/2013 Positive 2.3    
360 V2 Mare 4 yes no yes 18/08/2013 Positive 3.6    
361 V3 Mare 4 yes no yes 18/08/2013 Positive 3.9    
362 V4 Mare 10 yes yes yes 18/08/2013 Positive 3.2    
363 V5 Mare 9 yes yes yes 18/08/2013 Positive 3.6    
364 V6 Mare 15 yes yes yes 18/08/2013 Positive 1.5    
365 V7 Mare 10 yes no yes 18/08/2013 Positive 3.4    
366 V8 Mare 5 yes no yes 18/08/2013 Positive 3.2    
367 V9 Mare 8 yes no yes 18/08/2013 Positive 3.5    
368 V10 Mare 8 yes yes yes 18/08/2013 Positive 2.9    
369 V11 Mare 5 yes no yes 18/08/2013 Positive 2.5    
370 V12 Mare 8 yes no yes 18/08/2013 Positive 3.2    
371 V13 Mare 4 yes no yes 18/08/2013 Positive 3    
372 V14 Mare 5 yes yes yes 18/08/2013 Positive 3.5    
373 V15 Mare 4 yes no yes 18/08/2013 N.I. 2.6    
374 V16 Mare 2 no n/a no 18/08/2013 Positive 3.9 Equivocal >2.6 2.1 
375 V17 Mare 5 yes yes yes 18/08/2013 Positive 3.2    
376 V18 Stallion 2 no n/a no 18/08/2013 Positive 2.8 Negative   
377 V19 Stallion 3 no n/a no 18/08/2013 Positive 3.4 Positive >2.6 2.4 
378 V20 Stallion 3 yes no no 18/08/2013 Positive 2 Negative   
379 V21 Stallion 10 yes no no 18/08/2013 Positive 2.6 Positive >2.6 >2.6 
380 V22 Stallion 5 yes no no 18/08/2013 Positive 3.4 Positive >2.6 2.2 
381 V23 Stallion 5 yes no no 18/08/2013 Negative  Positive >2.6 2.5 
 235 
 
No ID SEX AGE 
ACTIVE 
BREEDER 
REPRODUCTIVE 
PROBLEMS 
EHV-1/-4 
VACCINATION 
SAMPLING 
DATE 
EVA 
ELISA 
EVA 
SN 
EHV 
ELISA 
EHV-1 
SN 
EHV-4 
SN 
382 V24 Stallion 9 yes no no 18/08/2013 Positive 3.3 Positive >2.6 >2.6 
383 V25 Mare 8 yes no yes 18/08/2013 Positive 3.2    
384 V26 Mare 9 yes no yes 18/08/2013 Positive 3.4    
385 V27 Mare 3 no n/a no 18/08/2013 Positive 2.4 Negative   
386 V28 Stallion 1 no n/a no 18/08/2013 Positive 2.8 Negative   
387 V29 Mare 1 no n/a no 18/08/2013 Positive 3.5 Negative   
388 W1 Stallion 12 yes no no 28/08/2013 Positive 1.5 Positive >2.6 2.4 
389 W2 Stallion 6 yes no no 28/08/2013 Negative  Negative   
390 W3 Stallion 4 yes no no 28/08/2013 Negative  Negative   
391 W4 Stallion 1 no n/a no 28/08/2013 Negative  Positive 2.5 2.3 
392 W5 Stallion 1 no n/a no 28/08/2013 Negative  Equivocal >2.6 2.5 
393 W6 Stallion 1 no n/a no 28/08/2013 Negative  Negative   
394 W7 Mare 3 no n/a no 28/08/2013 Positive < 0.6 Positive 2.4 2.3 
395 X1 Stallion 10 yes no yes 29/08/2013 Negative     
396 X2 Mare 11 yes no yes 29/08/2013 Negative     
397 X3 Mare 3 no n/a yes 29/08/2013 Negative     
398 X4 Stallion 4 no n/a yes 29/08/2013 Negative     
399 Y1 Mare 7 yes no yes 30/08/2013 Negative     
400 Y2 Mare 6 yes no yes 30/08/2013 Negative     
401 Y3 Mare 3 no n/a no 30/08/2013 Negative  Equivocal 2.5 1.8 
402 Y4 Mare 4 no n/a no 30/08/2013 Negative  Negative   
403 Y5 Mare 5 yes no yes 30/08/2013 Negative     
404 Y6 Mare 16 yes no yes 30/08/2013 Positive 2    
405 Y7 Mare 14 yes no yes 30/08/2013 Positive 2.5    
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406 Y8 Mare 6 yes no yes 30/08/2013 Negative     
407 Y9 Mare 6 yes no yes 30/08/2013 Negative     
408 Y10 Mare 6 yes yes yes 30/08/2013 Negative     
409 Y11 Stallion 8 yes no no 30/08/2013 Negative  Positive 2.5 >2.6 
410 Y12 Stallion 4 no n/a no 30/08/2013 Negative  Equivocal >2.6 2.4 
411 Y13 Stallion 5 no n/a no 30/08/2013 Positive < 0.6 Equivocal 2.5 2.2 
412 Y14 Stallion 6 yes no no 30/08/2013 Negative  Negative   
413 Z1 Stallion 7 no n/a no 31/08/2013 Negative  Positive >2.6 2.3 
414 Z2 Stallion 5 no n/a no 31/08/2013 Negative  Negative   
415 Z3 Stallion 9 no n/a no 31/08/2013 Negative  Equivocal >2.6 2.3 
416 Z4 Stallion 12 yes no no 31/08/2013 Negative  Positive >2.6 2.4 
417 Z5 Stallion 3 no n/a no 31/08/2013 Negative  Negative   
418 Z6 Stallion 2 no n/a no 31/08/2013 Negative  Equivocal >2.6 2.3 
419 Z7 Stallion 3 no n/a no 31/08/2013 Negative  Equivocal 2.5 2.5 
420 Z8 Stallion 5 no n/a no 31/08/2013 Negative  Equivocal >2.6 >2.6 
421 Z9 Mare 11 yes yes yes 31/08/2013 Negative     
422 Z10 Mare 4 yes no yes 31/08/2013 Negative     
423 Z11 Mare 5 yes no yes 31/08/2013 Negative     
424 Z12 Mare 6 yes no yes 31/08/2013 Negative     
425 Z13 Mare 16 yes no yes 31/08/2013 Negative     
426 Z14 Mare 12 yes no yes 31/08/2013 Negative     
427 Z15 Mare 5 yes no yes 31/08/2013 Negative     
428 AA1 Mare 5 no n/a no 31/08/2013 Negative  Equivocal >2.6 2.5 
429 AA2 Mare 13 yes yes no 31/08/2013 Negative  Positive >2.6 2.4 
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430 AA3 Mare 10 no n/a no 31/08/2013 Negative  Equivocal >2.6 2 
431 AA4 Mare 4 no n/a no 31/08/2013 Negative  Equivocal >2.6 >2.6 
432 AA5 Stallion 4 no n/a no 31/08/2013 Negative  Negative   
433 AA6 Stallion 2 no n/a no 31/08/2013 Negative  Negative   
434 AB1 Stallion 3 yes no no 03/09/2013 Negative  Positive >2.6 2.3 
435 AB2 Stallion 3 no n/a no 03/09/2013 Negative  Equivocal 2.5 2.2 
436 AB3 Stallion 4 no n/a no 03/09/2013 Positive < 0.6 Positive >2.6 2.4 
437 AB4 Stallion 3 no n/a no 03/09/2013 Negative  Equivocal 2.5 2.4 
438 AB5 Stallion 4 no n/a no 03/09/2013 Negative  Positive >2.6 >2.6 
439 AB6 Stallion 16 no n/a no 03/09/2013 Positive < 0.6 Positive 2.5 1.9 
440 AB7 Stallion 5 no n/a no 03/09/2013 Negative  Positive >2.6 >2.6 
441 AB8 Stallion 22 no n/a no 03/09/2013 N.I. < 0.6 Positive >2.6 2.3 
442 AB9 Mare 7 yes no no 03/09/2013 Negative  Negative   
443 AB10 Mare 7 yes no no 03/09/2013 Negative  Negative   
444 AB11 Mare 20 yes no no 03/09/2013 Negative  Positive >2.6 1.9 
445 AB12 Mare 4 yes no no 03/09/2013 Negative  Equivocal >2.6 2.3 
446 AB13 Mare 14 yes no no 03/09/2013 Negative  Equivocal 2.5 2.1 
447 AB14 Mare 6 yes no no 03/09/2013 Negative  Positive >2.6 2.1 
448 AB15 Mare 5 yes no no 03/09/2013 Negative  Positive >2.6 2.5 
449 AB16 Mare 7 yes no no 03/09/2013 Positive < 0.6 Positive 2.5 1.7 
450 AB17 Mare 7 yes no no 03/09/2013 Negative  Positive 2.5 2.4 
451 AC1 Mare 7 yes yes yes 04/09/2013 Positive 2    
452 AC2 Mare 8 yes yes yes 04/09/2013 Negative     
453 AC3 Mare 9 yes no no 04/09/2013 Negative  Positive 2.3 1.9 
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454 AC4 Mare 8 yes yes yes 04/09/2013 Negative     
455 AC5 Mare 8 yes yes yes 04/09/2013 Negative     
456 AC6 Mare 8 yes yes yes 04/09/2013 Negative     
457 AC7 Mare 4 yes no no 04/09/2013 Positive 2.6 Equivocal 2.5 2.2 
458 AC8 Mare 8 yes no yes 04/09/2013 Negative     
459 AC9 Stallion 9 yes yes no 04/09/2013 Negative  Positive >2.6 2 
460 AC10 Mare 6 yes yes no 30/10/2013 Negative  Positive 2.4 2.2 
461 AD1 Mare 4 yes no no 04/09/2013 Negative  Negative   
462 AD2 Mare 15 yes no no 04/09/2013 Negative  Positive >2.6 1.3 
463 AE1 Stallion 2,5 no n/a no 15/09/2013 Negative  Negative   
464 AE2 Stallion 2,5 no n/a no 15/09/2013 Negative  Equivocal 2.1 1.2 
465 AE3 Stallion 3,5 no n/a no 15/09/2013 Positive < 0.6 Positive >2.6 >2.6 
466 AE4 Stallion 15 yes no no 15/09/2013 Negative  Positive >2.6 1.8 
467 AE5 Stallion 3,5 no n/a no 15/09/2013 Negative  Equivocal >2.6 1.8 
468 AE6 Stallion 12 yes no no 15/09/2013 Negative  Positive >2.6 1.6 
469 AE7 Stallion 7 yes no no 15/09/2013 Negative  Positive 2.5 1.3 
470 AE8 Mare 4 no n/a no 15/09/2013 Negative  Equivocal 2.3 1.1 
471 AE9 Mare 3 no n/a no 15/09/2013 Negative  Positive >2.6 1.7 
472 AE10 Mare 2 no n/a no 15/09/2013 Negative  Positive 2.5 1.4 
473 AE11 Mare 12 yes yes no 15/09/2013 Negative  Positive >2.6 2.2 
474 AE12 Mare 7 no n/a no 15/09/2013 Equivocal < 0.6 Positive >2.6 2.4 
475 AE13 Mare 11 yes no no 15/09/2013 Negative  Positive >2.6 1.6 
476 AE14 Mare 7 no n/a no 15/09/2013 Negative  Positive >2.6 1.6 
477 AE15 Mare 15 yes yes no 15/09/2013 Negative  Positive 2.4 1.5 
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478 AE16 Mare 2 no n/a no 15/09/2013 Negative  Positive 2.4 1.9 
479 AF1 Stallion 1 no n/a no 18/09/2013 Negative  Negative   
480 AF2 Stallion 3 no n/a no 18/09/2013 Negative  Equivocal 2.2 1.4 
481 AF3 Stallion 4 no n/a no 18/09/2013 Negative  Positive 2.4 1.4 
482 AF4 Stallion 12 no n/a no 18/09/2013 Negative  Negative   
483 AF5 Stallion 5 no n/a no 18/09/2013 Negative  Equivocal 2.2 1.4 
484 AF6 Mare 4 yes no yes 18/09/2013 Negative     
485 AF7 Mare 7 yes no yes 18/09/2013 N.I. < 0.6    
486 AF8 Mare 14 yes yes yes 18/09/2013 Negative     
487 AF9 Mare 8 yes no yes 18/09/2013 N.I. < 0.6    
488 AF10 Stallion 24 no n/a no 18/09/2013 Negative  Positive 2.4 1.6 
489 AF11 Stallion 4 no n/a no 18/09/2013 Negative  Negative   
490 AF12 Stallion 20 no n/a no 18/09/2013 N.I. < 0.6 Positive >2.6 >2.6 
491 AF13 Stallion 18 no n/a no 18/09/2013 Negative  Positive 2.5 1.5 
492 AF14 Stallion 14 yes no no 18/09/2013 Negative  Equivocal 2.1 1.1 
493 AG1 Stallion 11 no n/a no 19/09/2013 Negative  Positive 2.2 1 
494 AG2 Stallion 6 no n/a no 19/09/2013 Negative  Negative   
495 AG3 Stallion 4 no n/a no 19/09/2013 Negative  Positive 2.1 0.8 
496 AG4 Stallion 4 no n/a no 19/09/2013 Negative  Negative   
497 AG5 Stallion 3 no n/a no 19/09/2013 Negative  Positive 2.2 1.4 
498 AG6 Stallion 3 no n/a no 19/09/2013 Negative  Equivocal >2.6 1.5 
499 AG7 Stallion 2 no n/a no 19/09/2013 Negative  Equivocal 2 1.3 
500 AG8 Stallion 2 no n/a no 19/09/2013 Negative  Positive >2.6 1.4 
501 AG9 Stallion 1 no n/a no 19/09/2013 Negative  Equivocal 2.5 1.4 
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502 AG10 Stallion 1 no n/a no 19/09/2013 Negative  Equivocal >2.6 1.8 
503 AG11 Mare 7 no n/a no 19/09/2013 Negative  Positive 2.5 1.7 
504 AG12 Mare 6 yes no no 19/09/2013 Negative  Equivocal 2.4 1.4 
505 AG13 Mare 6 no n/a no 19/09/2013 Negative  Equivocal 2.4 1.7 
506 AG14 Mare 5 yes no no 19/09/2013 Negative  Positive >2.6 1.7 
507 AG15 Mare 9 yes no no 19/09/2013 Negative  Positive >2.6 1.6 
508 AG16 Mare 5 yes no no 19/09/2013 Negative  Equivocal 1.8 1.3 
509 AG17 Mare 6 no n/a no 19/09/2013 Negative  Positive 2.3 1.6 
510 AG18 Mare 6 no n/a no 19/09/2013 Negative  Positive 2 1.6 
511 AG19 Mare 14 no n/a no 19/09/2013 N.I. < 0.6 Positive >2.6 2.5 
512 AG20 Mare 9 no n/a no 19/09/2013 Negative  Positive >2.6 1.5 
513 AH1 Mare 6 yes no no 05/11/2013 Negative  Positive 2.5 1.8 
514 AH2 Mare 16 yes no no 05/11/2013 Negative  Positive 2.6 1 
515 AH3 Mare 10 yes no no 05/11/2013 Negative  Positive 2.3 1.5 
516 AH4 Stallion 20 yes no no 05/11/2013 Negative  Positive 2 1.5 
517 AH5 Stallion 3 no n/a no 05/11/2013 Negative  Equivocal 2 1.3 
518 AH6 Mare 3 no n/a no 05/11/2013 Negative  Equivocal 2.1 1.4 
519 AH7 Stallion 20 yes no no 05/11/2013 Negative  Positive >2.6 1.1 
520 AH8 Mare 11 yes yes no 05/11/2013 Negative  Positive 2.4 1.7 
521 AH9 Mare 8 yes no no 05/11/2013 Negative  Positive 2.5 1.7 
522 AH10 Mare 7 yes no no 05/11/2013 Negative  Equivocal 1.5 1.2 
523 AH11 Mare 17 yes no no 05/11/2013 Negative  Positive 2.5 1.2 
524 AI1 Mare 11 yes no yes 06/11/2013 Positive 2.8    
525 AI2 Stallion 8 yes no no 06/11/2013 Negative  Positive >2.6 1.3 
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526 AI3 Mare 16 yes no yes 06/11/2013 Positive 2.1    
527 AI4 Mare 17 yes yes yes 06/11/2013 Positive 2    
528 AI5 Stallion 2 no n/a no 06/11/2013 Negative  Equivocal 1.6 0.9 
529 AI6 Stallion 12 yes no no 06/11/2013 Negative  Positive >2.6 1.8 
530 AI7 Stallion 3 no n/a no 06/11/2013 Negative  Equivocal 2.2 1.3 
531 AI8 Mare 20 yes no yes 06/11/2013 Negative     
532 AI9 Mare 13 yes no yes 06/11/2013 Positive 2.3    
533 AI10 Stallion 5 no n/a no 06/11/2013 Negative  Positive 1.8 2.5 
534 AI11 Stallion 3 no n/a no 06/11/2013 Negative  Positive 1.6 2.5 
535 AI12 Mare 17 yes no yes 06/11/2013 Positive 1.8    
536 AI13 Stallion 19 yes no no 06/11/2013 Negative  Positive 1 2.5 
537 AI14 Mare 2 no n/a no 06/11/2013 Negative  Negative   
538 AI15 Stallion 2 no n/a no 06/11/2013 Negative  Positive 1.6 >2.6 
539 AI16 Mare 4 yes no no 06/11/2013 Negative  Equivocal 2.3 1.2 
540 AI17 Mare 18 yes no yes 06/11/2013 Positive 1.9    
541 AI18 Mare 11 yes no yes 06/11/2013 N.I. 1.7    
542 AI19 Stallion 3 no n/a no 06/11/2013 Negative  Negative   
543 AI20 Stallion 4 no n/a no 06/11/2013 Negative  Positive 1.9 1.4 
544 AI21 Stallion 9 yes no no 06/11/2013 Positive 3 Positive >2.6 1.9 
545 AI22 Stallion 10 yes no no 06/11/2013 Negative  Positive >2.6 1.8 
546 AI23 Stallion 5 no n/a no 06/11/2013 Positive < 0.6 Negative   
547 AI24 Stallion 7 yes no no 06/11/2013 Negative  Positive 2.5 1.3 
548 AI25 Stallion 11 yes no no 06/11/2013 Negative  Positive >2.6 1.9 
549 AI26 Stallion 5 yes no no 06/11/2013 Negative  Positive >2.6 2.1 
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550 AI27 Stallion 11 yes no no 06/11/2013 Positive 2 Equivocal 2.4 2.2 
551 AI28 Stallion 5 yes no no 06/11/2013 Negative  Positive 2.5 1.1 
552 AI29 Stallion 6 no n/a no 06/11/2013 Negative  Equivocal 2.3 1.6 
553 AI30 Stallion 5 yes no no 06/11/2013 Negative  Positive >2.6 2.2 
554 AI31 Mare 13 yes no yes 06/11/2013 Positive 2.3    
555 AI32 Stallion 4 yes no no 06/11/2013 Negative  Positive >2.6 1.6 
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